[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"KOB GmbH\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":411},{"warningLetters":4,"total":410},[5,31,54,77,96,114,137,159,179,198,220,240,259,283,301,321,335,354,373,391],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2233,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-01-31T05:00:00Z\">01\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-27T05:00:00Z\">01\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkobayashi-healthcare-international-inc-637313-01272023\">Kobayashi Healthcare International, Inc.\u003C\u002Fa>","Office of Pharmaceutical Quality","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Norikazu Toyoda\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kobayashi Healthcare International, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>245 Kraft Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dalton\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30721-1502\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 27, 2023\u003C\u002Fp>\n\n\u003Cp>Case #637313\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Toyoda:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kobayashi America Manufacturing, LLC, FEI 3003079019, at 245 Kraft Drive, Dalton, Georgia, from May 23 to 27, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352 (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 21, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm released over-the-counter (OTC) drug products, Zim’s Max Freeze Gel, Zim’s Max Freeze Roll-on, and Zim’s Max Freeze Liquid, without testing batches for microbiological quality. For example, Zim’s Max Freeze Roll-on, lot B87695, was released by your quality unit (QU) on January 20, 2022, without undergoing microbiological testing. Your Quality Assurance Director informed our investigators, during the inspection, that microbiological testing is not a part of finished product release testing.\u003C\u002Fp>\n\n\u003Cp>Microbiological testing is essential to ensure each batch of your finished drug products conform to appropriate microbiological specifications. Testing prior to release and throughout the drug product’s life cycle is imperative to accomplish this standard.\u003C\u002Fp>\n\n\u003Cp>In your response, you claimed there was no danger of objectionable microorganisms in the finished drug product as the percentages of alcohol in the products do not support microbial growth or survival. You also indicated that the finished drug products currently on the market are safe.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide an appropriate scientific basis to support that your finished drug products are free from microbial growth or survival. It is well established that certain microorganisms are known to survive and thrive in alcohol. Additionally, you did not provide any retrospective testing to support the safety of your drug products currently on the market.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of microbiological specifications (i.e., total counts, objectionable microorganisms), including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An independent assessment of the microbiological test methods you plan to use to ensure that they are adequately validated and\u002For verified to be suitable for their intended purposes.\u003C\u002Fli>\n\t\u003Cli>Appropriate scientific studies to evaluate antimicrobial effectiveness testing (AET) for your aqueous multi-dose drug products. AET by USP &lt;51&gt; testing should be performed at a range of preservative concentrations and should be inclusive of concentrations at or below that listed in the formulation for each drug product. In addition to initial USP &lt;51&gt; studies on your formulations, one of the primary batches of the drug product should be tested for antimicrobial preservative effectiveness (in addition to preservative content) at the end of the proposed shelf life. The drug product specification should include a test for preservative content, and this attribute should be tested in all stability studies.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked an adequate QU. Your QU failed to establish and follow procedures\u003Cbr>\ndescribing its roles, responsibilities, and authorities. Furthermore, your QU’s oversight\u003Cbr>\nof drug manufacturing operations was inadequate. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Production and control records from your OTC drug product contract manufacturer were not reviewed or approved prior to release and distribution.\u003C\u002Fli>\n\t\u003Cli>Zim’s Max Freeze S, lot B77086 was intended for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but you relabeled the lot for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> without review and approval of manufacturing, packaging, and testing records to assure it met \u003Cstrong>(b)(4)\u003C\u002Fstrong> standards.\u003C\u002Fli>\n\t\u003Cli>There was a failure to establish adequate procedures for maintaining and investigating customer complaints.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you stated that your batch record review and complaint investigation deficiencies were due to the lack of QU documentation and sufficient detail.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response failed to provide an adequate retrospective review of production records to ensure all batches currently on the market were manufactured to your established specifications.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Also describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A retrospective review of each batch currently on the market and its related information to determine if all established specifications were met before the QU disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality&nbsp;\u003C\u002Fem>\u003Cem>Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs, regardless of agreements in place with your CMOs. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm353925.pdf.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We strongly recommend engaging a consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as an external analgesic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from the product’s labeling, including the website listed on product label, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; “BACK, Hip, Neck, Shoulder, Knee . . . \u003Cem>Drug Facts\u003C\u002Fem> . . . \u003Cem>Uses\u003C\u002Fem> . . . For the temporary relief of pain” [from your product’s outer carton]\u003C\u002Fp>\n\n\u003Cp>&nbsp; “Zim’s Max Freeze Hydro Cooling Pain Relief Patches provide immediate cooling relief . . . ready to use anywhere and anytime you need deep penetrating pain relief. Gently adheres to back, hips, neck, shoulders, and knees. . . . targeted pain relief that penetrates to the source of your discomfort.” [amazon.com\u002FZims-Max-Lidocaine-Cooling-P251220\u002Fdp\u002FBOB33B3ZKM?ref_=ast+sto_dp] [from the website of one of your retailers, Amazon.com; your website “WHERE TO BUY” provides a direct link to this and other retailers].\u003C\u002Fp>\n\n\u003Cp>“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a topical external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the of the FD&amp;C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be GRASE and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under section 505G(b)(8) of the FD&amp;C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\u003C\u002Fp>\n\n\u003Cp>This final administrative order addresses counterirritants, analgesic\u002Fanesthetics, and antipruritics, and it identifies active ingredients, dosage strengths, and indications for use corresponding to each of these categories of external analgesic drug products. Your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH,” product does not conform to the conditions of use specified in the final administrative order, as described below.\u003C\u002Fp>\n\n\u003Cp>Your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is labeled for use as a counterirritant external analgesic drug product because it includes claims related to the relief of pain in muscles and joints. For example, your product is labeled with the indication “For the temporary relief of pain,” and it identifies the back, hip, neck, shoulder, and knee. The labeling thus conveys that the product is intended for use in the temporary relief of pain in muscles and joints, including the back, hip, neck, shoulder, and knee. Further, the outer carton describes “deep penetrating” and “cooling” relief, and the product’s name includes the term “cooling.” The final administrative order requires the statement of indication for counterirritant external analgesic drug products include the phrase, “For the temporary relief of minor aches and pains of muscles and joints,” and it allows certain other statements including “penetrating pain relief” and “cooling pain relief.” Other categories of products addressed in the final administrative order, including analgesic and anesthetic drug products, are not permitted to include such an indication or statements in their labeling.\u003C\u002Fp>\n\n\u003Cp>However, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not formulated as a counterirritant external analgesic drug product consistent with the final administrative order. The product is labeled to contain the active ingredients lidocaine at a dosage strength of 4% and menthol at a dosage strength of 1%. Lidocaine is not included as an active ingredient in the final administrative order for an external analgesic counterirritant drug product. Further, the final administrative order includes menthol in a dosage range of 1.25 – 16% for counterirritant external analgesic drug products. Therefore, even if menthol was the sole active ingredient, at a dosage of 1%, it falls below the allowable dosage strength range of 1.25 – 16% for menthol used in counterirritant external analgesic drug products.\u003C\u002Fp>\n\n\u003Cp>We note that, pursuant to the final administrative order, analgesic and anesthetic drug products may contain lidocaine at a dosage strength of 0.5% to 4% and menthol at a dosage strength of 0.1% to 1%. However, as noted above, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not labeled with statements that the final administrative order permits for analgesic or anesthetic drug products (not counterirritants).\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Accordingly, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (\u003Cstrong>Case #637313\u003C\u002Fstrong>). Please electronically submit your signed reply on your firm’s letterhead to Ronda R. Loyd-Jones, Director, Compliance Branch, at email to: Ronda.Loyd-Jones@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nDivision Director\u003Cbr>\nOffice of Pharmaceutical Quality Operation\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>cc: Via Electronic Mail\u003Cbr>\nMr. Hajime Furuie\u003Cbr>\nQuality Assurance\u002FRegulatory Affairs Director\u003Cbr>\nKobayashi Healthcare International, Inc.\u003Cbr>\n245 Kraft Drive\u003Cbr>\nDalton, GA 30721\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Norikazu Toyoda\n\nRecipient Title\n\nPresident and CEO\n\nKobayashi Healthcare International, Inc.\n\n245 Kraft Dr.\n\nDalton, GA 30721-1502\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality\n\nUnited States\n\nJanuary 27, 2023\n\nCase #637313\n\nWARNING LETTER\n\nDear Mr. Toyoda:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kobayashi America Manufacturing, LLC, FEI 3003079019, at 245 Kraft Drive, Dalton, Georgia, from May 23 to 27, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352 (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your June 21, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nYour firm released over-the-counter (OTC) drug products, Zim’s Max Freeze Gel, Zim’s Max Freeze Roll-on, and Zim’s Max Freeze Liquid, without testing batches for microbiological quality. For example, Zim’s Max Freeze Roll-on, lot B87695, was released by your quality unit (QU) on January 20, 2022, without undergoing microbiological testing. Your Quality Assurance Director informed our investigators, during the inspection, that microbiological testing is not a part of finished product release testing.\n\nMicrobiological testing is essential to ensure each batch of your finished drug products conform to appropriate microbiological specifications. Testing prior to release and throughout the drug product’s life cycle is imperative to accomplish this standard.\n\nIn your response, you claimed there was no danger of objectionable microorganisms in the finished drug product as the percentages of alcohol in the products do not support microbial growth or survival. You also indicated that the finished drug products currently on the market are safe.\n\nYour response is inadequate. You did not provide an appropriate scientific basis to support that your finished drug products are free from microbial growth or survival. It is well established that certain microorganisms are known to survive and thrive in alcohol. Additionally, you did not provide any retrospective testing to support the safety of your drug products currently on the market.\n\nIn response to this letter, provide:\n\nA list of microbiological specifications (i.e., total counts, objectionable microorganisms), including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\no An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\nAn independent assessment of the microbiological test methods you plan to use to ensure that they are adequately validated and\u002For verified to be suitable for their intended purposes.\n\nAppropriate scientific studies to evaluate antimicrobial effectiveness testing (AET) for your aqueous multi-dose drug products. AET by USP \u003C51> testing should be performed at a range of preservative concentrations and should be inclusive of concentrations at or below that listed in the formulation for each drug product. In addition to initial USP \u003C51> studies on your formulations, one of the primary batches of the drug product should be tested for antimicrobial preservative effectiveness (in addition to preservative content) at the end of the proposed shelf life. The drug product specification should include a test for preservative content, and this attribute should be tested in all stability studies.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm lacked an adequate QU. Your QU failed to establish and follow procedures\n\ndescribing its roles, responsibilities, and authorities. Furthermore, your QU’s oversight\n\nof drug manufacturing operations was inadequate. For example:\n\nProduction and control records from your OTC drug product contract manufacturer were not reviewed or approved prior to release and distribution.\n\nZim’s Max Freeze S, lot B77086 was intended for the (b)(4), but you relabeled the lot for the (b)(4) without review and approval of manufacturing, packaging, and testing records to assure it met (b)(4) standards.\n\nThere was a failure to establish adequate procedures for maintaining and investigating customer complaints.\n\nIn your response, you stated that your batch record review and complaint investigation deficiencies were due to the lack of QU documentation and sufficient detail.\n\nYour response is inadequate. Your response failed to provide an adequate retrospective review of production records to ensure all batches currently on the market were manufactured to your established specifications.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA retrospective review of each batch currently on the market and its related information to determine if all established specifications were met before the QU disposition decision.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs, regardless of agreements in place with your CMOs. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm353925.pdf.\n\nConsultant Recommended\n\nWe strongly recommend engaging a consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nUnapproved New Drug and Misbranding Violations\n\n“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as an external analgesic.\n\nExamples of claims from the product’s labeling, including the website listed on product label, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“BACK, Hip, Neck, Shoulder, Knee . . . Drug Facts . . . Uses . . . For the temporary relief of pain” [from your product’s outer carton]\n\n“Zim’s Max Freeze Hydro Cooling Pain Relief Patches provide immediate cooling relief . . . ready to use anywhere and anytime you need deep penetrating pain relief. Gently adheres to back, hips, neck, shoulders, and knees. . . . targeted pain relief that penetrates to the source of your discomfort.” [amazon.com\u002FZims-Max-Lidocaine-Cooling-P251220\u002Fdp\u002FBOB33B3ZKM?ref_=ast+sto_dp] [from the website of one of your retailers, Amazon.com; your website “WHERE TO BUY” provides a direct link to this and other retailers].\n\n“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a topical external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the of the FD&C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be GRASE and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under section 505G(b)(8) of the FD&C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\n\nThis final administrative order addresses counterirritants, analgesic\u002Fanesthetics, and antipruritics, and it identifies active ingredients, dosage strengths, and indications for use corresponding to each of these categories of external analgesic drug products. Your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH,” product does not conform to the conditions of use specified in the final administrative order, as described below.\n\nYour “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is labeled for use as a counterirritant external analgesic drug product because it includes claims related to the relief of pain in muscles and joints. For example, your product is labeled with the indication “For the temporary relief of pain,” and it identifies the back, hip, neck, shoulder, and knee. The labeling thus conveys that the product is intended for use in the temporary relief of pain in muscles and joints, including the back, hip, neck, shoulder, and knee. Further, the outer carton describes “deep penetrating” and “cooling” relief, and the product’s name includes the term “cooling.” The final administrative order requires the statement of indication for counterirritant external analgesic drug products include the phrase, “For the temporary relief of minor aches and pains of muscles and joints,” and it allows certain other statements including “penetrating pain relief” and “cooling pain relief.” Other categories of products addressed in the final administrative order, including analgesic and anesthetic drug products, are not permitted to include such an indication or statements in their labeling.\n\nHowever, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not formulated as a counterirritant external analgesic drug product consistent with the final administrative order. The product is labeled to contain the active ingredients lidocaine at a dosage strength of 4% and menthol at a dosage strength of 1%. Lidocaine is not included as an active ingredient in the final administrative order for an external analgesic counterirritant drug product. Further, the final administrative order includes menthol in a dosage range of 1.25 – 16% for counterirritant external analgesic drug products. Therefore, even if menthol was the sole active ingredient, at a dosage of 1%, it falls below the allowable dosage strength range of 1.25 – 16% for menthol used in counterirritant external analgesic drug products.\n\nWe note that, pursuant to the final administrative order, analgesic and anesthetic drug products may contain lidocaine at a dosage strength of 0.5% to 4% and menthol at a dosage strength of 0.1% to 1%. However, as noted above, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not labeled with statements that the final administrative order permits for analgesic or anesthetic drug products (not counterirritants).\n\nFDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Accordingly, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to the Warning Letter Number above (Case #637313). Please electronically submit your signed reply on your firm’s letterhead to Ronda R. Loyd-Jones, Director, Compliance Branch, at email to: Ronda.Loyd-Jones@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nDivision Director\n\nOffice of Pharmaceutical Quality Operation\n\nDivision II\n\ncc: Via Electronic Mail\n\nMr. Hajime Furuie\n\nQuality Assurance\u002FRegulatory Affairs Director\n\nKobayashi Healthcare International, Inc.\n\n245 Kraft Drive\n\nDalton, GA 30721","Kobayashi Healthcare International, Inc.","kobayashi-healthcare-international-inc-637313-01272023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkobayashi-healthcare-international-inc-637313-01272023","2026-10-26T08:09:09.897874+00:00","Warning Letter","Issued","2023-01-31","637313","Drugs","Mr. Norikazu Toyoda","2026-08-20T01:16:59.473+00:00","VIA Electronic Mail","2023-01-27",{"id":32,"raw":33,"subject":38,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":47,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":51,"issuing_office":37,"recipient_name":52,"body_fetched_at":53,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":48,"medical_device_id":19,"response_letter_date":19},3483,[34,35,36,37,38,13,39,13],"\u003Ctime datetime=\"2021-03-04T21:30:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-04T05:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkogniz-inc-613569-03042021\">Kogniz, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Adulterated and Misbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkogniz-inc-613569-08162024\">\u003Ctime datetime=\"2024-08-30T04:00:00Z\">08\u002F30\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jed Putterman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Kogniz, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>225 Miller Avenue Building B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mill Valley\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94941\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jed@kogniz.com\"> jed@kogniz.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Kogniz, Inc.\u003Cbr>\n225 Miller Avenue Building B\u003Cbr>\nMill Valley, California&nbsp; 94941\u003C\u002Fp>\n\n\u003Cp>jed@kogniz.com – Jed Putterman\u003C\u002Fp>\n\n\u003Cp>&nbsp;&nbsp;\u003Cbr>\nRE:&nbsp;&nbsp;&nbsp;&nbsp; Adulterated and Misbranded Products\u003C\u002Fp>\n\n\u003Cp>Dear Sir,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.kogniz.com\u002F on February 12, 2021. The FDA has observed that your website offers a product for measuring human body temperature, specifically the “KOGNIZ TC20”, for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), the KOGNIZ TC20 is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Telethermographic systems are devices when they are intended for a medical purpose, such as body temperature measurement, including such use in non-medical environments.\u003C\u002Fp>\n\n\u003Cp>The KOGNIZ TC20 is offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce this product into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic\u003C\u002Fp>\n\n\u003Cp>devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.kogniz.com\u002F, includes statements that indicate that the KOGNIZ TC20 is intended to scan multiple individuals simultaneously, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp; “Large groups of people get screened at the same time.” [Published on your website, https:\u002F\u002Fwww.kogniz.com\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“Accurately measure body temperatures of groups of people entering a building.” [Published on your website, https:\u002F\u002Fwww.kogniz.com\u002F]\u003Cbr>\nYour firm should take prompt action to correct any violations. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.&nbsp;\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. After you receive this letter, please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct any violations, as well as an explanation of how your firm plans to prevent their recurrence.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your response should include documentation of the corrections and\u002For corrective actions (including those that address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n&nbsp;\u003Cbr>\nYour firm’s response should be sent to:\u003Cbr>\n&nbsp;\u003Cbr>\nAttn: CAPT Alan Stevens\u003Cbr>\nActing Director, Division of Drug Delivery and General Hospital Devices,\u003Cbr>\n&nbsp;&nbsp;and Human Factors\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn, General Hospital, and Urology Devices\u003Cbr>\nDocument Control Center (DCC) – WO66-G609\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003Cbr>\n&nbsp;\u003Cbr>\nRefer to the reference number CMS 613569 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jake Lindstrom, PhD at \u003Ca href=\"mailto:Jake.Lindstrom@fda.hhs.gov\">Jake.Lindstrom@fda.hhs.gov\u003C\u002Fa> or (301( 796-5716.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp;&nbsp;&nbsp; General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJed Putterman\n\nKogniz, Inc.\n\n225 Miller Avenue Building B\n\nMill Valley, CA 94941\n\nUnited States\n\njed@kogniz.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nKogniz, Inc.\n\n225 Miller Avenue Building B\n\nMill Valley, California 94941\n\njed@kogniz.com – Jed Putterman\n\nRE: Adulterated and Misbranded Products\n\nDear Sir,\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.kogniz.com\u002F on February 12, 2021. The FDA has observed that your website offers a product for measuring human body temperature, specifically the “KOGNIZ TC20”, for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), the KOGNIZ TC20 is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Telethermographic systems are devices when they are intended for a medical purpose, such as body temperature measurement, including such use in non-medical environments.\n\nThe KOGNIZ TC20 is offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce this product into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic\n\ndevices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.kogniz.com\u002F, includes statements that indicate that the KOGNIZ TC20 is intended to scan multiple individuals simultaneously, including:\n\n• “Large groups of people get screened at the same time.” [Published on your website, https:\u002F\u002Fwww.kogniz.com\u002F]\n\n• “Accurately measure body temperatures of groups of people entering a building.” [Published on your website, https:\u002F\u002Fwww.kogniz.com\u002F]\n\nYour firm should take prompt action to correct any violations. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. After you receive this letter, please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct any violations, as well as an explanation of how your firm plans to prevent their recurrence.\n\nYour response should include documentation of the corrections and\u002For corrective actions (including those that address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent to:\n\nAttn: CAPT Alan Stevens\n\nActing Director, Division of Drug Delivery and General Hospital Devices,\n\nand Human Factors\n\nU.S. Food and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Product Evaluation and Quality\n\nOHT3: Office of GastroRenal, ObGyn, General Hospital, and Urology Devices\n\nDocument Control Center (DCC) – WO66-G609\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nRefer to the reference number CMS 613569 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jake Lindstrom, PhD at Jake.Lindstrom@fda.hhs.gov or (301( 796-5716.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Kogniz, Inc.","kogniz-inc-613569-03042021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkogniz-inc-613569-03042021","2026-10-26T08:09:09.930304+00:00","Closed Out","2021-03-04","613569","Medical Devices","2024-08-30","Jed Putterman","2026-08-20T03:19:01.806+00:00",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":72,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":19,"reference_number":19,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},1982,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2023-07-25T13:20:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-18T04:00:00Z\">07\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkoi-cbd-llc-651252-07182023\">Koi CBD, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations West V ","Adulterated Human Foods\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brad L. Ridenour\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Koi CBD, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14631 Best Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Norwalk\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90650\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL 651252\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Ridenour:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address koicbd.com in June 2023 through July 2023 and has determined that you take orders there for various human products, which you represent as containing Delta-8 tetrahydrocannabinol (THC). FDA also inspected your Koi CBD facility, which distributes human food products containing Delta-8, located at 14631 Best Ave, Norwalk, CA 90650, on December 12-15, 2022.\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your products, Koi brand “Delta 8 Gummies” and Hemp Living brand “Pot Rocks,” are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce adulterated food into interstate commerce under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulationcannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\u003Cbr>\n\u003Cbr>\nFDA has observed a proliferation of products containing the cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-knowabout-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products that may pose a serious health risk to consumers.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Foods\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your Koi brand “Delta 8 Gummies” and Hemp Living brand “Pot Rocks” are foods to which Delta-8 THC has been added.\u003C\u002Fp>\n\n\u003Cp>As defined in section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the term \"food additive\" refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects of Delta-8 THC on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to conventional foods is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Therefore, your Koi brand “Delta 8 Gummies” and Hemp Living brand “Pot Rocks” are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>* * *\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n19701 Fairchild\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number \u003Cstrong>651252\u003C\u002Fstrong> when replying.\u003C\u002Fp>\n\n\u003Cp>If you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the FD&amp;C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nBrad L. Ridenour\n\nRecipient Title\n\nChief Executive Officer\n\nKoi CBD, LLC\n\n14631 Best Ave\n\nNorwalk, CA 90650\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nWL 651252\n\nDear Mr. Ridenour:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address koicbd.com in June 2023 through July 2023 and has determined that you take orders there for various human products, which you represent as containing Delta-8 tetrahydrocannabinol (THC). FDA also inspected your Koi CBD facility, which distributes human food products containing Delta-8, located at 14631 Best Ave, Norwalk, CA 90650, on December 12-15, 2022.\n\nFDA has determined that your products, Koi brand “Delta 8 Gummies” and Hemp Living brand “Pot Rocks,” are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce adulterated food into interstate commerce under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulationcannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nFDA has observed a proliferation of products containing the cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-knowabout-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products that may pose a serious health risk to consumers.\n\nAdulterated Human Foods\n\nAccording to your product labeling, your Koi brand “Delta 8 Gummies” and Hemp Living brand “Pot Rocks” are foods to which Delta-8 THC has been added.\n\nAs defined in section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the term \"food additive\" refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.1\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThere is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects of Delta-8 THC on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to conventional foods is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your Koi brand “Delta 8 Gummies” and Hemp Living brand “Pot Rocks” are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\n* * *\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n19701 Fairchild\n\nIrvine, CA 92612\n\nRefer to Unique Identification Number 651252 when replying.\n\nIf you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5\n\n_______________________\n\n1 Under section 201(s) of the FD&C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.","Koi CBD, LLC","koi-cbd-llc-651252-07182023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkoi-cbd-llc-651252-07182023","2026-10-26T08:09:09.964243+00:00","2023-07-25","651252","Food & Beverages","Division of Human and Animal Food Operations West V","Brad L. Ridenour","2026-08-20T00:51:42.621+00:00","United Parcel Service","2023-07-18",{"id":78,"raw":79,"subject":12,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":66,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":26,"closeout_date":19,"issuing_office":92,"recipient_name":93,"body_fetched_at":94,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},1836,[80,81,82,83,12,13,13,13],"\u003Ctime datetime=\"2023-09-19T13:20:00Z\">09\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-11T04:00:00Z\">09\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkor-chem-inc-661280-09112023\">Kor-Chem, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John E. Fitzwater\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer, and Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kor-Chem, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5800 Bucknell Drive SW\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Atlanta\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30336-2514\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 9\u002F11\u002F2023\u003C\u002Fp>\n\n\u003Cp>Case #: 661280\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Fitzwater:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility Kor-Chem, Inc., FEI 3000204701, at 5800 Bucknell Drive SW, Atlanta from April 26 to May 5, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We have not received a detailed response from your firm for corrective actions to the specific observations identified during the inspection and cited on our Form FDA 483. However, we note your correspondence dated August 14, 2023, indicating that you are conducting a review of your operations and developing a remedial plan, and that you had “discontinued” your drug products.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures topical over the counter (OTC) hand sanitizer drug products. You also manufacture commercial industrial chemical products on the same manufacturing equipment as your OTC drug products. Labels for some of the industrial chemicals that preceded the manufacture of your hand sanitizer drug products state that they are “Corrosive. Causes irreversible eye damage and skin burns. Harmful if swallowed, inhaled, or absorbed through the skin,” and “Causes severe burns and eye damage.” In addition, your equipment usage logs for the shared tanks lacked documentation of cleaning following the manufacture of batches of industrial chemical non-drug products that preceded the manufacture of batches of hand sanitizer drug products.\u003C\u002Fp>\n\n\u003Cp>It is unacceptable as a matter of CGMP to manufacture drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Confirmation that you will discontinue manufacturing drugs on shared equipment with non-drug products in your facility.\u003C\u002Fp>\n\n\u003Cp>• If you intend to continue manufacturing both pharmaceutical and non- pharmaceutical products at your facility, provide a plan to show how you will maintain dedicated manufacturing equipment and separate manufacturing areas for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>• A risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential cross- contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any products still in distribution, including potential recalls or market withdrawals.\u003C\u002Fp>\n\n\u003Cp>• Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component&nbsp;\u003C\u002Fstrong>\u003Cstrong>supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to conduct an identity test on each lot of the components (i.e., benzalkonium chloride and glycerin) and failed to conduct adequate identity testing of the active ingredient ethanol, used in the manufacture of your hand sanitizer drug products. You also relied on your suppliers’ certificates of analysis (COA) without establishing the reliability of your suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Products Containing Glycerin\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain glycerin. Glycerin, along with other high-risk components, requires identification testing per the United States Pharmacopeia (USP) to ensure that it meets safety limits for diethylene glycol (DEG) or ethylene glycol (EG). Notably, EG is a component in your tire sealant products. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of glycerin used in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fp>\n\n\u003Cp>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fp>\n\n\u003Cp>• The chemical quality control specifications you use to test each incoming lot of high- risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\n\n\u003Cp>• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Products Containing Ethanol\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to test your hand sanitizer drug products for microbiological attributes. Without testing each batch prior to release, you lack scientific evidence that all your drug product batches were free of microbial contamination that is objectionable in view of their intended use.\u003Cbr>\n\u003Cbr>\nIn response to this letter, provide a list of chemical and microbial test methods and specifications used to analyze each lot of your drug products before making a lot disposition decision, and the associated written procedures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacture of your drug products. For example, your QU failed to ensure:\u003C\u002Fp>\n\n\u003Cp>• Validation of drug product manufacturing processes, as well as validation and monitoring of your firm’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system (21 CFR 211.100(a)).\u003C\u002Fp>\n\n\u003Cp>• Validated analytical methods are used for drug product testing (21 CFR 211.160(b)).\u003C\u002Fp>\n\n\u003Cp>• Adherence to an adequate stability program (21 CFR 211.166(a)).\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>• A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fp>\n\n\u003Cp>• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fp>\n\n\u003Cp>• A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fp>\n\n\u003Cp>• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>• Also describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of drugs at this facility. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility in the future. If you plan to resume manufacturing drugs, notify this office prior to resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Registration and Listing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A query of FDA’s drug registration and listing database determined that Kor-Chem, Inc.’s establishment registration is current and is associated with two active drug listings, Instant Hand Sanitizer (62881-001) and Handy San (62881-003). Under section 510(j)(1) of the FD&amp;C Act, 21 U.S.C. 360(j)(1), and 21 CFR 207.41, all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA.\u003C\u002Fp>\n\n\u003Cp>If you discontinue the manufacture of any of your products, you must review and update your drug listing information in June or December after the change, submitting the date you discontinued the manufacture and providing the expiration date of the last lot manufactured, repacked, relabeled, or salvaged (21 CFR 207.57(b)(ii)). Although updates to drug listings are required in June or December after a change to the listed drug occurs (including discontinuation), registrants are encouraged to update listing information as soon as the change occurs (21 CFR 207 207.57(c)). Additionally, if you no longer plan to manufacture drug products for U.S. commercial distribution, FDA requests that you deregister as a drug manufacturing establishment (21 CFR 207.29).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>661280\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, Director, Compliance Branch at ronda-loyd-jones@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Ms. Asente via (504) 846-6104 or Rebecca.asente@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJohn E. Fitzwater\n\nRecipient Title\n\nChief Executive Officer, and Owner\n\nKor-Chem, Inc.\n\n5800 Bucknell Drive SW\n\nAtlanta, GA 30336-2514\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 9\u002F11\u002F2023\n\nCase #: 661280\n\nWARNING LETTER\n\nDear Mr. Fitzwater:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility Kor-Chem, Inc., FEI 3000204701, at 5800 Bucknell Drive SW, Atlanta from April 26 to May 5, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe have not received a detailed response from your firm for corrective actions to the specific observations identified during the inspection and cited on our Form FDA 483. However, we note your correspondence dated August 14, 2023, indicating that you are conducting a review of your operations and developing a remedial plan, and that you had “discontinued” your drug products.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following:\n\n1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYour firm manufactures topical over the counter (OTC) hand sanitizer drug products. You also manufacture commercial industrial chemical products on the same manufacturing equipment as your OTC drug products. Labels for some of the industrial chemicals that preceded the manufacture of your hand sanitizer drug products state that they are “Corrosive. Causes irreversible eye damage and skin burns. Harmful if swallowed, inhaled, or absorbed through the skin,” and “Causes severe burns and eye damage.” In addition, your equipment usage logs for the shared tanks lacked documentation of cleaning following the manufacture of batches of industrial chemical non-drug products that preceded the manufacture of batches of hand sanitizer drug products.\n\nIt is unacceptable as a matter of CGMP to manufacture drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination.\n\nIn response to this letter, provide:\n\n• Confirmation that you will discontinue manufacturing drugs on shared equipment with non-drug products in your facility.\n\n• If you intend to continue manufacturing both pharmaceutical and non- pharmaceutical products at your facility, provide a plan to show how you will maintain dedicated manufacturing equipment and separate manufacturing areas for your pharmaceutical manufacturing and industrial product manufacturing operations.\n\n• A risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential cross- contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any products still in distribution, including potential recalls or market withdrawals.\n\n• Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\n\nYou failed to conduct an identity test on each lot of the components (i.e., benzalkonium chloride and glycerin) and failed to conduct adequate identity testing of the active ingredient ethanol, used in the manufacture of your hand sanitizer drug products. You also relied on your suppliers’ certificates of analysis (COA) without establishing the reliability of your suppliers’ test analyses at appropriate intervals.\n\nProducts Containing Glycerin\n\nYou manufacture drugs that contain glycerin. Glycerin, along with other high-risk components, requires identification testing per the United States Pharmacopeia (USP) to ensure that it meets safety limits for diethylene glycol (DEG) or ethylene glycol (EG). Notably, EG is a component in your tire sealant products. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of glycerin used in the manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\n• The chemical quality control specifications you use to test each incoming lot of high- risk drug components to determine acceptability for use in manufacturing.\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\nProducts Containing Ethanol\n\nYou manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\n3. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nYou failed to test your hand sanitizer drug products for microbiological attributes. Without testing each batch prior to release, you lack scientific evidence that all your drug product batches were free of microbial contamination that is objectionable in view of their intended use.\n\nIn response to this letter, provide a list of chemical and microbial test methods and specifications used to analyze each lot of your drug products before making a lot disposition decision, and the associated written procedures.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacture of your drug products. For example, your QU failed to ensure:\n\n• Validation of drug product manufacturing processes, as well as validation and monitoring of your firm’s (b)(4) water system (21 CFR 211.100(a)).\n\n• Validated analytical methods are used for drug product testing (21 CFR 211.160(b)).\n\n• Adherence to an adequate stability program (21 CFR 211.166(a)).\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\n• A determination of whether procedures used by your firm are robust and appropriate.\n\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\n• A complete and final review of each batch and its related information before the QU disposition decision.\n\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\n• Also describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of drugs at this facility. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility in the future. If you plan to resume manufacturing drugs, notify this office prior to resuming your operations.\n\nDrug Registration and Listing\n\nA query of FDA’s drug registration and listing database determined that Kor-Chem, Inc.’s establishment registration is current and is associated with two active drug listings, Instant Hand Sanitizer (62881-001) and Handy San (62881-003). Under section 510(j)(1) of the FD&C Act, 21 U.S.C. 360(j)(1), and 21 CFR 207.41, all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA.\n\nIf you discontinue the manufacture of any of your products, you must review and update your drug listing information in June or December after the change, submitting the date you discontinued the manufacture and providing the expiration date of the last lot manufactured, repacked, relabeled, or salvaged (21 CFR 207.57(b)(ii)). Although updates to drug listings are required in June or December after a change to the listed drug occurs (including discontinuation), registrants are encouraged to update listing information as soon as the change occurs (21 CFR 207 207.57(c)). Additionally, if you no longer plan to manufacture drug products for U.S. commercial distribution, FDA requests that you deregister as a drug manufacturing establishment (21 CFR 207.29).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 661280.\n\nPlease electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, Director, Compliance Branch at ronda-loyd-jones@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Ms. Asente via (504) 846-6104 or Rebecca.asente@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n______________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Kor-Chem, Inc.","kor-chem-inc-661280-09112023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkor-chem-inc-661280-09112023","2026-10-26T08:09:10.085863+00:00","2023-09-19","661280","Division of Pharmaceutical Quality Operations II","John E. Fitzwater","2026-08-20T00:39:19.537+00:00","2023-09-11",{"id":97,"raw":98,"subject":103,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":108,"fei_number":19,"letter_url":109,"updated_at":110,"action_type":22,"case_status":23,"posted_date":111,"marcs_cms_no":19,"product_type":26,"closeout_date":19,"issuing_office":102,"recipient_name":19,"body_fetched_at":112,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},502,[99,100,101,102,103,13,13,13],"\u003Ctime datetime=\"2025-11-05T05:00:00Z\">11\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-03T05:00:00Z\">11\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmo-korea-11032025\">COSMO KOREA\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u002FMisbranded\u002FBotox","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>COSMO KOREA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 3, 2025\u003C\u002Fp>\u003Cp>COSMO KOREA:\u003C\u002Fp>\u003Cp>This is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.cosmo-korea.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. As discussed below, FDA has observed that www.cosmo-korea.com introduces into interstate commerce unapproved and misbranded injectable botulinum toxin drug products.\u003C\u002Fp>\u003Cp>There are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Accordingly, FDA requests that www.cosmo-korea.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Certain products offered for sale by www.cosmo-korea.com are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&amp;C Act are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>An example of an unapproved botulinum toxin drug product you offer for sale on www.cosmo-korea.com is botulinum toxin type A marketed as “Nabota 200ui”. Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claims “blepharospasm elimination” and “hyperhidrosis elimination” under “Scope of Nabota 200ui”.\u003C\u002Fp>\u003Cp>While there are FDA-approved versions of botulinum toxin drug products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for “Nabota 200ui” offered by www.cosmo-korea.com. Currently there are several botulinum toxin products FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. Examples of FDA-approved botulinum toxin products with a summary of their indications are: BOTOX® (onabotulinumtoxinA), indicated for the treatment of overactive bladder, neurogenic detrusor overactivity, chronic migraine, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, strabismus, and blepharospasm and prophylaxis of headaches in adults with chronic migraines; DAXXIFY® (daxibotulinumtoxinA-lanm), indicated for the temporary improvement in the appearance of glabellar lines and the treatment of cervical dystonia; and MYOBLOC® (rimabotulinumtoxinB), indicated for the treatment of cervical dystonia and chronic sialorrhea.\u003C\u002Fp>\u003Cp>Furthermore, FDA-approved botulinum toxin drug products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of distant spread of toxin effect to produce symptoms consistent with botulinum toxin effects. In addition, swallowing and breathing difficulties can be life threatening and there have been reports of death.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] if its labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fail to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&amp;C Act. In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. By offering these drugs for sale to U.S. consumers, www.cosmo-korea.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>FDA is sending this warning letter to www.cosmo-korea.com because of the inherent risks to consumers who purchase misbranded and unapproved new drugs. This letter is not intended to identify all the ways in which your products or operations might be in violation of the law. It is your responsibility to ensure that all products you offer for sale are in compliance with the FD&amp;C Act and its implementing regulations. You should take prompt action to address any violations of the FD&amp;C Act (which may include the offer for sale of similarly misbranded and\u002For unapproved new drugs other than the drug products noted above). We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a use for which they have not been approved by FDA and that you are not distributing misbranded and unapproved drug products in violation of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction, without further notice. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within 15 working days.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the U.S. Please direct your response and any inquiries to FDA at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002Fs\u002F\u003C\u002Fp>\u003Cp>__________________________________\u003Cbr>Sangeeta Vaswani Chatterjee, Pharm.D.\u003Cbr>Acting Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nCOSMO KOREA\n\nSouth Korea\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nNovember 3, 2025\nCOSMO KOREA:\nThis is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.cosmo-korea.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. As discussed below, FDA has observed that www.cosmo-korea.com introduces into interstate commerce unapproved and misbranded injectable botulinum toxin drug products.\nThere are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Accordingly, FDA requests that www.cosmo-korea.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\nUnapproved New Drugs:\nCertain products offered for sale by www.cosmo-korea.com are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act.\nAn example of an unapproved botulinum toxin drug product you offer for sale on www.cosmo-korea.com is botulinum toxin type A marketed as “Nabota 200ui”. Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claims “blepharospasm elimination” and “hyperhidrosis elimination” under “Scope of Nabota 200ui”.\nWhile there are FDA-approved versions of botulinum toxin drug products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for “Nabota 200ui” offered by www.cosmo-korea.com. Currently there are several botulinum toxin products FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. Examples of FDA-approved botulinum toxin products with a summary of their indications are: BOTOX® (onabotulinumtoxinA), indicated for the treatment of overactive bladder, neurogenic detrusor overactivity, chronic migraine, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, strabismus, and blepharospasm and prophylaxis of headaches in adults with chronic migraines; DAXXIFY® (daxibotulinumtoxinA-lanm), indicated for the temporary improvement in the appearance of glabellar lines and the treatment of cervical dystonia; and MYOBLOC® (rimabotulinumtoxinB), indicated for the treatment of cervical dystonia and chronic sialorrhea.\nFurthermore, FDA-approved botulinum toxin drug products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of distant spread of toxin effect to produce symptoms consistent with botulinum toxin effects. In addition, swallowing and breathing difficulties can be life threatening and there have been reports of death.\nMisbranded Drugs:\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if its labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner.\nBecause the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fail to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, www.cosmo-korea.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nFDA is sending this warning letter to www.cosmo-korea.com because of the inherent risks to consumers who purchase misbranded and unapproved new drugs. This letter is not intended to identify all the ways in which your products or operations might be in violation of the law. It is your responsibility to ensure that all products you offer for sale are in compliance with the FD&C Act and its implementing regulations. You should take prompt action to address any violations of the FD&C Act (which may include the offer for sale of similarly misbranded and\u002For unapproved new drugs other than the drug products noted above). We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a use for which they have not been approved by FDA and that you are not distributing misbranded and unapproved drug products in violation of the FD&C Act.\nPlease notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction, without further notice. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days.\nIf you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the U.S. Please direct your response and any inquiries to FDA at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.\nSincerely,\n\u002Fs\u002F\n__________________________________\nSangeeta Vaswani Chatterjee, Pharm.D.\nActing Director\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research","COSMO KOREA","cosmo-korea-11032025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmo-korea-11032025","2026-10-26T08:08:18.680125+00:00","2025-11-05","2026-08-19T16:10:22.166+00:00","2025-11-03",{"id":115,"raw":116,"subject":121,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":66,"fei_number":19,"letter_url":127,"updated_at":128,"action_type":22,"case_status":47,"posted_date":129,"marcs_cms_no":130,"product_type":71,"closeout_date":131,"issuing_office":132,"recipient_name":133,"body_fetched_at":134,"delivery_method":135,"recipient_title":19,"reference_number":19,"action_taken_date":136,"medical_device_id":19,"response_letter_date":19},1501,[117,118,119,120,121,13,122,13],"\u003Ctime datetime=\"2024-04-30T13:20:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-08T05:00:00Z\">01\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkorean-food-inc-669241-01082024\">Korean Food, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations West III","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkorean-food-inc-669241-09232024\">\u003Ctime datetime=\"2024-09-27T04:00:00Z\">09\u002F27\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Overnight\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Sung Hee Pak\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Korean Food, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1311 Luke St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irving\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75061\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 8, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS #669241\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Pak:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your sprout and kimchi production facility located at 1311 Luke St, Irving, Texas on August 21 through August 25, 2023. Our inspection revealed serious violations of the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption, Title 21, Code of Federal Regulations, Part 112 (21 CFR Part 112) (Produce Safety Rule) (PSR), specifically Subpart M – Sprouts, and the Food Labeling regulation, Title 21, Code of Federal Regulations, Part 101 (21 CFR Part 101).\u003C\u002Fp>\n\n\u003Cp>Based on our inspectional findings and a subsequent review of your product labels collected during the inspection, we have determined that the soybean sprouts grown in your operation are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC § 342(a)(4)], in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. Additionally, the labeling for the kimchi products manufactured in your facility are misbranded within the meaning of Section 403 of the Act [21 U.S.C. § 343(a)(1)]. Failure to comply with the PSR is a prohibited act under section 301(vv) of the Act [21 U.S.C. § 331(vv)]. You may find the Act and its implementing regulations through internet links on FDA's home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of our inspection, we to issued you a Form FDA 483, Inspectional Observations, listing observations found during our inspection. We received your responses via email on August 26, 2023; September 6, 2023; September 18, 2023; September 22, 2023; and September 24, 2023. We address your responses below.\u003Cbr>\n\u003Cbr>\n\u003Cu>\u003Cstrong>Produce Safety Rule Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>During the inspection, our investigator observed the following significant violations of the PSR, 21 CFR Part 112:\u003C\u002Fp>\n\n\u003Cp>1. You did not establish and implement a written environmental monitoring plan that is designed to identify \u003Cem>Listeria\u003C\u002Fem> species or \u003Cem>Listeria monocytogenes\u003C\u002Fem> if it is present in your growing, harvesting, packing, and holding environment in accordance with the requirements of 21 CFR 112.145. During our inspection, our investigator found that you have not established a written environmental monitoring plan, and do not conduct any testing for \u003Cem>Listeria\u003C\u002Fem> species or \u003Cem>Listeria monocytogenes\u003C\u002Fem> in your growing, harvesting, packing, and holding environment. You stated that you were not aware of the requirement, and, to the best of your knowledge, you have never conducted environmental sampling in your operation’s history.\u003C\u002Fp>\n\n\u003Cp>In your written response dated August 26, 2023, you stated you will conduct environmental testing and have a written record \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In your supplemental written response dated September 22, 2023, you provided a laboratory testing result. This testing result was for one sponge swab, taken from an operation table, which was analyzed for \u003Cem>Listeria\u003C\u002Fem>, and the result of that analysis was negative. The Produce Safety Rule requires environmental swabs to be collected from both food-contact and non‐food‐contact surfaces (21 CFR 112.145(c)(3)). Your written responses are not adequate to address this violation in that you have not provided any documentation related to your establishment and implementation of a written environmental monitoring plan that meets the requirements of 21 CFR 112.145.\u003C\u002Fp>\n\n\u003Cp>2. You did not establish and implement a written sampling plan that identifies the number and location of samples (of spent sprout irrigation water (SSIW) or sprouts) to be collected for each production batch of sprouts to ensure that the collected samples are representative of the production batch when testing for contamination as specified in 21 CFR 112.147 and in accordance with 21 CFR 112.144(b). Production batch of sprouts means all sprouts that are started at the same time in a single growing unit. 21 CFR 112.3. You routinely plant soybean sprouts&nbsp;&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and you stated that you harvest sprouts after approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Each planting would be, at a minimum, one production batch of sprouts. However, you only test SSIW \u003Cstrong>(b)(4)\u003C\u002Fstrong> from a randomly selected batch. This is insufficient to ensure that representative samples of SSIW are collected for each production batch of sprouts.\u003C\u002Fp>\n\n\u003Cp>In your written response dated August 26, 2023, you stated that you will talk to the lab and see if you can arrange \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing schedule. In your supplemental written response dated September 22, 2023, you provided a laboratory testing result. This testing result was for a sample identified as “Sprout Water Pulled Out Today At 8 AM”, which was tested for \u003Cem>Listeria monocytogene\u003C\u002Fem>s and \u003Cem>Salmonella\u003C\u002Fem>. The testing results were negative for both pathogens. This sample was not analyzed for E. coli O157:H7 as required under 21 CFR 112.144(b), and the documentation did not identify a specific production batch of sprouts from which the sample was collected. Your written responses are not adequate to address this violation in that none of your written responses included documentation related to your establishment and implementation of a written sampling plan for collecting and testing SSIW or sprouts to meet the requirements of 21 CFR 112.147.\u003C\u002Fp>\n\n\u003Cp>3. You did not clean and sanitize food contact surfaces used to grow sprouts before contact with sprouts or seeds for sprouting, as required by 21 CFR 112.143(b). Food contact surfaces means those surfaces that contact human food and those surfaces from which drainage, or other transfer, onto the food or onto surfaces that contact the food ordinarily occurs during the normal course of operations. Food contact surfaces include equipment and tools used during harvest, packing, and holding (See 21 CFR 112.3).\u003C\u002Fp>\n\n\u003Cp>During your facility’s cleaning operation, our investigator observed the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An employee sprayed a \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid on the sprout washer and spinner that was not properly cleaned, as evidenced by soil on the equipment. You identified this liquid as a sanitizer. Cleaning must be done before sanitizing because sanitizing is generally not effective unless the surface is cleaned first. In addition, you did not know what the \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid was or the directions for use, as you had discarded the original container.\u003C\u002Fli>\n\t\u003Cli>Black organic residues present on the exit panel of the sprout washer and on the lid edge of the sprout spinner. Sprouts were observed touching these areas during the washing and \u003Cstrong>(b)(4)\u003C\u002Fstrong>‐drying processes.\u003C\u002Fli>\n\t\u003Cli>The sprout irrigation machine was covered with foil that was torn and soiled with a black\u002Fbrown residue in growing room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Soybean sprouts were observed growing in \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>underneath this foil, and water was observed dripping from the irrigation machine.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your written response dated August 26, 2023, you stated that you will write down the cleaning and sanitation procedures. You stated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid sanitizer has been discontinued, you have replaced it with something else, and will use it to the proper dilution. You stated that the edge of the sprout spinner has been cleaned thoroughly and the irrigation machine will be regularly repaired, cleaned, and sanitized.\u003C\u002Fp>\n\n\u003Cp>In your written response dated September 6, 2023, you provided a written cleaning procedure and a photograph of the sprout washer, which you identified as having been cleaned with soap and sanitized. To date, you have not provided documentation demonstrating corrective action taken to address the condition of the sprout irrigation machine. We reviewed your responses and are unable to assess the adequacy of your responses. We will evaluate the adequacy of your corrective action in the next inspection.\u003C\u002Fp>\n\n\u003Cp>4. You did not provide adequate drainage in all areas where normal operations release or discharge water or other liquid waste on the ground or floor of the building, as required by 21 CFR 112.126(a)(2). \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for collecting soybean sprouts were stored on a low‐lying shelf\u002Frack over a clogged drain near the sprout washer. Water from the sprout washer, the hand sink in the production area, and the hose that employees were observed to use to wash their hands, was observed to discharge directly onto this floor. Water from these sources pools on the floor contacting the bottom of \u003Cstrong>(b)(4)\u003C\u002Fstrong> holding sprouts and is splashed into the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>holding sprouts while employees walk around. Additionally, the floor of the production area is not maintained in accordance with 21 CFR 112.126(a)(1), in that it is a rough, pitted, unsealed surface. The floor is not able to be adequately cleaned and sanitized.\u003C\u002Fp>\n\n\u003Cp>In your written response dated August 26, 2023, you stated that you moved the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a high shelf and will retrain your staff on hand hygiene. In your written response dated September 6, 2023, you provided photographs of taller racks. In addition, you provided written procedures for cleaning and sanitizing, employee health and hygiene, personnel requirements, and hand washing, which you stated you would have your employees read. You have not included, as a part of your response, a corrective action that addresses the clogged drain or pooling water on the production floor. Furthermore, your responses do not provide a corrective action to addresses the discharge of water from the handwashing sink onto your production room floor, which affects equipment and tools that you store close to the floor. We will evaluate the adequacy of your corrective action in the next inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>1. The GO‐HYANG MAK KIMCHI, 16 oz., 32 oz., ½ Gallon, and 1 Gallon container sizes, and the Radish Leaves Kimchi products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product labels fail to declare the major food allergen, sand lance and, seasonally, wheat, as required by section 403(w)(1) of the Act.\u003C\u002Fp>\n\n\u003Cp>Section 201(qq) of the Act [21 U.S.C. § 321(qq)], defines milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybeans, and sesame, as well as any food ingredient that contains protein derived from one of these foods, with the exception of highly refined oils as major food allergens. A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The word Contains followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\u003C\u002Fli>\n\t\u003Cli>The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., Whey (Milk)), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Specifically, during the inspection, investigators were told that Salted Anchovy was listed as an ingredient from “Sand Lance Fish Sauce”; however, the “Sand Lance Fish Sauce” ingredient does not contain anchovies and you fail to declare the sand lance ingredient on the finished product labels. Further, you mention that you sometimes use Oyster Sauce as an ingredient, which is made with the major food allergen, wheat. However, your labels declare oyster sauce, but fail to declare the wheat ingredient.\u003Cbr>\n\u003Cbr>\n2. The GO‐HYANG MAK KIMCHI and Radish Leaves Kimchi products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] because the labels for the 16 oz., 32 oz., ½ Gallon, and 1 Gallon container sizes:\u003C\u002Fp>\n\n\u003Cp>a. When the kimchi products do have oyster sauce as an ingredient, then the sub‐ingredients of the oyster sauce must be declared in accordance with 21 CFR 101.4(b)(2). According to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or sub‐ingredients) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient [21 CFR 101.4(b)(2)(i)], or by listing the component ingredients without listing the ingredient itself [21 CFR 101.4(b)(2)(ii)]. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi‐component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\u003Cbr>\nb. For the 32 oz. Go‐Hyang Mak Kimchi and for the Radish Leaves Kimchi, the labels declare the ingredient “M.S.G.” In accordance with 21 CFR 101.22(h)(5), any monosodium glutamate used as an ingredient in food must be declared by its common or usual name, monosodium glutamate.\u003Cbr>\nc. The Radish Leaves Kimchi product does not list radish leaves as part of its ingredient, as required by 21 CFR 101.4(a).\u003Cbr>\nd. The oyster sauce and salted anchovies must be declared only when they are added as ingredients.\u003C\u002Fp>\n\n\u003Cp>3. The GO‐HYANG MAK KIMCHI and Radish Leaves Kimchi products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. § 343(q)] because each label fails to declare:\u003C\u002Fp>\n\n\u003Cp>a. The correct number of servings per container in accordance with 21 CFR 101.9(b)(8). The number of servings must be calculated from the serving size and the total contents of the package. The labels for the GO‐HYANG MAK KIMCHI products list 10 servings per container for all sizes of product while Radish Leaves Kimchi lists 22 servings per container. The serving size on each product is 30 g which is 300 grams (30g multiplied by 10 servings) or approximately 10.5 ounces for the GO‐HYANG MAK KIMCHI product and 660 grams (30g multiplied by 22 servings) or approximately 23 ounces for the Radish Leaves Kimchi product. Therefore, none of the labels list the correct number of servings per container.\u003Cbr>\nb. The serving size is not expressed in a common household measure that is appropriate to the food, as required by 21 CFR 101.9(b)(1).\u003Cbr>\nc. The nutrients using the format and nutrients required to be declared in accordance with 21 CFR 101.9(c) and (d). For example, the nutrition facts information is not in the current format and therefore does not declare all of the required nutrients, vitamins and minerals, their quantitative amounts, and the correct footnote.\u003C\u002Fp>\n\n\u003Cp>4. Your GO‐HYANG MAK KIMCHI and Radish Leaves Kimchi products are misbranded within the meaning of section 403(f) of the Act [21 U.S.C. §343(f)] because:\u003C\u002Fp>\n\n\u003Cp>a. The GO‐HYANG MAK KIMCHI product label contains information in a foreign language; therefore, all required information must be in both languages (i.e., the English language as well as the foreign language). For example, the Nutrition Facts label must be declared in both the foreign language and English as required by 21 CFR 101.15(c)(2).\u003Cbr>\nb. Your Radish Leaves Kimchi product label fails to list all required statements in English as required by 21 CFR 101.15(c)(1).\u003C\u002Fp>\n\n\u003Cp>5. Your Radish Leaves Kimchi products are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. §343(e)(2)] because:\u003C\u002Fp>\n\n\u003Cp>a. 21 CFR 101.7 does not provide for the use of check boxes for different net quantity of contents statement.\u003Cbr>\nb. 21 CFR 101.7(f) requires that it must appear as a distinct item on the principal display panel and be placed within the bottom 30 percent of the area of the label panel in lines generally parallel to the base on which the package rests as it is designed to be displayed.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all‐inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comments regarding the labeling of your products:\u003C\u002Fp>\n\n\u003Cp>1. Your GO‐HYANG MAK KIMCHI product labels include the following statement: “ALLERGEN INFORMATION CONTAINS SHRIMP &amp; SHELLFISH.” If this statement is intended to be advisory in nature, then it must be truthful and not misleading to the consumer. If this statement is intended to be the “Contains” statement provided for in section 403(w) of the Act, we advise you that:\u003Cbr>\n• Only “Contains” is the acceptable statement phrase.\u003Cbr>\n• You must list all of the major food allergens present in the product.\u003Cbr>\n• You must list the major food allergen or the source of the major food allergen by the common or usual name of the source ingredient or if it is a fish, the actual type of fish. For example, you may not call or list the major food allergen as “fish” but must state “sand lance.”\u003Cbr>\n• It must appear on the label immediately after or adjacent to, and in the same type (i.e., print or font) size as that used for the ingredient list.\u003C\u002Fp>\n\n\u003Cp>2. The GO‐HYANG MAK KIMCHI product label fails to bear an accurate statement of the net quantity of contents within the bottom 30 percent of the area of the label panel, as required by 21 CFR 101.7(f).\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to René R. Ramirez, Compliance Officer, U.S. Food and Drug Administration, 1201 North Main Street, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Ramirez at rene.ramirez@fda.hhs.gov or (210) 308‐1425.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Edmundo Garcia, Jr.\u003Cbr>\nProgram Division Director HAF West 3\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Texas Department of State Health Services\u003Cbr>\nLori Woznicki, M.P.H.\u003Cbr>\nFood and Drug Inspections Branch Manager\u003Cbr>\n1100 West 49th Street\u003Cbr>\nAustin, TX 78756\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Overnight\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Sung Hee Pak\n\nRecipient Title\n\nOwner\n\nKorean Food, Inc.\n\n1311 Luke St\n\nIrving, TX 75061\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West III\n\nUnited States\n\nJanuary 8, 2024\n\nWARNING LETTER\n\nCMS #669241\n\nDear Ms. Pak:\n\nThe U.S. Food and Drug Administration (FDA) inspected your sprout and kimchi production facility located at 1311 Luke St, Irving, Texas on August 21 through August 25, 2023. Our inspection revealed serious violations of the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption, Title 21, Code of Federal Regulations, Part 112 (21 CFR Part 112) (Produce Safety Rule) (PSR), specifically Subpart M – Sprouts, and the Food Labeling regulation, Title 21, Code of Federal Regulations, Part 101 (21 CFR Part 101).\n\nBased on our inspectional findings and a subsequent review of your product labels collected during the inspection, we have determined that the soybean sprouts grown in your operation are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC § 342(a)(4)], in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. Additionally, the labeling for the kimchi products manufactured in your facility are misbranded within the meaning of Section 403 of the Act [21 U.S.C. § 343(a)(1)]. Failure to comply with the PSR is a prohibited act under section 301(vv) of the Act [21 U.S.C. § 331(vv)]. You may find the Act and its implementing regulations through internet links on FDA's home page at http:\u002F\u002Fwww.fda.gov.\n\nAt the conclusion of our inspection, we to issued you a Form FDA 483, Inspectional Observations, listing observations found during our inspection. We received your responses via email on August 26, 2023; September 6, 2023; September 18, 2023; September 22, 2023; and September 24, 2023. We address your responses below.\n\nProduce Safety Rule Violations\n\nDuring the inspection, our investigator observed the following significant violations of the PSR, 21 CFR Part 112:\n\n1. You did not establish and implement a written environmental monitoring plan that is designed to identify Listeria species or Listeria monocytogenes if it is present in your growing, harvesting, packing, and holding environment in accordance with the requirements of 21 CFR 112.145. During our inspection, our investigator found that you have not established a written environmental monitoring plan, and do not conduct any testing for Listeria species or Listeria monocytogenes in your growing, harvesting, packing, and holding environment. You stated that you were not aware of the requirement, and, to the best of your knowledge, you have never conducted environmental sampling in your operation’s history.\n\nIn your written response dated August 26, 2023, you stated you will conduct environmental testing and have a written record (b)(4). In your supplemental written response dated September 22, 2023, you provided a laboratory testing result. This testing result was for one sponge swab, taken from an operation table, which was analyzed for Listeria, and the result of that analysis was negative. The Produce Safety Rule requires environmental swabs to be collected from both food-contact and non‐food‐contact surfaces (21 CFR 112.145(c)(3)). Your written responses are not adequate to address this violation in that you have not provided any documentation related to your establishment and implementation of a written environmental monitoring plan that meets the requirements of 21 CFR 112.145.\n\n2. You did not establish and implement a written sampling plan that identifies the number and location of samples (of spent sprout irrigation water (SSIW) or sprouts) to be collected for each production batch of sprouts to ensure that the collected samples are representative of the production batch when testing for contamination as specified in 21 CFR 112.147 and in accordance with 21 CFR 112.144(b). Production batch of sprouts means all sprouts that are started at the same time in a single growing unit. 21 CFR 112.3. You routinely plant soybean sprouts (b)(4), and you stated that you harvest sprouts after approximately (b)(4). Each planting would be, at a minimum, one production batch of sprouts. However, you only test SSIW (b)(4) from a randomly selected batch. This is insufficient to ensure that representative samples of SSIW are collected for each production batch of sprouts.\n\nIn your written response dated August 26, 2023, you stated that you will talk to the lab and see if you can arrange (b)(4) testing schedule. In your supplemental written response dated September 22, 2023, you provided a laboratory testing result. This testing result was for a sample identified as “Sprout Water Pulled Out Today At 8 AM”, which was tested for Listeria monocytogenes and Salmonella. The testing results were negative for both pathogens. This sample was not analyzed for E. coli O157:H7 as required under 21 CFR 112.144(b), and the documentation did not identify a specific production batch of sprouts from which the sample was collected. Your written responses are not adequate to address this violation in that none of your written responses included documentation related to your establishment and implementation of a written sampling plan for collecting and testing SSIW or sprouts to meet the requirements of 21 CFR 112.147.\n\n3. You did not clean and sanitize food contact surfaces used to grow sprouts before contact with sprouts or seeds for sprouting, as required by 21 CFR 112.143(b). Food contact surfaces means those surfaces that contact human food and those surfaces from which drainage, or other transfer, onto the food or onto surfaces that contact the food ordinarily occurs during the normal course of operations. Food contact surfaces include equipment and tools used during harvest, packing, and holding (See 21 CFR 112.3).\n\nDuring your facility’s cleaning operation, our investigator observed the following:\n\nAn employee sprayed a (b)(4) liquid on the sprout washer and spinner that was not properly cleaned, as evidenced by soil on the equipment. You identified this liquid as a sanitizer. Cleaning must be done before sanitizing because sanitizing is generally not effective unless the surface is cleaned first. In addition, you did not know what the (b)(4) liquid was or the directions for use, as you had discarded the original container.\n\nBlack organic residues present on the exit panel of the sprout washer and on the lid edge of the sprout spinner. Sprouts were observed touching these areas during the washing and (b)(4)‐drying processes.\n\nThe sprout irrigation machine was covered with foil that was torn and soiled with a black\u002Fbrown residue in growing room (b)(4). Soybean sprouts were observed growing in (b)(4) underneath this foil, and water was observed dripping from the irrigation machine.\n\nIn your written response dated August 26, 2023, you stated that you will write down the cleaning and sanitation procedures. You stated that the (b)(4) liquid sanitizer has been discontinued, you have replaced it with something else, and will use it to the proper dilution. You stated that the edge of the sprout spinner has been cleaned thoroughly and the irrigation machine will be regularly repaired, cleaned, and sanitized.\n\nIn your written response dated September 6, 2023, you provided a written cleaning procedure and a photograph of the sprout washer, which you identified as having been cleaned with soap and sanitized. To date, you have not provided documentation demonstrating corrective action taken to address the condition of the sprout irrigation machine. We reviewed your responses and are unable to assess the adequacy of your responses. We will evaluate the adequacy of your corrective action in the next inspection.\n\n4. You did not provide adequate drainage in all areas where normal operations release or discharge water or other liquid waste on the ground or floor of the building, as required by 21 CFR 112.126(a)(2). (b)(4) used for collecting soybean sprouts were stored on a low‐lying shelf\u002Frack over a clogged drain near the sprout washer. Water from the sprout washer, the hand sink in the production area, and the hose that employees were observed to use to wash their hands, was observed to discharge directly onto this floor. Water from these sources pools on the floor contacting the bottom of (b)(4) holding sprouts and is splashed into the (b)(4) holding sprouts while employees walk around. Additionally, the floor of the production area is not maintained in accordance with 21 CFR 112.126(a)(1), in that it is a rough, pitted, unsealed surface. The floor is not able to be adequately cleaned and sanitized.\n\nIn your written response dated August 26, 2023, you stated that you moved the (b)(4) to a high shelf and will retrain your staff on hand hygiene. In your written response dated September 6, 2023, you provided photographs of taller racks. In addition, you provided written procedures for cleaning and sanitizing, employee health and hygiene, personnel requirements, and hand washing, which you stated you would have your employees read. You have not included, as a part of your response, a corrective action that addresses the clogged drain or pooling water on the production floor. Furthermore, your responses do not provide a corrective action to addresses the discharge of water from the handwashing sink onto your production room floor, which affects equipment and tools that you store close to the floor. We will evaluate the adequacy of your corrective action in the next inspection.\n\nMisbranding Violations\n\n1. The GO‐HYANG MAK KIMCHI, 16 oz., 32 oz., ½ Gallon, and 1 Gallon container sizes, and the Radish Leaves Kimchi products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product labels fail to declare the major food allergen, sand lance and, seasonally, wheat, as required by section 403(w)(1) of the Act.\n\nSection 201(qq) of the Act [21 U.S.C. § 321(qq)], defines milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybeans, and sesame, as well as any food ingredient that contains protein derived from one of these foods, with the exception of highly refined oils as major food allergens. A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\n\nThe word Contains followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\n\nThe common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., Whey (Milk)), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\n\nSpecifically, during the inspection, investigators were told that Salted Anchovy was listed as an ingredient from “Sand Lance Fish Sauce”; however, the “Sand Lance Fish Sauce” ingredient does not contain anchovies and you fail to declare the sand lance ingredient on the finished product labels. Further, you mention that you sometimes use Oyster Sauce as an ingredient, which is made with the major food allergen, wheat. However, your labels declare oyster sauce, but fail to declare the wheat ingredient.\n\n2. The GO‐HYANG MAK KIMCHI and Radish Leaves Kimchi products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] because the labels for the 16 oz., 32 oz., ½ Gallon, and 1 Gallon container sizes:\n\na. When the kimchi products do have oyster sauce as an ingredient, then the sub‐ingredients of the oyster sauce must be declared in accordance with 21 CFR 101.4(b)(2). According to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or sub‐ingredients) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient [21 CFR 101.4(b)(2)(i)], or by listing the component ingredients without listing the ingredient itself [21 CFR 101.4(b)(2)(ii)]. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi‐component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\n\nb. For the 32 oz. Go‐Hyang Mak Kimchi and for the Radish Leaves Kimchi, the labels declare the ingredient “M.S.G.” In accordance with 21 CFR 101.22(h)(5), any monosodium glutamate used as an ingredient in food must be declared by its common or usual name, monosodium glutamate.\n\nc. The Radish Leaves Kimchi product does not list radish leaves as part of its ingredient, as required by 21 CFR 101.4(a).\n\nd. The oyster sauce and salted anchovies must be declared only when they are added as ingredients.\n\n3. The GO‐HYANG MAK KIMCHI and Radish Leaves Kimchi products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. § 343(q)] because each label fails to declare:\n\na. The correct number of servings per container in accordance with 21 CFR 101.9(b)(8). The number of servings must be calculated from the serving size and the total contents of the package. The labels for the GO‐HYANG MAK KIMCHI products list 10 servings per container for all sizes of product while Radish Leaves Kimchi lists 22 servings per container. The serving size on each product is 30 g which is 300 grams (30g multiplied by 10 servings) or approximately 10.5 ounces for the GO‐HYANG MAK KIMCHI product and 660 grams (30g multiplied by 22 servings) or approximately 23 ounces for the Radish Leaves Kimchi product. Therefore, none of the labels list the correct number of servings per container.\n\nb. The serving size is not expressed in a common household measure that is appropriate to the food, as required by 21 CFR 101.9(b)(1).\n\nc. The nutrients using the format and nutrients required to be declared in accordance with 21 CFR 101.9(c) and (d). For example, the nutrition facts information is not in the current format and therefore does not declare all of the required nutrients, vitamins and minerals, their quantitative amounts, and the correct footnote.\n\n4. Your GO‐HYANG MAK KIMCHI and Radish Leaves Kimchi products are misbranded within the meaning of section 403(f) of the Act [21 U.S.C. §343(f)] because:\n\na. The GO‐HYANG MAK KIMCHI product label contains information in a foreign language; therefore, all required information must be in both languages (i.e., the English language as well as the foreign language). For example, the Nutrition Facts label must be declared in both the foreign language and English as required by 21 CFR 101.15(c)(2).\n\nb. Your Radish Leaves Kimchi product label fails to list all required statements in English as required by 21 CFR 101.15(c)(1).\n\n5. Your Radish Leaves Kimchi products are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. §343(e)(2)] because:\n\na. 21 CFR 101.7 does not provide for the use of check boxes for different net quantity of contents statement.\n\nb. 21 CFR 101.7(f) requires that it must appear as a distinct item on the principal display panel and be placed within the bottom 30 percent of the area of the label panel in lines generally parallel to the base on which the package rests as it is designed to be displayed.\n\nThis letter is not intended to be an all‐inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe also offer the following comments regarding the labeling of your products:\n\n1. Your GO‐HYANG MAK KIMCHI product labels include the following statement: “ALLERGEN INFORMATION CONTAINS SHRIMP & SHELLFISH.” If this statement is intended to be advisory in nature, then it must be truthful and not misleading to the consumer. If this statement is intended to be the “Contains” statement provided for in section 403(w) of the Act, we advise you that:\n\n• Only “Contains” is the acceptable statement phrase.\n\n• You must list all of the major food allergens present in the product.\n\n• You must list the major food allergen or the source of the major food allergen by the common or usual name of the source ingredient or if it is a fish, the actual type of fish. For example, you may not call or list the major food allergen as “fish” but must state “sand lance.”\n\n• It must appear on the label immediately after or adjacent to, and in the same type (i.e., print or font) size as that used for the ingredient list.\n\n2. The GO‐HYANG MAK KIMCHI product label fails to bear an accurate statement of the net quantity of contents within the bottom 30 percent of the area of the label panel, as required by 21 CFR 101.7(f).\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to René R. Ramirez, Compliance Officer, U.S. Food and Drug Administration, 1201 North Main Street, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Ramirez at rene.ramirez@fda.hhs.gov or (210) 308‐1425.\n\nSincerely,\n\n\u002FS\u002F\n\nEdmundo Garcia, Jr.\n\nProgram Division Director HAF West 3\n\nCc:\n\nTexas Department of State Health Services\n\nLori Woznicki, M.P.H.\n\nFood and Drug Inspections Branch Manager\n\n1100 West 49th Street\n\nAustin, TX 78756","Korean Food, Inc.","korean-food-inc-669241-01082024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkorean-food-inc-669241-01082024","2026-10-26T08:09:10.177186+00:00","2024-04-30","669241","2024-09-27","Division of Human and Animal Food Operations West III","Ms. Sung Hee Pak","2026-08-20T00:09:23.033+00:00","UPS Overnight","2024-01-08",{"id":138,"raw":139,"subject":144,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":149,"fei_number":19,"letter_url":150,"updated_at":151,"action_type":22,"case_status":23,"posted_date":152,"marcs_cms_no":153,"product_type":71,"closeout_date":19,"issuing_office":154,"recipient_name":155,"body_fetched_at":156,"delivery_method":157,"recipient_title":19,"reference_number":19,"action_taken_date":158,"medical_device_id":19,"response_letter_date":19},2710,[140,141,142,143,144,13,13,13],"\u003Ctime datetime=\"2022-05-03T13:20:00Z\">05\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-14T04:00:00Z\">04\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsco-koladen-llc-629661-04142022\">SCO Koladen LLC\u003C\u002Fa>","West Coast Import District Compliance Branch - Team 2 (WCID-CB) ","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wolfgang P. Steitz\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FManager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SCO Koladen LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>751 N Canyons Pkwy\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Livermore\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94551-9479\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>West Coast Import District Compliance Branch - Team 2 (WCID-CB) \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 14, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 629661\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wolfgang P. Steitz:\u003C\u002Fp>\n\n\u003Cp>On December 1 to December 7, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of SCO Koladen LLC located at 751 N Canyons Pkwy, Livermore, CA 94551-9479. We also conducted an inspection on June 21 to June 24, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplierverification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplierverification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your email response dated December 20, 2021 to the Form FDA 483a in which you indicated that you would develop and implement an FSVP on or before March 11, 2022. However, we are unable to evaluate the adequacy of your response because to date you have not provided FSVP records or additional information regarding your corrections.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the foods you import, including:\u003C\u002Fp>\n\n\u003Cp>• \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Milk Chocolate with Almonds imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n• \u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n• Advent Calendar with chocolate pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection you provided three documents which you obtained from your foreign suppliers: a “FSMA” document for \u003Cstrong>(b)(4)\u003C\u002Fstrong>; an Audit Report for \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and a Food Safety Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the documents that are relevant to an FSVP are incomplete, and you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Lin Liu, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Mr. Lin Liu via email at lin.liu@fda.hhs.gov. Please reference CMS # 629661 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nWolfgang P. Steitz\n\nRecipient Title\n\nOwner\u002FManager\n\nSCO Koladen LLC\n\n751 N Canyons Pkwy\n\nLivermore, CA 94551-9479\n\nUnited States\n\nIssuing Office:\n\nWest Coast Import District Compliance Branch - Team 2 (WCID-CB)\n\nUnited States\n\nApril 14, 2022\n\nWARNING LETTER\n\nRe: CMS # 629661\n\nDear Mr. Wolfgang P. Steitz:\n\nOn December 1 to December 7, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of SCO Koladen LLC located at 751 N Canyons Pkwy, Livermore, CA 94551-9479. We also conducted an inspection on June 21 to June 24, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplierverification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\n\nWe acknowledge receipt of your email response dated December 20, 2021 to the Form FDA 483a in which you indicated that you would develop and implement an FSVP on or before March 11, 2022. However, we are unable to evaluate the adequacy of your response because to date you have not provided FSVP records or additional information regarding your corrections.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the foods you import, including:\n\n• (b)(4) Milk Chocolate with Almonds imported from (b)(4), located in (b)(4)\n\n• (b)(4) imported from (b)(4), located in (b)(4)\n\n• Advent Calendar with chocolate pieces imported from (b)(4), located in (b)(4)\n\nDuring our inspection you provided three documents which you obtained from your foreign suppliers: a “FSMA” document for (b)(4); an Audit Report for (b)(4); and a Food Safety Plan for (b)(4). However, the documents that are relevant to an FSVP are incomplete, and you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Lin Liu, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Mr. Lin Liu via email at lin.liu@fda.hhs.gov. Please reference CMS # 629661 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","SCO Koladen LLC","sco-koladen-llc-629661-04142022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsco-koladen-llc-629661-04142022","2026-10-26T08:09:54.632239+00:00","2022-05-03","629661","West Coast Import District Compliance Branch - Team 2 (WCID-CB)","Wolfgang P. Steitz","2026-08-20T01:57:48.885+00:00","Via Express Delivery","2022-04-14",{"id":160,"raw":161,"subject":166,"body_html":167,"body_text":168,"firm_name":169,"letter_id":170,"created_at":149,"fei_number":19,"letter_url":171,"updated_at":172,"action_type":22,"case_status":23,"posted_date":173,"marcs_cms_no":174,"product_type":26,"closeout_date":19,"issuing_office":165,"recipient_name":175,"body_fetched_at":176,"delivery_method":177,"recipient_title":19,"reference_number":19,"action_taken_date":178,"medical_device_id":19,"response_letter_date":19},2609,[162,163,164,165,166,13,13,13],"\u003Ctime datetime=\"2022-06-28T13:20:00Z\">06\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-22T04:00:00Z\">06\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmirfeel-korea-co-ltd-627401-06222022\">Mirfeel Korea Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Moon Su Eun\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mirfeel Korea Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>77 Hwanggeum-ro 323 beon-gil\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yangchon-eup\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gimpo-si\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gyeonggi-do\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>10049\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-22-16\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 22, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Eun:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the U.S. Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). FDA conducted testing of a consumer hand sanitizer drug product, labeled as MOISTURIZING HAND SANITIZER Peppermint Scented. This drug product was manufactured at your facility, Mirfeel Korea Co., Ltd., FEI 3016921925, 77 Hwanggeum-ro 323 beon-gil, Yangchon-eup, Gimpo, Gyeonggi- do, Republic of Korea, and distributed in the U.S.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of this product in U.S. distribution demonstrate that this drug product manufactured at your facility is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) (21 U.S.C. 351(a)(2)(B))\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, in that contamination with the impurity benzene at unacceptable levels demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>Additionally, FDA has reviewed the records you submitted in response to our initial August 3, 2021 request for records and other information, and subsequent correspondence, pursuant to section 704(a)(4) of the FD&amp;C Act for your facility. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>This warning letter also summarizes significant violations of CGMP regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>In addition, your MOISTURIZING HAND SANITIZER product line packaged in 1.01 ounce containers\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that resemble food pouches customarily purchased by U.S. consumers are misbranded under section 502(i) of the FD&amp;C Act (21 U.S.C. 352(i)). In this letter, we collectively refer to these products as “MOISTURIZING HAND SANITIZERS.” Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>MOISTURIZING HAND SANITIZER Peppermint Scented was manufactured at your facility. FDA laboratory testing of a batch of this product in U.S. distribution found that the drug product contained impurities at unacceptable levels. Benzene impurity levels were found to be between 5 parts per million (ppm) to 6 ppm.\u003C\u002Fp>\n\n\u003Cp>Manufacturers should not use benzene in the manufacture of drugs because it is a known human carcinogen that causes leukemia and other blood disorders. FDA has alerted all drug manufacturers to the known risk factors for contamination with benzene. For more information see \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>On February 10, 2022, FDA held a teleconference with you. We recommended you consider removing the adulterated batch of MOISTURIZING HAND SANITIZER Peppermint Scented drug product currently in distribution from the U.S. market. We also requested that you commit to providing impurity testing results, including for benzene, for all batches of hand sanitizer drug product sent to the U.S. market which are within expiry. Because benzene contamination is a known risk of the manufacturing process, a finished product specification for benzene in hand sanitizers is appropriate under 21 CFR 211.160(b). Further, finished product testing of each batch of drug product and documentation thereof are required by 21 CFR 211.165. As of the date of this letter, you have yet to initiate a recall or provide complete impurity testing results.\u003C\u002Fp>\n\n\u003Cp>On February 23, 2022, FDA notified the public of the unacceptable benzene results in your hand sanitizer drug products at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation into how the hand sanitizer drug product described above, which was manufactured at your facility, contained unacceptable levels of benzene contamination.\u003C\u002Fli>\n\t\u003Cli>A list of all raw materials used to manufacture your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003C\u002Fli>\n\t\u003Cli>A list of all batches of any hand sanitizer drug products shipped to the U.S. by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fli>\n\t\u003Cli>Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fli>\n\t\u003Cli>Impurity testing results (including benzene impurity testing results) for all batches of hand sanitizer drug products sent to the U.S. market which are within expiry.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The contamination with benzene in a drug product manufactured in your facility, in addition to the deficiencies in your response to the information we requested during the February 10, 2022 teleconference, demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>704(a)(4) Request for Records and Related CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactured an OTC drug product, MOISTURIZING HAND SANITIZER Peppermint Scented. Your response to our request for records and other information under section 704(a)(4) indicated that you did not conduct adequate finished drug product testing on all drug products shipped to the U.S.\u003C\u002Fp>\n\n\u003Cp>Specifically, you provided records which demonstrate that your hand sanitizer drug product is only tested for appearance, odor, pH, viscosity, and specific gravity. Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Methanol, benzene, acetal, and acetaldehyde test results for all hand sanitizer batches released and distributed.\u003C\u002Fli>\n\t\u003Cli>A list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision. Specify which tests are performed by your facility and which, if any, are performed by a contract testing laboratory.\u003C\u002Fli>\n\t\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\n\t\u003Cli>A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate that you are adequately testing each lot of incoming raw materials used to manufacture your drug products to determine their identity, and you accepted test results from suppliers without verifying information provided by suppliers.\u003C\u002Fp>\n\n\u003Cp>For example, in response to our request for information pertaining to identity testing of raw materials, you only submitted the component’s Certificate of Analysis (COA). You did not provide specific identity testing records, and there is no indication that you have established the reliability of your component supplier’s analyses through adequate initial validation and subsequent verification of the supplier’s test results at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate that you established and followed an adequate stability program to determine appropriate storage conditions and expiration dates of drug products manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>You have failed to provide the expiry dates of hand sanitizer drug products manufactured at your facility in response to our specific request. Additionally, you reported that stability tests were only composed of appearance and physical characteristic testing. Without appropriate stability studies, there is no scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>\n&nbsp; &nbsp; o Stability-indicating methods.\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each drug product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fp>\n\n\u003Cp>• All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding Violation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>MOISTURIZING HAND SANITIZERS are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act (21 U.S.C. 321(g)(1)(B)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act (21 U.S.C. 321(g)(1)(C)) because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as topical consumer antiseptics.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the product label for MOISTURIZING HAND SANITIZER Peppermint Scented that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Hand Sanitizer\u003C\u002Fstrong> . . . Anti-Bacterial”\u003Cbr>\n“\u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . \u003Cstrong>Purpose\u003C\u002Fstrong> Antiseptic . . . \u003Cstrong>Uses\u003C\u002Fstrong> ◦ to decrease bacteria on the skin that could cause disease . . . \u003Cstrong>Directions\u003C\u002Fstrong> ◦ wet hands thoroughly with product and allow to dry without wiping . . . .”\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the product labeling for MOISTURIZING HAND SANITERS, including the product website https:\u002F\u002Fwww.thecremeshop.com\u002F, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Hand Sanitizer \u003C\u002Fstrong>. . . Anti-Bacterial”\u003Cbr>\n“How To Use 1. Wet hands thoroughly with product and allow to dry without wiping.”\u003C\u002Fp>\n\n\u003Cp>Section 502(i)(1) of the FD&amp;C Act (21 U.S.C. 352(i)(1)) provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” On August 27, 2020, FDA published a news release titled, “COVID-19 Update: FDA Warns Consumers About Hand Sanitizer Packaged in Food and Drink Containers,” see \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Fcovid-19-update-fda-warns-consumers-about-hand-sanitizer-packaged-food-and-drink-containers\">https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Fcovid-19-update-fda-warns-consumers-about-hand-sanitizer-packaged-food-and-drink-containers\u003C\u002Fa>. This news release warns consumers about alcohol-based hand sanitizers packaged in containers that resemble food or drink containers customarily purchased by U.S. consumers and may put consumers at risk of serious injury or death if ingested.\u003C\u002Fp>\n\n\u003Cp>Your MOISTURIZING HAND SANITIZERS are packaged in containers that resemble food pouches customarily purchased by U.S. consumers. OTC hand sanitizer drug products packaged in containers that resemble food pouches commonly used by adults and children may mislead consumers into believing the products are food and, thereby, increase the risk of accidental ingestion. As such, your OTC hand sanitizers, packaged in 1.01 ounce containers that have a similar shape, size, and function as a pouch ordinarily used to package food are misbranded under section 502(i)(1) of the FD&amp;C Act (21 U.S.C. 352(i)(1)).\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alerts 66-78 and 66-40 on March 24, 2022, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on these import alerts until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3016921925.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent:\u003Cbr>\nJ.S. Chem International Co.\u003Cbr>\n3530 Wilshire Blvd. Suite 1210\u003Cbr>\nLos Angeles, CA 90010-2318\u003Cbr>\nahn3060@naver.com\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that your drug product also does not conform to any temporary policy FDA has implemented during the public health emergency (PHE). In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 PHE. Additionally, on December 31, 2021, these guidances were withdrawn, and firms were required to cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> This includes the products MOISTURIZING HAND SANITIZER Eucalyptus Scented, MOISTURIZING HAND SANITIZER Green Tea Scented, MOISTURIZING HAND SANITIZER Strawberry Scented, MOISTURIZING HAND SANITIZER Candy Apple Scented, MOISTURIZING HAND SANITIZER Watermelon Scented, MOISTURIZING HAND SANITIZER Mixed Berries Scented, MOISTURIZING HAND SANITIZER Peach Scented, MOISTURIZING HAND SANITIZER Peppermint Scented, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> that are packaged in 1.01 oz. containers.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Moon Su Eun\n\nRecipient Title\n\nPresident\n\nMirfeel Korea Co., Ltd.\n\n77 Hwanggeum-ro 323 beon-gil\n\nYangchon-eup\n\nGimpo-si\n\nGyeonggi-do\n\n10049\n\nSouth Korea\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-22-16\n\nJune 22, 2022\n\nDear Mr. Eun:\n\nYour facility is registered with the U.S. Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). FDA conducted testing of a consumer hand sanitizer drug product, labeled as MOISTURIZING HAND SANITIZER Peppermint Scented. This drug product was manufactured at your facility, Mirfeel Korea Co., Ltd., FEI 3016921925, 77 Hwanggeum-ro 323 beon-gil, Yangchon-eup, Gimpo, Gyeonggi- do, Republic of Korea, and distributed in the U.S.\n\nThe results of the FDA laboratory testing of a batch of this product in U.S. distribution demonstrate that this drug product manufactured at your facility is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 351(a)(2)(B))1, in that contamination with the impurity benzene at unacceptable levels demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nAdditionally, FDA has reviewed the records you submitted in response to our initial August 3, 2021 request for records and other information, and subsequent correspondence, pursuant to section 704(a)(4) of the FD&C Act for your facility. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\nThis warning letter also summarizes significant violations of CGMP regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nIn addition, your MOISTURIZING HAND SANITIZER product line packaged in 1.01 ounce containers2 that resemble food pouches customarily purchased by U.S. consumers are misbranded under section 502(i) of the FD&C Act (21 U.S.C. 352(i)). In this letter, we collectively refer to these products as “MOISTURIZING HAND SANITIZERS.” Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&C Act (21 U.S.C. 331(a)). These violations are described in more detail below.\n\nAdulteration Violations\n\nMOISTURIZING HAND SANITIZER Peppermint Scented was manufactured at your facility. FDA laboratory testing of a batch of this product in U.S. distribution found that the drug product contained impurities at unacceptable levels. Benzene impurity levels were found to be between 5 parts per million (ppm) to 6 ppm.\n\nManufacturers should not use benzene in the manufacture of drugs because it is a known human carcinogen that causes leukemia and other blood disorders. FDA has alerted all drug manufacturers to the known risk factors for contamination with benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs\n\nOn February 10, 2022, FDA held a teleconference with you. We recommended you consider removing the adulterated batch of MOISTURIZING HAND SANITIZER Peppermint Scented drug product currently in distribution from the U.S. market. We also requested that you commit to providing impurity testing results, including for benzene, for all batches of hand sanitizer drug product sent to the U.S. market which are within expiry. Because benzene contamination is a known risk of the manufacturing process, a finished product specification for benzene in hand sanitizers is appropriate under 21 CFR 211.160(b). Further, finished product testing of each batch of drug product and documentation thereof are required by 21 CFR 211.165. As of the date of this letter, you have yet to initiate a recall or provide complete impurity testing results.\n\nOn February 23, 2022, FDA notified the public of the unacceptable benzene results in your hand sanitizer drug products at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nIn response to this letter, provide the following:\n\nA detailed investigation into how the hand sanitizer drug product described above, which was manufactured at your facility, contained unacceptable levels of benzene contamination.\n\nA list of all raw materials used to manufacture your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\nA list of all batches of any hand sanitizer drug products shipped to the U.S. by your firm, and a full reconciliation of all material you distributed.\n\nCopies of the complete batch records for all batches distributed to the U.S.\n\nImpurity testing results (including benzene impurity testing results) for all batches of hand sanitizer drug products sent to the U.S. market which are within expiry.\n\nThe contamination with benzene in a drug product manufactured in your facility, in addition to the deficiencies in your response to the information we requested during the February 10, 2022 teleconference, demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.\n\n704(a)(4) Request for Records and Related CGMP Violations\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYour firm manufactured an OTC drug product, MOISTURIZING HAND SANITIZER Peppermint Scented. Your response to our request for records and other information under section 704(a)(4) indicated that you did not conduct adequate finished drug product testing on all drug products shipped to the U.S.\n\nSpecifically, you provided records which demonstrate that your hand sanitizer drug product is only tested for appearance, odor, pH, viscosity, and specific gravity. Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nIn response to this letter, provide the following:\n\nMethanol, benzene, acetal, and acetaldehyde test results for all hand sanitizer batches released and distributed.\n\nA list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision. Specify which tests are performed by your facility and which, if any, are performed by a contract testing laboratory.\n\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\nA summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nBased on the records and information you provided, you did not demonstrate that you are adequately testing each lot of incoming raw materials used to manufacture your drug products to determine their identity, and you accepted test results from suppliers without verifying information provided by suppliers.\n\nFor example, in response to our request for information pertaining to identity testing of raw materials, you only submitted the component’s Certificate of Analysis (COA). You did not provide specific identity testing records, and there is no indication that you have established the reliability of your component supplier’s analyses through adequate initial validation and subsequent verification of the supplier’s test results at appropriate intervals.\n\nIn response to this letter, provide the following:\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nBased on the records and information you provided, you did not demonstrate that you established and followed an adequate stability program to determine appropriate storage conditions and expiration dates of drug products manufactured at your facility.\n\nYou have failed to provide the expiry dates of hand sanitizer drug products manufactured at your facility in response to our specific request. Additionally, you reported that stability tests were only composed of appearance and physical characteristic testing. Without appropriate stability studies, there is no scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\n\no Stability-indicating methods.\n\no An ongoing program in which representative batches of each drug product are added each year to the program to determine if the shelf-life claim remains valid.\n\no Detailed definition of the specific attributes to be tested at each station (timepoint).\n\n• All procedures that describe these and other elements of your remediated stability program.\n\nMisbranding Violation\n\nMOISTURIZING HAND SANITIZERS are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act (21 U.S.C. 321(g)(1)(B)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act (21 U.S.C. 321(g)(1)(C)) because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as topical consumer antiseptics.\n\nExamples of claims observed on the product label for MOISTURIZING HAND SANITIZER Peppermint Scented that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Hand Sanitizer . . . Anti-Bacterial”\n\n“Drug Facts . . . Purpose Antiseptic . . . Uses ◦ to decrease bacteria on the skin that could cause disease . . . Directions ◦ wet hands thoroughly with product and allow to dry without wiping . . . .”\n\nExamples of claims observed on the product labeling for MOISTURIZING HAND SANITERS, including the product website https:\u002F\u002Fwww.thecremeshop.com\u002F, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“Hand Sanitizer . . . Anti-Bacterial”\n\n“How To Use 1. Wet hands thoroughly with product and allow to dry without wiping.”\n\nSection 502(i)(1) of the FD&C Act (21 U.S.C. 352(i)(1)) provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” On August 27, 2020, FDA published a news release titled, “COVID-19 Update: FDA Warns Consumers About Hand Sanitizer Packaged in Food and Drink Containers,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Fcovid-19-update-fda-warns-consumers-about-hand-sanitizer-packaged-food-and-drink-containers. This news release warns consumers about alcohol-based hand sanitizers packaged in containers that resemble food or drink containers customarily purchased by U.S. consumers and may put consumers at risk of serious injury or death if ingested.\n\nYour MOISTURIZING HAND SANITIZERS are packaged in containers that resemble food pouches customarily purchased by U.S. consumers. OTC hand sanitizer drug products packaged in containers that resemble food pouches commonly used by adults and children may mislead consumers into believing the products are food and, thereby, increase the risk of accidental ingestion. As such, your OTC hand sanitizers, packaged in 1.01 ounce containers that have a similar shape, size, and function as a pouch ordinarily used to package food are misbranded under section 502(i)(1) of the FD&C Act (21 U.S.C. 352(i)(1)).\n\nThe introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act (21 U.S.C. 331(a)).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alerts 66-78 and 66-40 on March 24, 2022, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nAll drugs and drug products manufactured by your firm may remain listed on these import alerts until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3016921925.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\nCC:\n\nRegistered U.S. Agent:\n\nJ.S. Chem International Co.\n\n3530 Wilshire Blvd. Suite 1210\n\nLos Angeles, CA 90010-2318\n\nahn3060@naver.com\n\n_______________________\n\n1 We note that your drug product also does not conform to any temporary policy FDA has implemented during the public health emergency (PHE). In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 PHE. Additionally, on December 31, 2021, these guidances were withdrawn, and firms were required to cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.\n\n2 This includes the products MOISTURIZING HAND SANITIZER Eucalyptus Scented, MOISTURIZING HAND SANITIZER Green Tea Scented, MOISTURIZING HAND SANITIZER Strawberry Scented, MOISTURIZING HAND SANITIZER Candy Apple Scented, MOISTURIZING HAND SANITIZER Watermelon Scented, MOISTURIZING HAND SANITIZER Mixed Berries Scented, MOISTURIZING HAND SANITIZER Peach Scented, MOISTURIZING HAND SANITIZER Peppermint Scented, and (b)(4) that are packaged in 1.01 oz. containers.","Mirfeel Korea Co., Ltd.","mirfeel-korea-co-ltd-627401-06222022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmirfeel-korea-co-ltd-627401-06222022","2026-10-26T08:09:26.293229+00:00","2022-06-28","627401","Mr. Moon Su Eun","2026-08-20T01:49:01.856+00:00","VIA UPS","2022-06-22",{"id":180,"raw":181,"subject":185,"body_html":186,"body_text":187,"firm_name":188,"letter_id":189,"created_at":190,"fei_number":19,"letter_url":191,"updated_at":192,"action_type":22,"case_status":23,"posted_date":193,"marcs_cms_no":194,"product_type":50,"closeout_date":19,"issuing_office":37,"recipient_name":195,"body_fetched_at":196,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":197,"medical_device_id":19,"response_letter_date":19},7,[182,183,184,37,185,13,13,13],"\u003Ctime datetime=\"2026-08-04T04:00:00Z\">08\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkoven-technologies-inc-734643-07212026\">Koven Technologies, Inc.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Heather S. Bell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Koven Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>477 N. Lindbergh Blvd. Ste. 220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63141\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 734643\u003C\u002Fp>\u003Cp>July 21, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Bell:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Saint Louis, MO, conducted from February 2, 2026, through February 6, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and\u002For markets the Bidop 3 Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Management System Regulation Violation(s)\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Heather Bell, President, on February 27, 2026; April 17, 2026; and May 28, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include but are not limited to the following:\u003C\u002Fp>\u003Cp>1. Failure to document procedures to control design and development changes, and determine the significance of these changes to function, performance, usability, safety and regulatory requirements for the medical device and its intended use, as required by ISO 13485:2016 Clause 7.3.9.&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your firm failed to follow procedure 1-SOP-014, Design Control, which states, “All design changes must be identified, documented, where appropriate validated, reviewed and approved before the changes may be implemented.” Additionally, your firm failed to follow procedure 2-SOP-010, Device Registration, Submission and Notification, which requires that once a device or process is changed, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm did not document design and development changes related to expanding the indications for use of the Bidop 3 (K954397) to include a fetal application which was not cleared as an intended use. During the inspection, the Bidop 3 operations manual noted the indications for use include detection of fetal heart sounds. Your firm has not provided documentation of:\u003C\u002Fp>\u003Cp>A. The review and approval of design change documentation, including:\u003Cbr>i. Specific modifications made to the device (hardware, software, or performance specifications) to support fetal use.\u003Cbr>ii. Validation data demonstrating the device's safety and effectiveness for fetal applications.\u003C\u002Fp>\u003Cp>B. An evaluation to determine whether the change in indications for use (from non-fetal to fetal application) required a new 510(k) submission.\u003C\u002Fp>\u003Cp>C. The date when distribution was initiated for the Bidop 3 as a Fetal Doppler.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your responses mention that your firm notified customers via certified mail to suspend the use of fetal probes with Bidop 3 doppler units and that you conducted a 21 CFR 806 reportability assessment. FDA received your 806 report on 03\u002F06\u002F2026 and it is being processed under RES ID: 98556. The recall is on-going.\u003C\u002Fp>\u003Cp>2. Failure to document one or more processes for risk management in product realization and determine, as appropriate, quality objectives and requirements for the product, as required by ISO 13485:2016 Clause 7.1.\u003C\u002Fp>\u003Cp>Specifically, your firm’s risk management analysis for your devices revealed inadequate hazard identification and risk analysis as evidenced by the two (2) fetal dopplers below:\u003C\u002Fp>\u003Cp>A. Product ES-100V3 (Bidop 3), 510(k) K954397, cleared March 29, 1996: The risk management report (Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated September 3, 2025) was revised to include an indication for use as a fetal heart rate doppler, according to management. However, this report fails to evaluate risks to the fetus, despite the device being labeled for determining fetal heart rate and sounds.\u003C\u002Fp>\u003Cp>B. Product Bidop 7, 510(k) K201114, cleared January 5, 2021: The risk management report (Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated February 5, 2020) contains no evaluation of risks to the fetus, despite the device's indication for use, which includes displaying bi-directional velocity waveforms, numerical data, and fetal heart rate with a heartbeat indicator.\u003C\u002Fp>\u003Cp>The fetus is directly exposed to ultrasound energy and is the primary patient population for these devices. Failure to evaluate fetal-specific hazards (e.g., thermal effects, acoustic exposure, diagnostic accuracy affecting clinical decisions) represents inadequate risk analysis for the devices' intended use. Use of doppler ultrasound devices for fetal monitoring entails additional risks as compared to their use for blood flow monitoring. Fetal tissue is more vulnerable to prolonged or inappropriate ultrasound exposure than adult tissue. Additionally, improper use of the doppler for fetal monitoring may cause misinterpretation of maternal heartbeats or placental blood flow as fetal heartbeat, creating false reassurance. This can result in missed fetal distress signals, delayed care, and severe outcomes including fetal death. Conversely, failure to correctly detect a fetal heartbeat may cause anxiety and unnecessary clinical interventions.&nbsp;\u003C\u002Fp>\u003Cp>Therefore, the risk analysis of the fetal doppler ultrasound device should clearly assess these specific risks associated with use of the device for fetal monitoring as discussed above and specific hazards including fetal distress or death due to misinterpretation, and delayed care.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your firm completed a review of the risk management files for the Bidop 7 to address hazards consistent with the cleared intended use. However, your firm did not provide supporting documentation.\u003C\u002Fp>\u003Cp>3. Failure to establish criteria for the evaluation and selection of suppliers, as required by ISO 13485:2016 Clause 7.4.1.&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your firm has not established adequate criteria for the evaluation and selection of your approved suppliers based on their ability to provide product that meets requirements, the performance of the supplier, and the effect of the purchased product on the quality of the device. For example,\u003C\u002Fp>\u003Cp>A. Your firm holds 25 510(k) clearances for devices designed and manufactured by a contract manufacturer. During the inspection the Bidop 3 Doppler was found to have indications for use that differ from those in the cleared 510(k). The indications for use were changed from non-fetal to fetal application. This design change was implemented by your contract manufacturer and your firm does not have documentation of this change nor could your firm identify when this change occurred. The quality agreement between your firm and your contract manufacturer (Section 5.5, Labeling) requires that any changes to labeling \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This undocumented change represents a failure to ensure that \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeling changes as is established in your quality agreement. Furthermore, the quality agreement fails to \u003Cstrong>(b)(4)\u003C\u002Fstrong> design changes beyond labeling.\u003C\u002Fp>\u003Cp>B. Per procedure 1-SOP-020, \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier approval criteria include requirements that must be met such as having a quality agreement, product inspection, and site assessment. There is no documentation that a site assessment (supplier audit) has been conducted for the contract manufacturer, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier which your firm’s procedure defines as “Highest\u002FCritical Impact.”\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. We acknowledge that one of your corrective actions is that your firm amended the quality agreement with your contract manufacturer to include comprehensive design change notifications, access to change logs, and audit rights commensurate with the planned transfer of the 510(k)’s to your supplier. You mention that CAPA CA2026-3 is complete; however, it is in the effectiveness stage and your firm mentioned open corrective actions. As such, please ensure to keep the CAPA open and documented while you are completing all the steps of a CAPA.\u003C\u002Fp>\u003Cp>4. Failure to maintain records of the review, evaluation, and investigation for any complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications, as required by 21 CFR 820.35(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your firm failed to evaluate returned devices related to device failures affecting performance and reliability as complaints. Between January 1, 2024, and December 31, 2025, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> Returned Goods Authorizations (RGAs) were issued for device returns. The investigator reviewed 29 completed RGA forms coded as \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" and found that 13 of these forms reported device failures but were not evaluated as complaints. Your firm did not consider these reports as complaints and did not initiate or complete a complaint form as required by your complaint procedure, SOP 4-SOP-050 (Customer Complaint). This procedure defines a complaint as \"Any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, usability, safety, or performance of a medical device that has been released from the organization's control or related to a service that affects the performance of such medical devices.” For example:\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>RGA\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Number\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Date\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Device\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Code\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Failure\u002FInspection\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>10923\u003C\u002Ftd>\u003Ctd>6\u002F26\u002F2024\u003C\u002Ftd>\u003Ctd>Bidop 7\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>The doppler memory has been cleared and when it is turned off and on, it comes up memory store #11 or memory store #1. The doppler should go straight to the LCD screen.\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>11061\u003C\u002Ftd>\u003Ctd>9\u002F18\u002F2024\u003C\u002Ftd>\u003Ctd>Bidop 3\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>No consistent waveform with toe pressure sensor\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>11211\u003C\u002Ftd>\u003Ctd>1\u002F8\u002F2025\u003C\u002Ftd>\u003Ctd>Bidop 3\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Out of box failure\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>11509\u003C\u002Ftd>\u003Ctd>6\u002F27\u002F2025\u003C\u002Ftd>\u003Ctd>CRP-20H, cardiovascular probe\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Not picking up vascular flow\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>11402\u003C\u002Ftd>\u003Ctd>4\u002F22\u002F2025\u003C\u002Ftd>\u003Ctd>Aneroid Sphygmomanometer\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Doesn’t measure correctly on toe\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your firm provided the training records showing the employees trained to the updated procedures; however, you did not provide specifics on the evaluation conducted for the employees to confirm they understood the updates. Please provide this information.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Melissa Michurski, Establishment Assessment Team 2, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case [734643]” when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, Ashley.Mutawakkil@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CAPT Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nHeather S. Bell\n\nRecipient Title\n\nPresident\n\nKoven Technologies, Inc.\n\n477 N. Lindbergh Blvd. Ste. 220\n\nSaint Louis, MO 63141\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 734643\nJuly 21, 2026\nDear Ms. Bell:\nDuring an inspection of your firm located in Saint Louis, MO, conducted from February 2, 2026, through February 6, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and\u002For markets the Bidop 3 Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality Management System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Heather Bell, President, on February 27, 2026; April 17, 2026; and May 28, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include but are not limited to the following:\n1. Failure to document procedures to control design and development changes, and determine the significance of these changes to function, performance, usability, safety and regulatory requirements for the medical device and its intended use, as required by ISO 13485:2016 Clause 7.3.9.\nSpecifically, your firm failed to follow procedure 1-SOP-014, Design Control, which states, “All design changes must be identified, documented, where appropriate validated, reviewed and approved before the changes may be implemented.” Additionally, your firm failed to follow procedure 2-SOP-010, Device Registration, Submission and Notification, which requires that once a device or process is changed, (b)(4). Your firm did not document design and development changes related to expanding the indications for use of the Bidop 3 (K954397) to include a fetal application which was not cleared as an intended use. During the inspection, the Bidop 3 operations manual noted the indications for use include detection of fetal heart sounds. Your firm has not provided documentation of:\nA. The review and approval of design change documentation, including:\ni. Specific modifications made to the device (hardware, software, or performance specifications) to support fetal use.\nii. Validation data demonstrating the device's safety and effectiveness for fetal applications.\nB. An evaluation to determine whether the change in indications for use (from non-fetal to fetal application) required a new 510(k) submission.\nC. The date when distribution was initiated for the Bidop 3 as a Fetal Doppler.\nThe adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your responses mention that your firm notified customers via certified mail to suspend the use of fetal probes with Bidop 3 doppler units and that you conducted a 21 CFR 806 reportability assessment. FDA received your 806 report on 03\u002F06\u002F2026 and it is being processed under RES ID: 98556. The recall is on-going.\n2. Failure to document one or more processes for risk management in product realization and determine, as appropriate, quality objectives and requirements for the product, as required by ISO 13485:2016 Clause 7.1.\nSpecifically, your firm’s risk management analysis for your devices revealed inadequate hazard identification and risk analysis as evidenced by the two (2) fetal dopplers below:\nA. Product ES-100V3 (Bidop 3), 510(k) K954397, cleared March 29, 1996: The risk management report (Document (b)(4), dated September 3, 2025) was revised to include an indication for use as a fetal heart rate doppler, according to management. However, this report fails to evaluate risks to the fetus, despite the device being labeled for determining fetal heart rate and sounds.\nB. Product Bidop 7, 510(k) K201114, cleared January 5, 2021: The risk management report (Document (b)(4), dated February 5, 2020) contains no evaluation of risks to the fetus, despite the device's indication for use, which includes displaying bi-directional velocity waveforms, numerical data, and fetal heart rate with a heartbeat indicator.\nThe fetus is directly exposed to ultrasound energy and is the primary patient population for these devices. Failure to evaluate fetal-specific hazards (e.g., thermal effects, acoustic exposure, diagnostic accuracy affecting clinical decisions) represents inadequate risk analysis for the devices' intended use. Use of doppler ultrasound devices for fetal monitoring entails additional risks as compared to their use for blood flow monitoring. Fetal tissue is more vulnerable to prolonged or inappropriate ultrasound exposure than adult tissue. Additionally, improper use of the doppler for fetal monitoring may cause misinterpretation of maternal heartbeats or placental blood flow as fetal heartbeat, creating false reassurance. This can result in missed fetal distress signals, delayed care, and severe outcomes including fetal death. Conversely, failure to correctly detect a fetal heartbeat may cause anxiety and unnecessary clinical interventions.\nTherefore, the risk analysis of the fetal doppler ultrasound device should clearly assess these specific risks associated with use of the device for fetal monitoring as discussed above and specific hazards including fetal distress or death due to misinterpretation, and delayed care.\nThe adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your firm completed a review of the risk management files for the Bidop 7 to address hazards consistent with the cleared intended use. However, your firm did not provide supporting documentation.\n3. Failure to establish criteria for the evaluation and selection of suppliers, as required by ISO 13485:2016 Clause 7.4.1.\nSpecifically, your firm has not established adequate criteria for the evaluation and selection of your approved suppliers based on their ability to provide product that meets requirements, the performance of the supplier, and the effect of the purchased product on the quality of the device. For example,\nA. Your firm holds 25 510(k) clearances for devices designed and manufactured by a contract manufacturer. During the inspection the Bidop 3 Doppler was found to have indications for use that differ from those in the cleared 510(k). The indications for use were changed from non-fetal to fetal application. This design change was implemented by your contract manufacturer and your firm does not have documentation of this change nor could your firm identify when this change occurred. The quality agreement between your firm and your contract manufacturer (Section 5.5, Labeling) requires that any changes to labeling (b)(4). This undocumented change represents a failure to ensure that (b)(4) labeling changes as is established in your quality agreement. Furthermore, the quality agreement fails to (b)(4) design changes beyond labeling.\nB. Per procedure 1-SOP-020, (b)(4) supplier approval criteria include requirements that must be met such as having a quality agreement, product inspection, and site assessment. There is no documentation that a site assessment (supplier audit) has been conducted for the contract manufacturer, a (b)(4) supplier which your firm’s procedure defines as “Highest\u002FCritical Impact.”\nThe adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. We acknowledge that one of your corrective actions is that your firm amended the quality agreement with your contract manufacturer to include comprehensive design change notifications, access to change logs, and audit rights commensurate with the planned transfer of the 510(k)’s to your supplier. You mention that CAPA CA2026-3 is complete; however, it is in the effectiveness stage and your firm mentioned open corrective actions. As such, please ensure to keep the CAPA open and documented while you are completing all the steps of a CAPA.\n4. Failure to maintain records of the review, evaluation, and investigation for any complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications, as required by 21 CFR 820.35(a).\nSpecifically, your firm failed to evaluate returned devices related to device failures affecting performance and reliability as complaints. Between January 1, 2024, and December 31, 2025, approximately (b)(4) Returned Goods Authorizations (RGAs) were issued for device returns. The investigator reviewed 29 completed RGA forms coded as \"(b)(4)\" and found that 13 of these forms reported device failures but were not evaluated as complaints. Your firm did not consider these reports as complaints and did not initiate or complete a complaint form as required by your complaint procedure, SOP 4-SOP-050 (Customer Complaint). This procedure defines a complaint as \"Any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, usability, safety, or performance of a medical device that has been released from the organization's control or related to a service that affects the performance of such medical devices.” For example:\nRGA\nNumberDateDeviceCodeFailure\u002FInspection\n109236\u002F26\u002F2024Bidop 7(b)(4)The doppler memory has been cleared and when it is turned off and on, it comes up memory store #11 or memory store #1. The doppler should go straight to the LCD screen.\n110619\u002F18\u002F2024Bidop 3(b)(4)No consistent waveform with toe pressure sensor\n112111\u002F8\u002F2025Bidop 3(b)(4)Out of box failure\n115096\u002F27\u002F2025CRP-20H, cardiovascular probe(b)(4)Not picking up vascular flow\n114024\u002F22\u002F2025Aneroid Sphygmomanometer(b)(4)Doesn’t measure correctly on toe\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your firm provided the training records showing the employees trained to the updated procedures; however, you did not provide specifics on the evaluation conducted for the employees to confirm they understood the updates. Please provide this information.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Melissa Michurski, Establishment Assessment Team 2, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case [734643]” when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, Ashley.Mutawakkil@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCAPT Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Koven Technologies, Inc.","koven-technologies-inc-734643-07212026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkoven-technologies-inc-734643-07212026","2026-10-26T08:09:10.23134+00:00","2026-08-04","734643","Heather S. Bell","2026-08-19T04:27:26.915+00:00","2026-07-21",{"id":199,"raw":200,"subject":205,"body_html":206,"body_text":207,"firm_name":208,"letter_id":209,"created_at":66,"fei_number":19,"letter_url":210,"updated_at":211,"action_type":22,"case_status":23,"posted_date":212,"marcs_cms_no":213,"product_type":214,"closeout_date":19,"issuing_office":215,"recipient_name":216,"body_fetched_at":217,"delivery_method":218,"recipient_title":19,"reference_number":19,"action_taken_date":219,"medical_device_id":19,"response_letter_date":19},1639,[201,202,203,204,205,13,13,13],"\u003Ctime datetime=\"2024-01-30T14:20:00Z\">01\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-14T05:00:00Z\">11\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmartin-farm-konrad-martin-664784-11142023\">Martin Farm, Konrad Martin\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","New Animal Drug\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Konrad Martin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Part Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Martin Farm, Konrad Martin\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>68572 Country Road 11\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nappanee\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46550-8946\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 664784\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2023\u003Cbr>\n\u003Cbr>\nMailing Address:\u003Cbr>\n\u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Martin:\u003C\u002Fp>\n\n\u003Cp>An inspection of your dairy operation located at 68572 Country Road 46, Nappanee, Indiana, was conducted by representatives of the U.S. Food and Drug Administration (FDA) on May 24, 2023, and June 21, 2023. This letter notifies you of violations of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) that were revealed during our inspection of your operation. You can find the FD&amp;C Act and its associated regulations on the Internet through links on the FDA’s webpage at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, you were issued a form FDA 483, Inspectional Observations (FDA 483). We have not received a response to the FDA 483 as of the date of this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulteration of an Animal Offered for Human Consumption\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Our inspection found that you hold animals under conditions that are so inadequate that medicated animals bearing potentially harmful drug residues are likely to enter the food supply. Specifically, you failed to maintain complete and accurate treatment records. For example, you do not maintain any treatment records for drugs administered to calves on your farm, nor do you keep complete treatment records of drugs administered to cattle on your farm as those records lack dose, total days of treatment, route of administration, and person medicating animal and calves.\u003C\u002Fp>\n\n\u003Cp>Food held under such conditions is adulterated.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>&nbsp;\u003C\u002Fspan>\u003Cstrong>\u003Cu>Adulteration of a New Animal Drug\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We also found that you did not use \u003Cstrong>(b)(4)\u003C\u002Fstrong> (enrofloxacin, \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (ceftiofur hydrochloride, \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as directed by their approved labeling and prescription labels. Use of a drugs in a manner that is not consistent with its labeling is an extralabel use.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Our inspection found that you administered \u003Cstrong>(b)(4)\u003C\u002Fstrong> to calves without following the animal class, indications for use, route of administration, and withdrawal time. During the inspection, you stated that you administer \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to prevent and treat scours and respiratory disease in most calves, either intramuscularly (IM) or orally with milk, and you do not follow meat withdrawal periods. This drug is not approved for use in calves or for disease prevention purposes for scours, and cannot be administered IM or orally or used without a meat withhold period. Extra-label use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is prohibited.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Our inspection also found that you used \u003Cstrong>(b)(4)\u003C\u002Fstrong> without following the labeled dose. For example, during the inspection you explained that you used \u003Cstrong>(b)(4)\u003C\u002Fstrong> by giving \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This drug is labeled for administering no more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> per injection site. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a ceftiofur class drug, is prohibited from extra label use.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Because your use of these drugs was not in conformance with their approved labeling and did not comply with 21 CFR Part 530, you caused the drugs to be unsafe and adulterated.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility. You are responsible for investigating and determining the cause of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action without further notice, including without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that you have complied with the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Dylan C. Grippi, Compliance Officer, at 300 River Place Drive, Suite 5900, Detroit, MI 48207 or via email (preferred) to Dylan.Grippi@fda.hhs.gov. If you have any questions about this letter, please contact Mr. Grippi at (301)-452-1608, or by e-mail at Dylan.Grippi@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations East Division 6\u003C\u002Fp>\n\n\u003Cp>CC: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See section 402(a)(4) of the FD&amp;C Act [21 U.S.C. § 342(a)(4)]\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 530.3(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 530.41(a)(10).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 530.41(a)(13)(ii).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)], a new animal drug is deemed adulterated if it is unsafe within the meaning of section 512 of the FD&amp;C Act [21 U.S.C. § 360b].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nAnimal & Veterinary\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Konrad Martin\n\nRecipient Title\n\nPart Owner\n\nMartin Farm, Konrad Martin\n\n68572 Country Road 11\n\nNappanee, IN 46550-8946\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS 664784\n\nNovember 14, 2023\n\nMailing Address:\n\n(b)(6), (b)(7)(C)\n\nDear Mr. Martin:\n\nAn inspection of your dairy operation located at 68572 Country Road 46, Nappanee, Indiana, was conducted by representatives of the U.S. Food and Drug Administration (FDA) on May 24, 2023, and June 21, 2023. This letter notifies you of violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) that were revealed during our inspection of your operation. You can find the FD&C Act and its associated regulations on the Internet through links on the FDA’s webpage at www.fda.gov.\n\nAt the close of the inspection, you were issued a form FDA 483, Inspectional Observations (FDA 483). We have not received a response to the FDA 483 as of the date of this letter.\n\nAdulteration of an Animal Offered for Human Consumption\n\nOur inspection found that you hold animals under conditions that are so inadequate that medicated animals bearing potentially harmful drug residues are likely to enter the food supply. Specifically, you failed to maintain complete and accurate treatment records. For example, you do not maintain any treatment records for drugs administered to calves on your farm, nor do you keep complete treatment records of drugs administered to cattle on your farm as those records lack dose, total days of treatment, route of administration, and person medicating animal and calves.\n\nFood held under such conditions is adulterated.1\n\nAdulteration of a New Animal Drug\n\nWe also found that you did not use (b)(4) (enrofloxacin, (b)(4)) and (b)(4) (ceftiofur hydrochloride, (b)(4)) as directed by their approved labeling and prescription labels. Use of a drugs in a manner that is not consistent with its labeling is an extralabel use.2\n\nOur inspection found that you administered (b)(4) to calves without following the animal class, indications for use, route of administration, and withdrawal time. During the inspection, you stated that you administer (b)(4) of (b)(4) to prevent and treat scours and respiratory disease in most calves, either intramuscularly (IM) or orally with milk, and you do not follow meat withdrawal periods. This drug is not approved for use in calves or for disease prevention purposes for scours, and cannot be administered IM or orally or used without a meat withhold period. Extra-label use of (b)(4) is prohibited.3\n\nOur inspection also found that you used (b)(4) without following the labeled dose. For example, during the inspection you explained that you used (b)(4) by giving (b)(4). This drug is labeled for administering no more than (b)(4) per injection site. (b)(4), a ceftiofur class drug, is prohibited from extra label use.4\n\nBecause your use of these drugs was not in conformance with their approved labeling and did not comply with 21 CFR Part 530, you caused the drugs to be unsafe and adulterated.5 The introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act.6\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility. You are responsible for investigating and determining the cause of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action without further notice, including without limitation, seizure and\u002For injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that you have complied with the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to Dylan C. Grippi, Compliance Officer, at 300 River Place Drive, Suite 5900, Detroit, MI 48207 or via email (preferred) to Dylan.Grippi@fda.hhs.gov. If you have any questions about this letter, please contact Mr. Grippi at (301)-452-1608, or by e-mail at Dylan.Grippi@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations East Division 6\n\nCC: (b)(4)\n\n___________________\n\n1 See section 402(a)(4) of the FD&C Act [21 U.S.C. § 342(a)(4)]\n\n2 See 21 CFR 530.3(a).\n\n3 See 21 CFR 530.41(a)(10).\n\n4 See 21 CFR 530.41(a)(13)(ii).\n\n5 Under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)], a new animal drug is deemed adulterated if it is unsafe within the meaning of section 512 of the FD&C Act [21 U.S.C. § 360b].\n\n6 See section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]","Martin Farm, Konrad Martin","martin-farm-konrad-martin-664784-11142023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmartin-farm-konrad-martin-664784-11142023","2026-10-26T08:09:20.942897+00:00","2024-01-30","664784","Animal & VeterinaryFood & Beverages","Division of Human and Animal Food Operations East VI","Mr. Konrad Martin","2026-08-20T00:21:22.861+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2023-11-14",{"id":221,"raw":222,"subject":227,"body_html":228,"body_text":229,"firm_name":230,"letter_id":231,"created_at":149,"fei_number":19,"letter_url":232,"updated_at":233,"action_type":22,"case_status":23,"posted_date":234,"marcs_cms_no":235,"product_type":236,"closeout_date":19,"issuing_office":226,"recipient_name":237,"body_fetched_at":238,"delivery_method":239,"recipient_title":19,"reference_number":19,"action_taken_date":234,"medical_device_id":19,"response_letter_date":19},2970,[223,224,225,226,227,13,13,13],"\u003Ctime datetime=\"2021-12-16T20:00:00Z\">12\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-16T05:00:00Z\">12\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkokomo-pure-vapors-llc-622895-12162021\">Kokomo Pure Vapors LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeffrey W. Lamberson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kokomo Pure Vapors LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1216 East Markland Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kokomo\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46901\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:kpveliquids@gmail.com\"> kpveliquids@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 16, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Lamberson:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Kokomo Pure Vapors, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Kokomo Pure Vapors Horney Parrot 60ml 12mg e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 3,000 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100370, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJeffrey W. Lamberson\n\nRecipient Title\n\nOwner\n\nKokomo Pure Vapors LLC\n\n1216 East Markland Avenue\n\nKokomo, IN 46901\n\nUnited States\n\nkpveliquids@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDecember 16, 2021\n\nWARNING LETTER\n\nDear Mr. Lamberson:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Kokomo Pure Vapors, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Kokomo Pure Vapors Horney Parrot 60ml 12mg e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 3,000 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100370, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Kokomo Pure Vapors LLC","kokomo-pure-vapors-llc-622895-12162021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkokomo-pure-vapors-llc-622895-12162021","2026-10-26T08:09:09.994237+00:00","2021-12-16","622895","Tobacco","Jeffrey W. Lamberson","2026-08-20T02:19:54.222+00:00","VIA UPS and Electronic Mail",{"id":241,"raw":242,"subject":12,"body_html":246,"body_text":247,"firm_name":248,"letter_id":249,"created_at":250,"fei_number":19,"letter_url":251,"updated_at":252,"action_type":22,"case_status":23,"posted_date":253,"marcs_cms_no":254,"product_type":26,"closeout_date":19,"issuing_office":102,"recipient_name":255,"body_fetched_at":256,"delivery_method":257,"recipient_title":19,"reference_number":19,"action_taken_date":258,"medical_device_id":19,"response_letter_date":19},1232,[243,244,245,102,12,13,13,13],"\u003Ctime datetime=\"2024-10-01T13:20:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-26T04:00:00Z\">09\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmakra-kozmetika-doo-684125-09262024\">Makra Kozmetika D.O.O.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Belkisa Grbic\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Makra Kozmetika D.O.O.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Kolodvorska Cesta 2\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>4000\u003C\u002Fspan> \u003Cspan>Kranj\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Slovenia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-24-64\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>September 26, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Grbic:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Makra Kozmetika D.O.O., FEI 3019638306, at Kolodvorska Cesta 2, 4000 Kranj from April 8 to 12, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 29, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to conduct quality control testing for your over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ointment prior to release and distribution to the U.S. market. Finished product testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes that are appropriate for their intended use, including both chemical and microbiological specifications. Because you lacked testing of each batch of your drug products, there is no assurance that they conform to finished product specifications and are suitable for use by consumers.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you are in the process of implementing a quality management system (QMS) with robust procedures for establishing finished products specifications for all new and existing medicinal products. You commit to testing the last two batches of products distributed to the U.S. market to “confirm the proper quality of medicinal product from microbiological point of view.”\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You apply a cosmetic standard for microbiological testing instead of the appropriate United States Pharmacopeia (USP) protocols for examination of non-sterile drug products.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Additionally, you do not commit to performing a comprehensive retrospective review and full testing of all batches distributed to the United States and currently on the market within expiry.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>\n&nbsp; &nbsp;o An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp;o A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals. 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to test incoming raw materials including active pharmaceutical ingredients (API) (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and other components (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) used to manufacture your OTC drug products to determine their identity, purity, strength, and other appropriate quality attributes. Several API lots were released into production without performing adequate acceptance testing, including identity. Additionally, your firm accepted components from suppliers without establishing the reliability of suppliers’ test analyses. For instance, you provided only a certificate of analysis (COA) for your API \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Without adequate testing, you do not have suitable assurance that the components conform to appropriate specifications prior to use in the drug products you manufacture.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you identified a GMP laboratory with valid European Union issued GMP certificates for testing incoming materials. Your response is inadequate. You do not provide documentation that the laboratory is GMP compliant. Additionally, you do not commit to performing a risk assessment of products released without appropriate testing.\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003Cbr>\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003Cbr>\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003Cbr>\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003Cbr>\n• A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess. (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Inadequate Process Controls\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your production batch records were inadequate to ensure consistent manufacture of your OTC drug products. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ointment batch records lacked critical manufacturing parameters. You subsequently released drug products without validating your manufacturing process.\u003C\u002Fp>\n\n\u003Cp>Your firm lacked a process validation program. Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>In your response, you repeat that you are in the process of establishing your QMS and you will create procedures related to process validation. Your response is inadequate. You fail to provide sufficient details of your corrective actions, and you do not commit to a comprehensive retrospective review of all U.S. distributed products currently on the market and manufactured without a validated process.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003Cbr>\n• A timeline for performing appropriate PPQ for each of your marketed drug products.\u003Cbr>\n• Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003Cbr>\n• A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Inadequate (b)(4) System Controls\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to validate your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system and monitor the quality of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure it was suitable for use in the manufacture of your drug products. You also lacked procedures to maintain and monitor your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. There were no microbiological testing records provided from the point of use to ensure it consistently meets the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph and appropriate microbials limits.\u003Cbr>\n\u003Cbr>\nIn your response, you state that a validation protocol will be prepared in accordance to instructions provided by the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system manufacturer and the frequency of microbiological testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> will be based on the outcome of the validation studies\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not adequately describe details of your validation protocol and corrective actions to ensure your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system will consistently produce \u003Cstrong>(b)(4)\u003C\u002Fstrong> that is appropriate for its intended use.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003Cbr>\n&nbsp; o Validation report for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system obtained after an appropriately designed system has been installed. Include the system validation protocol, the complete test results, and the final validation report.\u003Cbr>\n• A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003Cbr>\n• The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003Cbr>\n• A procedure governing your program for ongoing control, maintenance and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong>, USP monograph specifications and appropriate microbial limits.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Inadequate Cleaning Controls\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to provide scientific data to demonstrate that you have validated your equipment cleaning processes. Additionally, you failed to have cleaning procedures and maintain cleaning logs for the non-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> and ointment filling equipment. You lack assurance that your cleaning methods will remove all residues and contaminants as well as carry over of products.\u003C\u002Fp>\n\n\u003Cp>In your response you acknowledge that you do not have cleaning validation studies and cleaning procedures for manufacturing equipment. You commit to writing cleaning validation protocols for each piece of equipment which will include sampling procedures, and to prepare analytical methods for products you manufacture.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response does not provide sufficient details or documentation on how you plan to remediate your operations to ensure compliance with CGMP regulations. For example, you did not provide validation protocols, cleaning procedures, cleaning logs or a description of the interim measures you plan to take to prevent cross contamination.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed. (21 CFR 211.22(a) and 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish a quality unit (QU). Additionally, you failed to ensure that adequate specifications were established for the drug products, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ointment, you manufacture and to ensure each batch was tested for, and conformed to, all appropriate quality attributes before release and distribution.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you lack written QMS procedures for, but not limited to, change control, complaints, recalls, investigations to deviations, out of specifications, corrective and preventative actions (CAPA), annual product reviews, adverse event reporting and training of employees.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you are recruiting a “qualified quality manager\u002Fqualified person” to implement your QMS. In addition, you provide a draft list of procedure titles which will be incorporated into your QMS system.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You failed to provide a risk assessment evaluating the products within expiry in the U.S. market.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>\n&nbsp; o Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 25, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Makra Kozmetica D.O.O., Kolodvorska Cesta 2, 4000 Kranj, Slovenia, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3019638306 and ATTN: Erika V. Butler, Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See USP Chapters &lt;61&gt;\u003Cem> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests and &lt;62&gt; Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Belkisa Grbic\n\nRecipient Title\n\nGeneral Manager\n\nMakra Kozmetika D.O.O.\n\nKolodvorska Cesta 2\n\n4000 Kranj\n\nSlovenia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-64\n\nSeptember 26, 2024\n\nDear Ms. Grbic:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Makra Kozmetika D.O.O., FEI 3019638306, at Kolodvorska Cesta 2, 4000 Kranj from April 8 to 12, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 29, 2024 response to our Form FDA 483 in detail.\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\n\nYour firm failed to conduct quality control testing for your over-the-counter (OTC) (b)(4) drug products, such as (b)(4) and (b)(4) Ointment prior to release and distribution to the U.S. market. Finished product testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes that are appropriate for their intended use, including both chemical and microbiological specifications. Because you lacked testing of each batch of your drug products, there is no assurance that they conform to finished product specifications and are suitable for use by consumers.\n\nIn your response, you state that you are in the process of implementing a quality management system (QMS) with robust procedures for establishing finished products specifications for all new and existing medicinal products. You commit to testing the last two batches of products distributed to the U.S. market to “confirm the proper quality of medicinal product from microbiological point of view.”\n\nYour response is inadequate. You apply a cosmetic standard for microbiological testing instead of the appropriate United States Pharmacopeia (USP) protocols for examination of non-sterile drug products.1 Additionally, you do not commit to performing a comprehensive retrospective review and full testing of all batches distributed to the United States and currently on the market within expiry.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid actions, such as notifying customers and product recalls.\n\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals. 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm failed to test incoming raw materials including active pharmaceutical ingredients (API) (e.g., (b)(4)) and other components (e.g., (b)(4)) used to manufacture your OTC drug products to determine their identity, purity, strength, and other appropriate quality attributes. Several API lots were released into production without performing adequate acceptance testing, including identity. Additionally, your firm accepted components from suppliers without establishing the reliability of suppliers’ test analyses. For instance, you provided only a certificate of analysis (COA) for your API (b)(4) and (b)(4). Without adequate testing, you do not have suitable assurance that the components conform to appropriate specifications prior to use in the drug products you manufacture.\n\nIn your response, you state that you identified a GMP laboratory with valid European Union issued GMP certificates for testing incoming materials. Your response is inadequate. You do not provide documentation that the laboratory is GMP compliant. Additionally, you do not commit to performing a risk assessment of products released without appropriate testing.\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\n\nIn response to this letter, provide:\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n• A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess. (21 CFR 211.100(a)).\n\nInadequate Process Controls\n\nYour production batch records were inadequate to ensure consistent manufacture of your OTC drug products. Your (b)(4) Ointment batch records lacked critical manufacturing parameters. You subsequently released drug products without validating your manufacturing process.\n\nYour firm lacked a process validation program. Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nIn your response, you repeat that you are in the process of establishing your QMS and you will create procedures related to process validation. Your response is inadequate. You fail to provide sufficient details of your corrective actions, and you do not commit to a comprehensive retrospective review of all U.S. distributed products currently on the market and manufactured without a validated process.\n\nIn response to this letter, provide:\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing appropriate PPQ for each of your marketed drug products.\n\n• Process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\n• A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nInadequate (b)(4) System Controls\n\nYou failed to validate your (b)(4) system and monitor the quality of your (b)(4) to ensure it was suitable for use in the manufacture of your drug products. You also lacked procedures to maintain and monitor your (b)(4) system. There were no microbiological testing records provided from the point of use to ensure it consistently meets the USP (b)(4) monograph and appropriate microbials limits.\n\nIn your response, you state that a validation protocol will be prepared in accordance to instructions provided by the (b)(4) system manufacturer and the frequency of microbiological testing of (b)(4) will be based on the outcome of the validation studies\n\nYour response is inadequate. You do not adequately describe details of your validation protocol and corrective actions to ensure your (b)(4) system will consistently produce (b)(4) that is appropriate for its intended use.\n\nIn response to this letter, provide:\n\n• A comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.\n\no Validation report for the (b)(4) system obtained after an appropriately designed system has been installed. Include the system validation protocol, the complete test results, and the final validation report.\n\n• A procedure for your (b)(4) system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\n• The current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system. Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the products produced by your firm.\n\n• A procedure governing your program for ongoing control, maintenance and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4), USP monograph specifications and appropriate microbial limits.\n\nInadequate Cleaning Controls\n\nYou failed to provide scientific data to demonstrate that you have validated your equipment cleaning processes. Additionally, you failed to have cleaning procedures and maintain cleaning logs for the non-dedicated (b)(4) and ointment filling equipment. You lack assurance that your cleaning methods will remove all residues and contaminants as well as carry over of products.\n\nIn your response you acknowledge that you do not have cleaning validation studies and cleaning procedures for manufacturing equipment. You commit to writing cleaning validation protocols for each piece of equipment which will include sampling procedures, and to prepare analytical methods for products you manufacture.\n\nYour response is inadequate. Your response does not provide sufficient details or documentation on how you plan to remediate your operations to ensure compliance with CGMP regulations. For example, you did not provide validation protocols, cleaning procedures, cleaning logs or a description of the interim measures you plan to take to prevent cross contamination.\n\nIn response to this letter, provide:\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n4. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed. (21 CFR 211.22(a) and 211.22(d)).\n\nYour firm failed to establish a quality unit (QU). Additionally, you failed to ensure that adequate specifications were established for the drug products, (b)(4) and (b)(4) Ointment, you manufacture and to ensure each batch was tested for, and conformed to, all appropriate quality attributes before release and distribution.\n\nFurthermore, you lack written QMS procedures for, but not limited to, change control, complaints, recalls, investigations to deviations, out of specifications, corrective and preventative actions (CAPA), annual product reviews, adverse event reporting and training of employees.\n\nIn your response, you state that you are recruiting a “qualified quality manager\u002Fqualified person” to implement your QMS. In addition, you provide a draft list of procedure titles which will be incorporated into your QMS system.\n\nYour response is inadequate. You failed to provide a risk assessment evaluating the products within expiry in the U.S. market.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\no Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on September 25, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Makra Kozmetica D.O.O., Kolodvorska Cesta 2, 4000 Kranj, Slovenia, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3019638306 and ATTN: Erika V. Butler, Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n____________________\n\n1 See USP Chapters \u003C61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests and \u003C62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms.","Makra Kozmetika D.O.O.","makra-kozmetika-doo-684125-09262024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmakra-kozmetika-doo-684125-09262024","2026-10-26T08:09:18.77573+00:00","2024-10-01","684125","Ms. Belkisa Grbic","2026-08-19T22:57:43.33+00:00","Via Email","2024-09-26",{"id":260,"raw":261,"subject":268,"body_html":269,"body_text":270,"firm_name":271,"letter_id":272,"created_at":250,"fei_number":19,"letter_url":273,"updated_at":274,"action_type":22,"case_status":47,"posted_date":275,"marcs_cms_no":276,"product_type":277,"closeout_date":278,"issuing_office":265,"recipient_name":271,"body_fetched_at":279,"delivery_method":280,"recipient_title":19,"reference_number":281,"action_taken_date":282,"medical_device_id":19,"response_letter_date":19},1320,[262,263,264,265,266,13,267,13],"\u003Ctime datetime=\"2024-08-13T13:20:00Z\">08\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-29T04:00:00Z\">05\u002F29\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkonrad-rejdak-md-phd-671405-05292024\">Konrad Rejdak, M.D., Ph.D.\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Bioresearch Monitoring Program\u002FIRB  ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkonrad-rejdak-md-phd-671405-05012025\">\u003Ctime datetime=\"2025-11-10T05:00:00Z\">11\u002F10\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","Bioresearch Monitoring Program\u002FIRB","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 24-671405\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Konrad Rejdak, M.D., Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Konrad Rejdak, M.D., Ph.D.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Kliniczny Nr 4 w Lublinie\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>ul. Jaczewskiego 8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>20-090\u003C\u002Fspan> \u003Cspan>Lublin\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Poland\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 29, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Rejdak:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during a United States Food and Drug Administration (FDA) inspection conducted between May 15 and May 19, 2023. During the inspection, an FDA investigator met with you and your staff to review the conduct and oversight of a clinical study titled:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA\u002FHyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID\u002FKIOVIG) for the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)\u003C\u002Fem> (Protocol 161403) (hereinafter, the protocol).\u003C\u002Fp>\n\n\u003Cp>FDA conducted this inspection under the Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of clinical research involving investigational products for compliance with applicable requirements, including under 21 CFR Parts 50, 56, and 312.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigator presented a Form FDA 483, List of Inspectional Observations (Form FDA 483) for your review and discussed with you and your staff the listed observations. Based upon our review of the Establishment Inspection Report (EIR), the accompanying exhibits and attachments, the Form FDA 483, and your written response, dated June 2, 2023, to the Form FDA 483 (“Response Letter”), we determined that you violated regulations governing the proper conduct of clinical studies involving investigational products in Title 21, Code of Federal Regulations (CFR) Part 312 (available at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcdrh\u002Fcfdocs\u002Fcfcfr\u002FCFRsearch.cfm?CFRPart=312).\u003Cbr>\n\u003Cbr>\nThe violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to prepare and maintain adequate and accurate case histories that record all observations and other data pertinent to the investigation on each individual administered the investigational product [21 CFR 312.62(b)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In multiple instances, subject ability assessment scores were not entered into \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets at the time of assessment. One of the three assessments used was the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale. The INCAT score was used as a primary efficacy assessment measure for the protocol. Gaps between assessment end time and data entry ranged from seven minutes to 25 days with no source documentation of 144 assessment values\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> for four subjects over the course of nine visits. Protocol section 18.2 states that data not entered during the study visit should be recorded on paper, and then this documentation will be considered source documentation.\u003C\u002Fp>\n\n\u003Cp>The subject ability assessment scores for these subjects were not entered at the time of assessment, there was no source documentation of the values, and the times and\u002For dates were later edited to appear as if the values were recorded at the time of assessment.\u003C\u002Fp>\n\n\u003Cp>Your Response Letter states that internet connections were poor due to the COVID-19 pandemic. As a result, raters entered the assessment data into the tablets at a later time, either based on written notes or on their memory. We find this response inadequate for several reasons: (1) it contradicts what was relayed by both sub investigators during the inspection; (2) all affected visits occurred prior to the beginning of the COVID-19 pandemic; and (3) values that were not recorded at the time of the assessment may not be accurate due to the length of time elapsed.\u003C\u002Fp>\n\n\u003Cp>Your Response Letter also states that scores could be entered into tablets in “offline mode” and uploaded once an internet connection was established. We find this explanation inadequate because this modality could not be demonstrated during the inspection. Your contradictory explanations, along with the gaps from assessment time to entry time, raise concerns about the reliability of the data and the integrity of your study conduct.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to ensure that the investigation was conducted according to the signed investigator statement, the investigational plan, and applicable regulations; failure to protect the rights, safety, and welfare of subjects under your care [21 CFR 312.60].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 18.2 of the protocol states: “If electronic CRFs [case report forms] are provided by the sponsor, only authorized study site personnel will record or change data on the CRFs. If data is not entered on the CRFs during the study visit, the data will be recorded on paper, and this documentation will be considered source documentation.”\u003C\u002Fp>\n\n\u003Cp>Times and\u002For dates for the aforementioned 144 assessment values were subsequently edited months after the assessment. These values were originally entered into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets between November 12, 2019 and February 8, 2020, by blinded raters, but their times and\u002For dates were later edited by non-study personnel on May 14, July 23, and July 28, 2020 and on July 12, 2022 to match the hand-written assessment times without source documentation of assessment values.\u003C\u002Fp>\n\n\u003Cp>During the inspection, the investigator questioned the revisions found in Audit Trail documents and you verbally stated that you did not know how or why assessment times and dates were edited.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you stated that assessment times and dates were manually entered by the eResearch Technology team at the sub investigator’s request for subjects \u003Cstrong>(b)(6)\u003C\u002Fstrong> due to connectivity or technical issues. We acknowledge that the Sponsor provided guidance that sites could request updates to the electronic CRF with the caveat that data was documented on paper at the time of assessment, however your site did not have source documentation of assessment scores.\u003C\u002Fp>\n\n\u003Cp>We do not find your response adequate because it contradicts what you stated during the inspection and connectivity issues would not explain why dates and times were subsequently edited. Your response also fails to provide documentation of how and which site staff requested modifications.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to retain records required to be maintained for a period of 2 years following the date a marketing application is approved. [21 CFR 312.62(c)]\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a clinical investigator, you are required to maintain records, including case histories, medical records, and doctor’s notes pertaining to the investigation for a period of 2 years following the date a marketing application is approved for the drug indication for which it is being investigated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(6)\u003C\u002Fstrong>&nbsp;recalled having written notes at the time of the two study visits, however she admitted that they may have been discarded. Discarding records prior to the 2-year post-approval period, whether intentional or unintentional, is a failure to retain records.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you submitted a photo (allegedly taken February 13, 2020) of an INCAT scale, dated February 7, 2020. You stated that the data was entered into the tablet on March 3, 2020 and \u003Cstrong>(b)(6)\u003C\u002Fstrong> destroyed the hand-written page but retained it in an electronic file. This photo file was not presented to the FDA investigator during the inspection but was found on \u003Cstrong>(b)(6)&nbsp;\u003C\u002Fstrong>phone following the inspection. You acknowledged that this was improper behavior and stated that it was an isolated event. We find your response inadequate because the photo was not presented during the inspection, and we cannot validate the date the photo was taken.\u003C\u002Fp>\n\n\u003Cp>We emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan and applicable regulations, to protect the rights, safety, and welfare of subjects, and to ensure the integrity of study data. Your lack of supervision and oversight, failure to maintain adequate and accurate subject case histories, and failure to conduct the clinical study in accordance with the protocol raises significant concerns about the validity and integrity of all the data collected at your site.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our observations of violations to the study protocol and provides you an opportunity to address the above deficiencies. You should investigate and determine the causes of any violations and take prompt actions to implement corrections to prevent the recurrence of similar violations in current and future studies for which are you are the study director.\u003C\u002Fp>\n\n\u003Cp>Your recent written response not only conflicts with information you gave during your inspection, it fails to address the observations and to provide any corrective action plans that you have implemented or plan to implement to prevent these types of violations in the future.\u003C\u002Fp>\n\n\u003Cp>If you believe that you have complied with the study protocol and applicable regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to FDA within fifteen (15) business days of receipt of this letter. In your response, please provide written documentation of additional actions you have taken or will take to correct any violations and to prevent the recurrence of similar violations in current and future studies for which you are the study director.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to me at the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., WO71-G112, Silver Spring, MD 20993-0002. If you have any questions regarding this letter, please contact the Division of Inspections and Surveillance, CBER at 240-402-8979.\u003C\u002Fp>\n\n\u003Cp>We also request that you send a copy of your response to the FDA Office listed below.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector, Office of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Baxalta US Inc.\u003Cbr>\n300 Shire Way\u003Cbr>\nLexington, MA 02421\u003C\u002Fp>\n\n\u003Cp>Barbara Wright, Supervisory Investigator\u003Cbr>\nFDA ORA-OBIMO Foreign Cadre\u003Cbr>\n2600 Citiplace Court, Suite 410\u003Cbr>\nBaton Rouge, LA, 70808\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Individual numeric assessment values were used to calculate the subject ability assessment scores.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS and Electronic Mail\n\nReference #:\n\nCBER 24-671405\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nKonrad Rejdak, M.D., Ph.D.\n\nKonrad Rejdak, M.D., Ph.D.\n\nKliniczny Nr 4 w Lublinie\n\nul. Jaczewskiego 8\n\n20-090 Lublin\n\nPoland\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nMay 29, 2024\n\nDear Dr. Rejdak:\n\nThis Warning Letter informs you of objectionable conditions observed during a United States Food and Drug Administration (FDA) inspection conducted between May 15 and May 19, 2023. During the inspection, an FDA investigator met with you and your staff to review the conduct and oversight of a clinical study titled:\n\nA Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA\u002FHyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID\u002FKIOVIG) for the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Protocol 161403) (hereinafter, the protocol).\n\nFDA conducted this inspection under the Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of clinical research involving investigational products for compliance with applicable requirements, including under 21 CFR Parts 50, 56, and 312.\n\nAt the conclusion of the inspection, the FDA investigator presented a Form FDA 483, List of Inspectional Observations (Form FDA 483) for your review and discussed with you and your staff the listed observations. Based upon our review of the Establishment Inspection Report (EIR), the accompanying exhibits and attachments, the Form FDA 483, and your written response, dated June 2, 2023, to the Form FDA 483 (“Response Letter”), we determined that you violated regulations governing the proper conduct of clinical studies involving investigational products in Title 21, Code of Federal Regulations (CFR) Part 312 (available at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcdrh\u002Fcfdocs\u002Fcfcfr\u002FCFRsearch.cfm?CFRPart=312).\n\nThe violations include, but are not limited to, the following:\n\n1. Failure to prepare and maintain adequate and accurate case histories that record all observations and other data pertinent to the investigation on each individual administered the investigational product [21 CFR 312.62(b)].\n\nIn multiple instances, subject ability assessment scores were not entered into (b)(4) tablets at the time of assessment. One of the three assessments used was the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale. The INCAT score was used as a primary efficacy assessment measure for the protocol. Gaps between assessment end time and data entry ranged from seven minutes to 25 days with no source documentation of 144 assessment values1 for four subjects over the course of nine visits. Protocol section 18.2 states that data not entered during the study visit should be recorded on paper, and then this documentation will be considered source documentation.\n\nThe subject ability assessment scores for these subjects were not entered at the time of assessment, there was no source documentation of the values, and the times and\u002For dates were later edited to appear as if the values were recorded at the time of assessment.\n\nYour Response Letter states that internet connections were poor due to the COVID-19 pandemic. As a result, raters entered the assessment data into the tablets at a later time, either based on written notes or on their memory. We find this response inadequate for several reasons: (1) it contradicts what was relayed by both sub investigators during the inspection; (2) all affected visits occurred prior to the beginning of the COVID-19 pandemic; and (3) values that were not recorded at the time of the assessment may not be accurate due to the length of time elapsed.\n\nYour Response Letter also states that scores could be entered into tablets in “offline mode” and uploaded once an internet connection was established. We find this explanation inadequate because this modality could not be demonstrated during the inspection. Your contradictory explanations, along with the gaps from assessment time to entry time, raise concerns about the reliability of the data and the integrity of your study conduct.\n\n2. Failure to ensure that the investigation was conducted according to the signed investigator statement, the investigational plan, and applicable regulations; failure to protect the rights, safety, and welfare of subjects under your care [21 CFR 312.60].\n\nSection 18.2 of the protocol states: “If electronic CRFs [case report forms] are provided by the sponsor, only authorized study site personnel will record or change data on the CRFs. If data is not entered on the CRFs during the study visit, the data will be recorded on paper, and this documentation will be considered source documentation.”\n\nTimes and\u002For dates for the aforementioned 144 assessment values were subsequently edited months after the assessment. These values were originally entered into the (b)(4) tablets between November 12, 2019 and February 8, 2020, by blinded raters, but their times and\u002For dates were later edited by non-study personnel on May 14, July 23, and July 28, 2020 and on July 12, 2022 to match the hand-written assessment times without source documentation of assessment values.\n\nDuring the inspection, the investigator questioned the revisions found in Audit Trail documents and you verbally stated that you did not know how or why assessment times and dates were edited.\n\nIn your Response Letter, you stated that assessment times and dates were manually entered by the eResearch Technology team at the sub investigator’s request for subjects (b)(6) due to connectivity or technical issues. We acknowledge that the Sponsor provided guidance that sites could request updates to the electronic CRF with the caveat that data was documented on paper at the time of assessment, however your site did not have source documentation of assessment scores.\n\nWe do not find your response adequate because it contradicts what you stated during the inspection and connectivity issues would not explain why dates and times were subsequently edited. Your response also fails to provide documentation of how and which site staff requested modifications.\n\n3. Failure to retain records required to be maintained for a period of 2 years following the date a marketing application is approved. [21 CFR 312.62(c)]\n\nAs a clinical investigator, you are required to maintain records, including case histories, medical records, and doctor’s notes pertaining to the investigation for a period of 2 years following the date a marketing application is approved for the drug indication for which it is being investigated.\n\n(b)(6) recalled having written notes at the time of the two study visits, however she admitted that they may have been discarded. Discarding records prior to the 2-year post-approval period, whether intentional or unintentional, is a failure to retain records.\n\nIn your Response Letter, you submitted a photo (allegedly taken February 13, 2020) of an INCAT scale, dated February 7, 2020. You stated that the data was entered into the tablet on March 3, 2020 and (b)(6) destroyed the hand-written page but retained it in an electronic file. This photo file was not presented to the FDA investigator during the inspection but was found on (b)(6) phone following the inspection. You acknowledged that this was improper behavior and stated that it was an isolated event. We find your response inadequate because the photo was not presented during the inspection, and we cannot validate the date the photo was taken.\n\nWe emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan and applicable regulations, to protect the rights, safety, and welfare of subjects, and to ensure the integrity of study data. Your lack of supervision and oversight, failure to maintain adequate and accurate subject case histories, and failure to conduct the clinical study in accordance with the protocol raises significant concerns about the validity and integrity of all the data collected at your site.\n\nThis letter notifies you of our observations of violations to the study protocol and provides you an opportunity to address the above deficiencies. You should investigate and determine the causes of any violations and take prompt actions to implement corrections to prevent the recurrence of similar violations in current and future studies for which are you are the study director.\n\nYour recent written response not only conflicts with information you gave during your inspection, it fails to address the observations and to provide any corrective action plans that you have implemented or plan to implement to prevent these types of violations in the future.\n\nIf you believe that you have complied with the study protocol and applicable regulations, please include your reasoning and any supporting information for our consideration.\n\nPlease submit a written response to FDA within fifteen (15) business days of receipt of this letter. In your response, please provide written documentation of additional actions you have taken or will take to correct any violations and to prevent the recurrence of similar violations in current and future studies for which you are the study director.\n\nYour response should be sent to me at the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., WO71-G112, Silver Spring, MD 20993-0002. If you have any questions regarding this letter, please contact the Division of Inspections and Surveillance, CBER at 240-402-8979.\n\nWe also request that you send a copy of your response to the FDA Office listed below.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector, Office of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\ncc:\n\nBaxalta US Inc.\n\n300 Shire Way\n\nLexington, MA 02421\n\nBarbara Wright, Supervisory Investigator\n\nFDA ORA-OBIMO Foreign Cadre\n\n2600 Citiplace Court, Suite 410\n\nBaton Rouge, LA, 70808\n\n__________________\n\n1 Individual numeric assessment values were used to calculate the subject ability assessment scores.","Konrad Rejdak, M.D., Ph.D.","konrad-rejdak-md-phd-671405-05292024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkonrad-rejdak-md-phd-671405-05292024","2026-10-26T08:09:10.045429+00:00","2024-08-13","671405","Biologics","2025-11-10","2026-08-19T23:53:49.156+00:00","UPS and Electronic Mail","CBER 24-671405","2024-05-29",{"id":284,"raw":285,"subject":12,"body_html":289,"body_text":290,"firm_name":291,"letter_id":292,"created_at":250,"fei_number":19,"letter_url":293,"updated_at":294,"action_type":22,"case_status":23,"posted_date":295,"marcs_cms_no":296,"product_type":26,"closeout_date":19,"issuing_office":102,"recipient_name":297,"body_fetched_at":298,"delivery_method":29,"recipient_title":19,"reference_number":299,"action_taken_date":300,"medical_device_id":19,"response_letter_date":19},1206,[286,287,288,102,12,13,13,13],"\u003Ctime datetime=\"2024-10-22T13:20:00Z\">10\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-10T04:00:00Z\">10\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsoliteint-kozmetikai-kft-685146-10102024\">Soliteint Kozmetikai KFT\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-03\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Hossam Mostafa\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Soliteint Kozmetikai KFT\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Fot, Pest\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Moricz Zsigmond UT 37\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>2151\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hungary\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 10, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-03&nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Mostafa:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Soliteint Kozmetikai KFT, FEI 3007001714, at Moricz Zsigmond UT 37, Fot, from April 15 to 19, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). &nbsp;\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B). &nbsp;\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 10, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP. &nbsp;\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately test the over-the-counter (OTC) external analgesic drug products you manufacture under contract (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Asutra Relieve your pain) for identity, and strength of each active ingredient prior to release and distribution. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that your drug product batches conform to appropriate specifications prior to release. &nbsp;\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision. &nbsp;\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter. &nbsp;\u003C\u002Fp>\n\n\u003Cp>o A summary of all results obtained from testing reserve samples from each batch of your drug products that remain within expiry. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate API Testing\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to ensure that incoming lots of active pharmaceutical ingredients (API) were suitable for use in manufacturing. For example, your firm used menthol and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture OTC external analgesic drug products based on a component supplier’s certificate of analysis (COA). However, you did not perform identity testing nor did your firm establish the reliability of the supplier’s analysis through appropriate validation. Although you stated that you routinely assessed your suppliers, the most recent inspection documented the last assessment was performed in March 2001.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Component Water\u003C\u002Fem> \u003Cem>Testing\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Due to problems with your water treatment system, your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong> water as a component in your drug products. You failed to provide data supporting the frequency of testing of your water system for total organic carbon. Pharmaceutical water must be suitable for its intended use, and routinely and adequately tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\n\n\u003Cp>Additionally, your water systems require monitoring to ensure the absence of biofilm forming microbes, e.g., \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex (BCC), in non-sterile, water-based topical drug products. For more information regarding the significance of BCC contamination in drug products, see FDA’s July 7, 2021 advisory for drug manufacturers.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Products Containing Glycerin\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Glycerin, along with other high-risk components, require identification testing per the USP to ensure that it meets safety limits for diethylene glycol (DEG) or ethylene glycol (EG). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of glycerin used in the manufacture of your drug products. &nbsp;\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other HighRisk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing. &nbsp;\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your water system design, control, and maintenance.\u003C\u002Fli>\n\t\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter. &nbsp;\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to conduct process validations for the OTC drug products you manufacture intended for the U.S. market. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies includes intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an&nbsp;initial state of control has been established. &nbsp;Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide: &nbsp;\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. &nbsp;\u003C\u002Fli>\n\t\u003Cli>A timeline for performing PPQ for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Your process performance protocol(s), and written procedures for qualification of equipment and facilities. &nbsp;\u003C\u002Fli>\n\t\u003Cli>A detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22). &nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked adequate procedures for an effective Quality Management System, including procedures describing the roles and responsibilities and controls for your quality unit over your OTC drug product manufacturing operations. You could not provide procedures for your CAPA, quality status labeling of components and OTC drug products, and control of master batch records. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm does not perform adequate stability testing to support the expiration date of \u003Cstrong>(b)(4)\u003C\u002Fstrong> assigned to the OTC external analgesic drug products. &nbsp;\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fp>\n\n\u003Cp>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fp>\n\n\u003Cp>o A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fp>\n\n\u003Cp>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Stability indicating methods.\u003C\u002Fp>\n\n\u003Cp>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003C\u002Fp>\n\n\u003Cp>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003C\u002Fp>\n\n\u003Cp>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. &nbsp;\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of all OTC drugs at this facility for the U.S. market. &nbsp;\u003C\u002Fp>\n\n\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.&nbsp; &nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong> &nbsp;\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on October 4, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Soliteint Kozmetikai KFT, Moricz Zsigmond UT 37, Fot, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B). &nbsp;\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007001714 and ATTN: Carrie Hughes. &nbsp; &nbsp; &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>Sincerely, &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC: &nbsp;\u003C\u002Fp>\n\n\u003Cp>Mr. Tamas Kalman, CEO, Wanadis KFT\u003Cbr>\nkalman.tamas@wanadiscosmetics.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-advises-drug-manufacturers-burkholderiacepacia-complex-poses-contamination-risk-non-sterile\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-03\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Hossam Mostafa\n\nRecipient Title\n\nManaging Director\n\nSoliteint Kozmetikai KFT\n\nFot, Pest\n\nMoricz Zsigmond UT 37\n\n2151\n\nHungary\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 10, 2024\n\nWarning Letter 320-25-03\n\nDear Dr. Mostafa:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Soliteint Kozmetikai KFT, FEI 3007001714, at Moricz Zsigmond UT 37, Fot, from April 15 to 19, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 10, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\n\nYour firm failed to adequately test the over-the-counter (OTC) external analgesic drug products you manufacture under contract (i.e., (b)(4), (b)(4), and Asutra Relieve your pain) for identity, and strength of each active ingredient prior to release and distribution.\n\nWithout adequate testing, you do not have scientific evidence that your drug product batches conform to appropriate specifications prior to release.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing reserve samples from each batch of your drug products that remain within expiry. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nInadequate API Testing\n\nYour firm failed to ensure that incoming lots of active pharmaceutical ingredients (API) were suitable for use in manufacturing. For example, your firm used menthol and (b)(4) to manufacture OTC external analgesic drug products based on a component supplier’s certificate of analysis (COA). However, you did not perform identity testing nor did your firm establish the reliability of the supplier’s analysis through appropriate validation. Although you stated that you routinely assessed your suppliers, the most recent inspection documented the last assessment was performed in March 2001.\n\nInadequate Component Water Testing\n\nDue to problems with your water treatment system, your firm used (b)(4) water as a component in your drug products. You failed to provide data supporting the frequency of testing of your water system for total organic carbon. Pharmaceutical water must be suitable for its intended use, and routinely and adequately tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\n\nAdditionally, your water systems require monitoring to ensure the absence of biofilm forming microbes, e.g., Burkholderia cepacia complex (BCC), in non-sterile, water-based topical drug products. For more information regarding the significance of BCC contamination in drug products, see FDA’s July 7, 2021 advisory for drug manufacturers.1\n\nProducts Containing Glycerin\n\nGlycerin, along with other high-risk components, require identification testing per the USP to ensure that it meets safety limits for diethylene glycol (DEG) or ethylene glycol (EG). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of glycerin used in the manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other HighRisk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA comprehensive, independent assessment of your water system design, control, and maintenance.\n\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\nRegarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm failed to conduct process validations for the OTC drug products you manufacture intended for the U.S. market.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies includes intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing PPQ for each of your marketed drug products.\n\nYour process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nA detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm lacked adequate procedures for an effective Quality Management System, including procedures describing the roles and responsibilities and controls for your quality unit over your OTC drug product manufacturing operations. You could not provide procedures for your CAPA, quality status labeling of components and OTC drug products, and control of master batch records.\n\nAdditionally, your firm does not perform adequate stability testing to support the expiration date of (b)(4) assigned to the OTC external analgesic drug products.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods.\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\n\no Detailed definition of the specific attributes to be tested at each station (timepoint).\n\nAll procedures that describe these and other elements of your remediated stability program.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of all OTC drugs at this facility for the U.S. market.\n\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on October 4, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Soliteint Kozmetikai KFT, Moricz Zsigmond UT 37, Fot, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007001714 and ATTN: Carrie Hughes.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nMr. Tamas Kalman, CEO, Wanadis KFT\n\nkalman.tamas@wanadiscosmetics.com\n\n___________________\n\n1 https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-advises-drug-manufacturers-burkholderiacepacia-complex-poses-contamination-risk-non-sterile","Soliteint Kozmetikai KFT","soliteint-kozmetikai-kft-685146-10102024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsoliteint-kozmetikai-kft-685146-10102024","2026-10-26T08:10:01.217397+00:00","2024-10-22","685146","Dr. Hossam Mostafa","2026-08-19T22:17:39.977+00:00","320-25-03","2024-10-10",{"id":302,"raw":303,"subject":308,"body_html":309,"body_text":310,"firm_name":311,"letter_id":312,"created_at":313,"fei_number":19,"letter_url":314,"updated_at":315,"action_type":22,"case_status":23,"posted_date":316,"marcs_cms_no":317,"product_type":26,"closeout_date":19,"issuing_office":165,"recipient_name":318,"body_fetched_at":319,"delivery_method":177,"recipient_title":19,"reference_number":19,"action_taken_date":320,"medical_device_id":19,"response_letter_date":19},3576,[304,305,306,165,307,13,13,13],"\u003Ctime datetime=\"2021-01-26T14:20:00Z\">01\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-25T05:00:00Z\">01\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrupo-plast-y-kosas-sa-de-cv-609493-01252021\">Grupo Plast-Y-Kosas, SA de CV\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Wenceslao Garcia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Grupo Plast-Y-Kosas, SA de CV\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Callejon Puebla 105-Co\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Col. Rodriguez\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>88630\u003C\u002Fspan> \u003Cspan>Reynosa\u003C\u002Fspan>, \u003Cspan>Tamps.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-18\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nJanuary 25, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Garcia:\u003C\u002Fp>\n\n\u003Cp>Your firm was registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of consumer antiseptic rub drug products (also referred to as a consumer hand sanitizer) labeled asM HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER. These drug products were labeled as manufactured at your facility, Grupo Plast-Y-Kosas SA de CV, FEI 3016756400, at Callejon Puebla 105, Reynosa, Tamaulipas, Mexico. Following an attempt to import M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER into the United States, they were detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch ofM HAND SANITIZER drug product detained at the border demonstrate that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of batches of Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER drug products detained at the border demonstrate that these drug products are adulterated within the meaning of section 501(c) of the FD&amp;C Act, 21 U.S.C. 351(c), in that their strength, purity, or quality falls below that which they purport or are represented to possess. In addition, these products are adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a) and are misbranded under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee). Additionally, M HAND SANITIZER is misbranded under sections 502(j) and (e) of the FD&amp;C Act, 21 U.S.C. 352(j) and (e). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>M HAND SANITIZER, labeled as being manufactured at your facility, is labeled to contain 80% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this drug product detained at the border found that the drug product contained an average of 0.87% ethanol v\u002Fv and 15% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products and adolescents and adults who drink these products as an alcohol (ethanol) substitute are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>Jalisco Paper Inc. HAND SANITIZER, labeled as manufactured at your facility, is labeled to contain 80% v\u002Fv of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained only 8.6% ethanol v\u002Fv. Additionally, O.K. PHARMACY HAND SANITIZER, labeled as manufactured at your facility, is labeled to contain 80% v\u002Fv of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained only 9.2% ethanol v\u002Fv. These hand sanitizer drug products are adulterated under section 501(c) of the FD&amp;C Act in that the active ingredient of ethanol is present at levels in the products lower than that which is declared on their labeling.\u003C\u002Fp>\n\n\u003Cp>CDC recommends that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>On August 11, 2020, FDA notified the public of the methanol contamination of your drugs at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003Cbr>\n\u003Cbr>\nOn August 20, 2020, FDA held a teleconference with your counsel, Davidson Law Group, P.A. which stated that it represents both you and your registered US Agent,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> MEDEK LLC. We recommended to your counsel that you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On September 9, 2020, you issued a voluntary nationwide recall of M HAND SANITIZER due to potential presence of undeclared methanol (Wood Alcohol), as noted on the following FDA website:\u003Cbr>\n\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fmedek-llc-issues-voluntary-nationwide-recall-m-hand-sanitizer-due-potential-presence-methanol-wood\">https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fmedek-llc-issues-voluntary-nationwide-recall-m-hand-sanitizer-due-potential-presence-methanol-wood\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed investigation into how the M HAND SANITIZER drug product, which was manufactured at your facility, and which was labeled as containing alcohol (ethanol), was substituted in part or in whole with methanol.\u003Cbr>\n• A detailed investigation into how the Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER drug products you manufactured, and labeled as containing 80% alcohol (ethanol), in fact contained 8.6% and 9.2% ethanol, respectively.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fp>\n\n\u003Cp>The substitution and contamination with methanol and the subpotency of hand sanitizer drug products labeled as manufactured in your facility demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are intended for use as consumer topical antiseptics.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER product labels and labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Drug Facts…Uses…Hand Sanitizer to help reduce bacteria that potentially can cause disease. For use when soap and water are not available.\u003C\u002Fp>\n\n\u003Cp>These topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for these products, as further described below). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your M HAND SANITIZER , Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER drug products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER Alcohol Free do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to their product labels, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER purportedly contain the active ingredient ethyl alcohol (ethanol) 80% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of these products detained at the border demonstrate that M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER contain ethanol in a concentration that is less than the 80% v\u002Fv stated on their product labels and less than the amount of ethanol described in the 1994 TFM. Such products do not conform with the TFM or the applicable requirements,\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> nor are they consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses also demonstrate that a batch of M HAND SANITIZER contains significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this methanol-containing drug product, M HAND SANITIZER, is misbranded under sections 502(j), (a), (e), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), and (ee). It is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death. M HAND SANITIZER is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false and misleading. As noted above, M HAND SANITIZER is labeled to contain ethyl alcohol (ethanol) 80% v\u002Fv. However, FDA laboratory analyses demonstrate that a batch of this product contains a concentration of ethyl alcohol (ethanol) that is far less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result…..” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). The failure of M HAND SANITIZER to list methanol as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A).\u003C\u002Fp>\n\n\u003Cp>Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because their labeling is false and misleading. As noted above, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are labeled to contain ethyl alcohol (ethanol) 80%. However, FDA laboratory analyses revealed that batches of these products contain concentrations of ethanol that are far less than that stated on their respective product labels.\u003C\u002Fp>\n\n\u003Cp>Lastly, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but they do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 11, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.go\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016756400 and ATTN: Michael Klapal\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered US Agent:\u003Cbr>\nDennis Garcia, Owner\u003Cbr>\nMEDEK LLC\u003Cbr>\n315 E Business Highway 83\u003Cbr>\nAlamo, TX 78516-9627\u003C\u002Fp>\n\n\u003Cp>Regulatory Counsel:\u003Cbr>\nScott J. Davidson\u003Cbr>\nDavidson Law Group, P.A.\u003Cbr>\n7950 NW 53rd Street\u003Cbr>\nSuite 337\u003Cbr>\nMiami, FL 33166\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under section 510(i)(1) of the FD&amp;C Act, 21 U.S.C. 360(i)(1), you are required to submit registration information annually by electronic means for each foreign establishment you own or operate engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States, and include the name of the United States Agent. On May 12, 2020, the registration for Grupo Plast Y Kosas identified Medek (DUNS 055524072) as the U.S. Agent. As a drug manufacturer, it is your responsibility to ensure complete and accurate registration information.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution and subpotency of hand sanitizer products declared or labeled as manufactured at your facility, FDA laboratory examination of the O.K. PHARMACY HAND SANITIZER found it to be a gel-like liquid which indicates undeclared ingredients were used in its manufacture and consequently it was not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are not consistent with the formulations in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in OTC monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Wenceslao Garcia\n\nRecipient Title\n\nOwner\n\nGrupo Plast-Y-Kosas, SA de CV\n\nCallejon Puebla 105-Co\n\nCol. Rodriguez\n\n88630 Reynosa, Tamps.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-18\n\nJanuary 25, 2021\n\nDear Mr. Garcia:\n\nYour firm was registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of consumer antiseptic rub drug products (also referred to as a consumer hand sanitizer) labeled asM HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER. These drug products were labeled as manufactured at your facility, Grupo Plast-Y-Kosas SA de CV, FEI 3016756400, at Callejon Puebla 105, Reynosa, Tamaulipas, Mexico. Following an attempt to import M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER into the United States, they were detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch ofM HAND SANITIZER drug product detained at the border demonstrate that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nThe results of the FDA laboratory testing of batches of Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER drug products detained at the border demonstrate that these drug products are adulterated within the meaning of section 501(c) of the FD&C Act, 21 U.S.C. 351(c), in that their strength, purity, or quality falls below that which they purport or are represented to possess. In addition, these products are adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements.\n\nIn addition, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a) and are misbranded under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee). Additionally, M HAND SANITIZER is misbranded under sections 502(j) and (e) of the FD&C Act, 21 U.S.C. 352(j) and (e). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nM HAND SANITIZER, labeled as being manufactured at your facility, is labeled to contain 80% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this drug product detained at the border found that the drug product contained an average of 0.87% ethanol v\u002Fv and 15% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products and adolescents and adults who drink these products as an alcohol (ethanol) substitute are most at risk for methanol poisoning.\n\nJalisco Paper Inc. HAND SANITIZER, labeled as manufactured at your facility, is labeled to contain 80% v\u002Fv of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained only 8.6% ethanol v\u002Fv. Additionally, O.K. PHARMACY HAND SANITIZER, labeled as manufactured at your facility, is labeled to contain 80% v\u002Fv of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained only 9.2% ethanol v\u002Fv. These hand sanitizer drug products are adulterated under section 501(c) of the FD&C Act in that the active ingredient of ethanol is present at levels in the products lower than that which is declared on their labeling.\n\nCDC recommends that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOn August 11, 2020, FDA notified the public of the methanol contamination of your drugs at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nOn August 20, 2020, FDA held a teleconference with your counsel, Davidson Law Group, P.A. which stated that it represents both you and your registered US Agent,1 MEDEK LLC. We recommended to your counsel that you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On September 9, 2020, you issued a voluntary nationwide recall of M HAND SANITIZER due to potential presence of undeclared methanol (Wood Alcohol), as noted on the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fmedek-llc-issues-voluntary-nationwide-recall-m-hand-sanitizer-due-potential-presence-methanol-wood.\n\nIn response to this letter provide the following:\n\n• A detailed investigation into how the M HAND SANITIZER drug product, which was manufactured at your facility, and which was labeled as containing alcohol (ethanol), was substituted in part or in whole with methanol.\n\n• A detailed investigation into how the Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER drug products you manufactured, and labeled as containing 80% alcohol (ethanol), in fact contained 8.6% and 9.2% ethanol, respectively.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the U.S.\n\nThe substitution and contamination with methanol and the subpotency of hand sanitizer drug products labeled as manufactured in your facility demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.2\n\nUnapproved New Drug and Misbranding Violations\n\nM HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are intended for use as consumer topical antiseptics.\n\nExamples of claims observed on the M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER, and O.K. PHARMACY HAND SANITIZER product labels and labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\nDrug Facts…Uses…Hand Sanitizer to help reduce bacteria that potentially can cause disease. For use when soap and water are not available.\n\nThese topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for these products, as further described below). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your M HAND SANITIZER , Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER drug products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER Alcohol Free do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to their product labels, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER purportedly contain the active ingredient ethyl alcohol (ethanol) 80% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of these products detained at the border demonstrate that M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER contain ethanol in a concentration that is less than the 80% v\u002Fv stated on their product labels and less than the amount of ethanol described in the 1994 TFM. Such products do not conform with the TFM or the applicable requirements,3 nor are they consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.4\n\nFDA laboratory analyses also demonstrate that a batch of M HAND SANITIZER contains significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.5\n\nAdditionally, this methanol-containing drug product, M HAND SANITIZER, is misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), and (ee). It is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death. M HAND SANITIZER is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false and misleading. As noted above, M HAND SANITIZER is labeled to contain ethyl alcohol (ethanol) 80% v\u002Fv. However, FDA laboratory analyses demonstrate that a batch of this product contains a concentration of ethyl alcohol (ethanol) that is far less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result…..” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). The failure of M HAND SANITIZER to list methanol as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A).\n\nJalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because their labeling is false and misleading. As noted above, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are labeled to contain ethyl alcohol (ethanol) 80%. However, FDA laboratory analyses revealed that batches of these products contain concentrations of ethanol that are far less than that stated on their respective product labels.\n\nLastly, M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but they do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 11, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.go\n\nIdentify your response with FEI 3016756400 and ATTN: Michael Klapal\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered US Agent:\n\nDennis Garcia, Owner\n\nMEDEK LLC\n\n315 E Business Highway 83\n\nAlamo, TX 78516-9627\n\nRegulatory Counsel:\n\nScott J. Davidson\n\nDavidson Law Group, P.A.\n\n7950 NW 53rd Street\n\nSuite 337\n\nMiami, FL 33166\n\n________________________________\n\n1 Under section 510(i)(1) of the FD&C Act, 21 U.S.C. 360(i)(1), you are required to submit registration information annually by electronic means for each foreign establishment you own or operate engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States, and include the name of the United States Agent. On May 12, 2020, the registration for Grupo Plast Y Kosas identified Medek (DUNS 055524072) as the U.S. Agent. As a drug manufacturer, it is your responsibility to ensure complete and accurate registration information.\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution and subpotency of hand sanitizer products declared or labeled as manufactured at your facility, FDA laboratory examination of the O.K. PHARMACY HAND SANITIZER found it to be a gel-like liquid which indicates undeclared ingredients were used in its manufacture and consequently it was not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n3 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n4 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because M HAND SANITIZER, Jalisco Paper Inc. HAND SANITIZER and O.K. PHARMACY HAND SANITIZER are not consistent with the formulations in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n5 An inactive ingredient used in OTC monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","Grupo Plast-Y-Kosas, SA de CV","grupo-plast-y-kosas-sa-de-cv-609493-01252021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrupo-plast-y-kosas-sa-de-cv-609493-01252021","2026-10-26T08:08:50.716277+00:00","2021-01-26","609493","Mr. Wenceslao Garcia","2026-08-20T03:26:37.801+00:00","2021-01-25",{"id":322,"raw":323,"subject":326,"body_html":327,"body_text":328,"firm_name":329,"letter_id":330,"created_at":190,"fei_number":19,"letter_url":331,"updated_at":332,"action_type":22,"case_status":23,"posted_date":111,"marcs_cms_no":333,"product_type":26,"closeout_date":19,"issuing_office":102,"recipient_name":19,"body_fetched_at":334,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},495,[324,100,325,102,326,13,13,13],"\u003Ctime datetime=\"2025-11-05T17:00:00Z\">11\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkorean-aesthetic-dba-korean-fillers-718842-11032025\">Korean Aesthetic dba Korean Fillers\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded Botox","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Korean Aesthetic dba Korean Fillers\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 3, 2025\u003C\u002Fp>\u003Cp>Korean Aesthetic dba Korean Fillers:\u003C\u002Fp>\u003Cp>This is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.koreanfillers.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. As discussed below, FDA has observed that www.koreanfillers.com introduces into interstate commerce unapproved and misbranded injectable botulinum toxin drug products.\u003C\u002Fp>\u003Cp>There are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Accordingly, FDA requests that www.koreanfillers.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Certain products offered for sale by www.koreanfillers.com are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&amp;C Act are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>An example of an unapproved botulinum toxin drug product you offer for sale on www.koreanfillers.com is botulinum toxin type A marketed as “MEDITOXIN BOTULINUM TOXIN”, “Cosmetics Medi 2”, and “Meditoxin Botulinum Toxin 200U”. Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claims “it can also function as a treatment for essential blepharospasm” and “It also shows significant effects on controlling cerebral palsy and helping to reduce post-stroke upper limb spasticity.”\u003C\u002Fp>\u003Cp>While there are FDA-approved versions of botulinum toxin drug products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for “MEDITOXIN BOTULINUM TOXIN”, “Cosmetics Medi 2”, and “Meditoxin Botulinum Toxin 200U” offered by www.koreanfillers.com. Currently there are several botulinum toxin products FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. Examples of FDA-approved botulinum toxin products with a summary of their indications are: BOTOX® (onabotulinumtoxinA), indicated for the treatment of overactive bladder, neurogenic detrusor overactivity, chronic migraine, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, strabismus, and blepharospasm and prophylaxis of headaches in adults with chronic migraines; DAXXIFY® (daxibotulinumtoxinA-lanm), indicated for the temporary improvement in the appearance of glabellar lines and the treatment of cervical dystonia; and MYOBLOC® (rimabotulinumtoxinB), indicated for the treatment of cervical dystonia and chronic sialorrhea.\u003C\u002Fp>\u003Cp>Furthermore, FDA-approved botulinum toxin drug products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of distant spread of toxin effect to produce symptoms consistent with botulinum toxin effects. In addition, swallowing and breathing difficulties can be life threatening and there have been reports of death.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] if its labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fail to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&amp;C Act. In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. By offering these drugs for sale to U.S. consumers, www.koreanfillers.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>FDA is sending this warning letter to www.koreanfillers.com because of the inherent risks to consumers who purchase misbranded and unapproved new drugs. This letter is not intended to identify all the ways in which your products or operations might be in violation of the law. It is your responsibility to ensure that all products you offer for sale are in compliance with the FD&amp;C Act and its implementing regulations. You should take prompt action to address any violations of the FD&amp;C Act (which may include the offer for sale of similarly misbranded and\u002For unapproved new drugs other than the drug products noted above). We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a use for which they have not been approved by FDA and that you are not distributing misbranded and unapproved drug products in violation of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction, without further notice. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within 15 working days.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please direct your response and any inquiries to FDA at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Sangeeta Vaswani Chatterjee, Pharm.D.\u003Cbr>Acting Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nKorean Aesthetic dba Korean Fillers\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nNovember 3, 2025\nKorean Aesthetic dba Korean Fillers:\nThis is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.koreanfillers.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. As discussed below, FDA has observed that www.koreanfillers.com introduces into interstate commerce unapproved and misbranded injectable botulinum toxin drug products.\nThere are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Accordingly, FDA requests that www.koreanfillers.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\nUnapproved New Drugs:\nCertain products offered for sale by www.koreanfillers.com are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act.\nAn example of an unapproved botulinum toxin drug product you offer for sale on www.koreanfillers.com is botulinum toxin type A marketed as “MEDITOXIN BOTULINUM TOXIN”, “Cosmetics Medi 2”, and “Meditoxin Botulinum Toxin 200U”. Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claims “it can also function as a treatment for essential blepharospasm” and “It also shows significant effects on controlling cerebral palsy and helping to reduce post-stroke upper limb spasticity.”\nWhile there are FDA-approved versions of botulinum toxin drug products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for “MEDITOXIN BOTULINUM TOXIN”, “Cosmetics Medi 2”, and “Meditoxin Botulinum Toxin 200U” offered by www.koreanfillers.com. Currently there are several botulinum toxin products FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. Examples of FDA-approved botulinum toxin products with a summary of their indications are: BOTOX® (onabotulinumtoxinA), indicated for the treatment of overactive bladder, neurogenic detrusor overactivity, chronic migraine, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, strabismus, and blepharospasm and prophylaxis of headaches in adults with chronic migraines; DAXXIFY® (daxibotulinumtoxinA-lanm), indicated for the temporary improvement in the appearance of glabellar lines and the treatment of cervical dystonia; and MYOBLOC® (rimabotulinumtoxinB), indicated for the treatment of cervical dystonia and chronic sialorrhea.\nFurthermore, FDA-approved botulinum toxin drug products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of distant spread of toxin effect to produce symptoms consistent with botulinum toxin effects. In addition, swallowing and breathing difficulties can be life threatening and there have been reports of death.\nMisbranded Drugs:\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if its labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner.\nBecause the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fail to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, www.koreanfillers.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nFDA is sending this warning letter to www.koreanfillers.com because of the inherent risks to consumers who purchase misbranded and unapproved new drugs. This letter is not intended to identify all the ways in which your products or operations might be in violation of the law. It is your responsibility to ensure that all products you offer for sale are in compliance with the FD&C Act and its implementing regulations. You should take prompt action to address any violations of the FD&C Act (which may include the offer for sale of similarly misbranded and\u002For unapproved new drugs other than the drug products noted above). We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a use for which they have not been approved by FDA and that you are not distributing misbranded and unapproved drug products in violation of the FD&C Act.\nPlease notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction, without further notice. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days.\nIf you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the U.S.\nPlease direct your response and any inquiries to FDA at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, Pharm.D.\nActing Director\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research","Korean Aesthetic dba Korean Fillers","korean-aesthetic-dba-korean-fillers-718842-11032025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkorean-aesthetic-dba-korean-fillers-718842-11032025","2026-10-26T08:09:10.131563+00:00","718842","2026-08-19T16:11:18.905+00:00",{"id":336,"raw":337,"subject":341,"body_html":342,"body_text":343,"firm_name":344,"letter_id":345,"created_at":190,"fei_number":19,"letter_url":346,"updated_at":347,"action_type":22,"case_status":23,"posted_date":348,"marcs_cms_no":349,"product_type":26,"closeout_date":19,"issuing_office":102,"recipient_name":350,"body_fetched_at":351,"delivery_method":177,"recipient_title":19,"reference_number":352,"action_taken_date":353,"medical_device_id":19,"response_letter_date":19},119,[338,339,340,102,341,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ferkul-kozmetik-sanayi-ve-ticaret-721964-06022026\">Erkul Kozmetik Sanayi ve Ticaret A.S.\u003C\u002Fa>","CGMP\u002FOTC Finished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-85\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Fatma Faize Aktar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Erkul Kozmetik Sanayi ve Ticaret A.S.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Cihangir Mahallesi, Petrol Ofisi Caddesi No: 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Avcilar\u003C\u002Fspan>\u002F\u003Cspan>İstanbul\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Turkey\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-26-85\u003C\u002Fp>\u003Cp>June 2, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Aktar:\u003C\u002Fp>\u003Cp>Your facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 25, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Erkul Kozmetik Sanayi ve Ticaret A.S., FEI 3012641739, at Cihangir Mahallesi, Petrol Ofisi Caddesi No: 1, Avcilar, Istanbul, as well as subsequent correspondence.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products labeled to contain the active drug ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These drug products are labeled and formulated to contain the inactive ingredient talc. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> is composed of more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>%\u003Cstrong> \u003C\u002Fstrong>talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products containing talc are considered higher-risk drugs as they pertain to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation.\u003C\u002Fp>\u003Cp>You have not demonstrated that you have appropriately tested incoming talc-containing drug components used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products for identity, purity, strength, and quality. In response to our 704(a)(4) request, you indicate that you did not conduct identity testing on the talc you used to manufacture drug products. Furthermore, your records indicate that neither you nor your suppliers conducted appropriate tests for asbestos in talc.\u003C\u002Fp>\u003Cp>In subsequent correspondence you provided documentation that you had a contract laboratory test components for the presence of asbestos, for which they reported “Not Detected” results, but you have not demonstrated that this testing was conducted on all lots used in drug product manufacturing. Additionally, you have not demonstrated that your test methods are validated to show that they are suitable for their intended use. Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Identity, assay and impurity test results from testing retains for all lots of talc-containing drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate written specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that your test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). The current United States Pharmacopeia (USP) talc monograph could be used to meet this requirement for talc; however, specifications for your components containing talc failed to include testing for assay and multiple impurities (e.g., limits of \u003Cstrong>(b)(4)\u003C\u002Fstrong>), as well as total combined molds and yeasts enumeration. Notably, you failed to have a specification that includes a test for the absence of asbestos. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fli>\u003Cli>A complete and final review of representative batches within expiry and their related information before the QU disposition decision.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Deregistration and Ceasing of Distribution of Drugs to the U.S.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Shortly after receiving our records request, you cancelled your drug registration, and sent correspondence indicating that you had not shipped drug products to the United States after December 2024. Contrary to this statement, FDA import records indicate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products had been shipped to the United States in 2025. FDA placed your firm on import alert on March 17, 2026, and your firm may remain on import alert until FDA can inspect your facility and verify you are in compliance with CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Specifications Regarding Talc\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Talc is a USP article, whose specification can be found in the current USP talc monograph. As mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that drugs including components, such as talc, that are recognized in the USP are generally required to meet the current applicable USP monograph under section 501(b) of the FD&amp;C Act. FDA reviewed your specifications for talc-containing components and they are incomplete when compared to the current USP specification. We note that the USP has recently revised its monograph for talc which includes updated technical requirements for asbestos testing in talc and is currently scheduled to be official in June 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs offered for import into the United States from your firm on Import Alert 66-40 on March 17, 2026.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Erkul Kozmetik Sanayi ve Ticaret A.S., Cihangir Mahallesi, Petrol Ofisi Caddesi No: 1, Avcilar, Istanbul into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012641739 and ATTN: Sena G. Dissmeyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>CC:\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cstrong>1\u003C\u002Fstrong> https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\u003C\u002Fp>\u003Cp>\u003Cstrong>2\u003C\u002Fstrong> https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-85\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Fatma Faize Aktar\n\nRecipient Title\n\nGeneral Manager\n\nErkul Kozmetik Sanayi ve Ticaret A.S.\n\nCihangir Mahallesi, Petrol Ofisi Caddesi No: 1\n\nAvcilar\u002Fİstanbul\n\nTurkey\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-85\nJune 2, 2026\nDear Ms. Aktar:\nYour facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 25, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Erkul Kozmetik Sanayi ve Ticaret A.S., FEI 3012641739, at Cihangir Mahallesi, Petrol Ofisi Caddesi No: 1, Avcilar, Istanbul, as well as subsequent correspondence.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\nYour firm manufactures OTC (b)(4) drug products labeled to contain the active drug ingredient (b)(4). These drug products are labeled and formulated to contain the inactive ingredient talc. For example, (b)(4) is composed of more than (b)(4)% talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.1,2 Your (b)(4) drug products containing talc are considered higher-risk drugs as they pertain to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation.\nYou have not demonstrated that you have appropriately tested incoming talc-containing drug components used in the manufacture of your (b)(4) drug products for identity, purity, strength, and quality. In response to our 704(a)(4) request, you indicate that you did not conduct identity testing on the talc you used to manufacture drug products. Furthermore, your records indicate that neither you nor your suppliers conducted appropriate tests for asbestos in talc.\nIn subsequent correspondence you provided documentation that you had a contract laboratory test components for the presence of asbestos, for which they reported “Not Detected” results, but you have not demonstrated that this testing was conducted on all lots used in drug product manufacturing. Additionally, you have not demonstrated that your test methods are validated to show that they are suitable for their intended use. Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\nAs a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\nIn response to this letter, provide:\nIdentity, assay and impurity test results from testing retains for all lots of talc-containing drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\nA description of how you will test each component lot for conformity with all appropriate written specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\nThe chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that your test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). The current United States Pharmacopeia (USP) talc monograph could be used to meet this requirement for talc; however, specifications for your components containing talc failed to include testing for assay and multiple impurities (e.g., limits of (b)(4)), as well as total combined molds and yeasts enumeration. Notably, you failed to have a specification that includes a test for the absence of asbestos. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\nYour QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate.\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\nA complete and final review of representative batches within expiry and their related information before the QU disposition decision.\nDeregistration and Ceasing of Distribution of Drugs to the U.S.\nShortly after receiving our records request, you cancelled your drug registration, and sent correspondence indicating that you had not shipped drug products to the United States after December 2024. Contrary to this statement, FDA import records indicate that your (b)(4) drug products had been shipped to the United States in 2025. FDA placed your firm on import alert on March 17, 2026, and your firm may remain on import alert until FDA can inspect your facility and verify you are in compliance with CGMP.\nQuality Specifications Regarding Talc\nTalc is a USP article, whose specification can be found in the current USP talc monograph. As mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that drugs including components, such as talc, that are recognized in the USP are generally required to meet the current applicable USP monograph under section 501(b) of the FD&C Act. FDA reviewed your specifications for talc-containing components and they are incomplete when compared to the current USP specification. We note that the USP has recently revised its monograph for talc which includes updated technical requirements for asbestos testing in talc and is currently scheduled to be official in June 2026.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs offered for import into the United States from your firm on Import Alert 66-40 on March 17, 2026.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Erkul Kozmetik Sanayi ve Ticaret A.S., Cihangir Mahallesi, Petrol Ofisi Caddesi No: 1, Avcilar, Istanbul into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012641739 and ATTN: Sena G. Dissmeyer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCC:\n(b)(4)\n_______________________\n1 https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\n2 https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F","Erkul Kozmetik Sanayi ve Ticaret A.S.","erkul-kozmetik-sanayi-ve-ticaret-721964-06022026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ferkul-kozmetik-sanayi-ve-ticaret-721964-06022026","2026-10-26T08:08:36.146271+00:00","2026-06-09","721964","Ms. Fatma Faize Aktar","2026-08-19T04:37:34.011+00:00","320-26-85","2026-06-02",{"id":355,"raw":356,"subject":361,"body_html":362,"body_text":363,"firm_name":364,"letter_id":365,"created_at":190,"fei_number":19,"letter_url":366,"updated_at":367,"action_type":22,"case_status":23,"posted_date":368,"marcs_cms_no":369,"product_type":71,"closeout_date":19,"issuing_office":360,"recipient_name":370,"body_fetched_at":371,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":372,"medical_device_id":19,"response_letter_date":19},187,[357,358,359,360,361,13,13,13],"\u003Ctime datetime=\"2026-05-05T04:00:00Z\">05\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-14T05:00:00Z\">01\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmin-jiang-food-store-inc-dba-koi-koi-trading-718312-01142026\">Min Jiang Food Store Inc dba Koi Koi Trading \u003C\u002Fa>","Human Foods Program","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Renfen Qiu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Min Jiang Food Store Inc dba Koi Koi Trading \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2710 Yates Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Commerce\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90040-2624\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:bobby@koikoitrading.com\"> bobby@koikoitrading.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 14, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS Case # 718312\u003C\u002Fp>\u003Cp>Dear Mr. Qiu:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your ready-to-eat (RTE) seafood processing facility, located at 2710 Yates Avenue, Commerce, CA 90040-2624, from June 10 through June 24, 2025. During our inspection, FDA investigators found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123. Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analysis of the environmental swabs found the presence of non-pathogenic \u003Cem>Listeria welshimeri (L. welshimeri)\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional and the analytical results for samples collected from your production environment, we have determined that your raw, RTE fish products, including salmon, are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. § 342(a)(4)) in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. Furthermore, in accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)]. Accordingly, your fresh tuna portions are also adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)]. You may find the Act, the seafood HACCP regulation, and the June 2022 Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator issued a Form FDA 483 (FDA-483), Inspectional Observations, listing the violations found at your facility. You provided a response to the inspection on July 3, 2025, describing corrective actions taken or planned by your firm. After reviewing the inspectional findings, analytical results, and the response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility. We address your response below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Environmental Samples\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA investigators collected environmental swabs (FDA Sample 1267630) from various areas in your processing facility on June 17, 2025, during the production of RTE fresh aquacultured imported salmon intended for raw consumption. FDA laboratory analysis found that forty-one (41) of the one hundred ten (110) environmental swabs were positive for non-pathogenic L. welshimeri. Of the 41 positive swabs, \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (fourteen (14) swabs) were collected from food-contact surfaces in areas where raw, RTE salmon products are processed. The positive food-contact surfaces included:\u003C\u002Fp>\u003Cul>\u003Cli>the blades of the small and large Victorinox knives on the shelf of table \u003Cstrong>(b)(4)\u003C\u002Fstrong> that are used to cut RTE fish;\u003C\u002Fli>\u003Cli>the blade of the Victorinox knife on the shelf of table \u003Cstrong>(b)(4)\u003C\u002Fstrong> that is used to cut RTE fish;\u003C\u002Fli>\u003Cli>the \u003Cstrong>(b)(4)\u003C\u002Fstrong> surface of table \u003Cstrong>(b)(4)\u003C\u002Fstrong> where RTE fish is prepared;\u003C\u002Fli>\u003Cli>the \u003Cstrong>(b)(4)\u003C\u002Fstrong> surfaces of table \u003Cstrong>(b)(4)\u003C\u002Fstrong> where RTE fish is prepared; and\u003C\u002Fli>\u003Cli>the \u003Cstrong>(b)(4)\u003C\u002Fstrong> surface of table \u003Cstrong>(b)(4)\u003C\u002Fstrong> where RTE fish is prepared.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Furthermore, your firm has a history of \u003Cem>Listeria\u003C\u002Fem> contamination, including pathogenic \u003Cem>Listeria monocytogenes (L. monocytogenes)\u003C\u002Fem> in your facility. During a previous FDA inspection, environmental sample 1132407 collected on March 9, 2020, from various areas in your firm’s processing facility identified three (3) of ninety-eight (98) swabs positive for \u003Cem>L. monocytogenes\u003C\u002Fem>, including one (1) positive swab from a food-contact surface (i.e., the top of table \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is the cutting board used for de-scaling and filleting RTE salmon). Whole genome sequencing (WGS) conducted on these \u003Cem>L. monocytogenes\u003C\u002Fem> isolates revealed that the isolates were genetically identical to one another, representing the same strain. Furthermore, this strain was highly related to another fifteen (15) environmental isolates collected in 2015 and 2016 from another food processing facility in California. Additionally, forty-eight (48) of ninety-eight (98) swabs were positive for \u003Cem>Listeria\u003C\u002Fem> species, including \u003Cem>L. innocua\u003C\u002Fem> and \u003Cem>L. welshimeri\u003C\u002Fem>. We advised you of the importance of these \u003Cem>Listeria\u003C\u002Fem> findings during a Regulatory Meeting held with your firm on May 5, 2020.\u003C\u002Fp>\u003Cp>The high-level of non-pathogenic \u003Cem>Listeria\u003C\u002Fem> species in your facility demonstrates your sanitation procedures have been inadequate to effectively control microbial contamination in your facility. Appropriate control of \u003Cem>Listeria\u003C\u002Fem> species in a food processing environment requires knowledge of the unique characteristics of the organism and implementation of the hygienic practices necessary to control this microbe. Once \u003Cem>Listeria\u003C\u002Fem> species is established in a production area, personnel or equipment can facilitate the microbe’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the harborage sites in the food processing plant and equipment where this organism is able to grow and survive, and to apply controls or take corrective actions as necessary to eradicate the organism by rendering these areas unable to support the survival and growth of the organism and to prevent the organism from being re-established in such sites.\u003C\u002Fp>\u003Cp>The presence of non-pathogenic \u003Cem>Listeria\u003C\u002Fem> species indicates insanitary conditions suitable for the survival and growth of the pathogenic \u003Cem>L. monocytogenes\u003C\u002Fem>, which, as noted above, has been previously found in your facility including on a food-contact surface. If \u003Cem>L. monocytogenes\u003C\u002Fem> is introduced into a food processing facility without proper controls, it can proliferate in food processing facilities where it may contaminate food. Consuming food contaminated with \u003Cem>L. monocytogenes\u003C\u002Fem> can lead to a severe, sometimes life-threatening illness called listeriosis, a foodborne illness which is a major public health concern due to the severity of the disease, its high case-fatality rate, long incubation time, and tendency to affect individuals with underlying conditions.\u003C\u002Fp>\u003Cp>We acknowledge that your July 3, 2025, response included an updated “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” revised June 23, 2025, and environmental sampling conducted on June 20 and 27, 2025, that showed negative results for \u003Cem>L. monocytogenes\u003C\u002Fem> for fourteen (14) swabs. However, FDA is unable to evaluate if you are adequately controlling \u003Cem>Listeria\u003C\u002Fem> and if you are monitoring the sanitary conditions and practices in your facility for the reasons discussed below.\u003C\u002Fp>\u003Cp>Your updated “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” includes \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your program lists analysis methodology for \u003Cem>L. monocytogenes\u003C\u002Fem> and the environmental sampling results you provided used method AOAC 2004.02 to determine that no L. monocytogenes was present. FDA recommends you provide evidence that your environmental monitoring tested for other species of \u003Cem>Listeria\u003C\u002Fem> such as \u003Cem>L. welshimeri\u003C\u002Fem>. Additionally, FDA recommends you provide records with details of the cleaning and sanitizing of the environmental surfaces where FDA detected \u003Cem>Listeria\u003C\u002Fem> species, and provide the corrective actions taken to prevent the recurrence of Listeria species in your facility such as a comprehensive investigation or root cause analysis to identify the source of the \u003Cem>Listeria\u003C\u002Fem> contamination. As a processor of raw, RTE fish, you are responsible for ensuring that you have \u003Cem>Listeria\u003C\u002Fem> controls in your facility to prevent \u003Cem>L. monocytogenes\u003C\u002Fem> from contaminating your products. If the likely source of contamination cannot be identified, then the root cause analysis should thoroughly investigate and evaluate all potential sources, implemented controls, and problems.\u003C\u002Fp>\u003Cp>Moreover, your environmental monitoring program is not clear on when corrective actions will be taken when testing for \u003Cem>Listeria\u003C\u002Fem> species. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA recommends your environmental monitoring program clearly state the methods of analysis for all \u003Cem>Listeria\u003C\u002Fem> species and a list of corrective actions your firm will take should any \u003Cem>Listeria\u003C\u002Fem> species be detected on a surface (i.e., positive).\u003C\u002Fp>\u003Cp>Furthermore, your program states that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This is not statistically robust sampling to determine control of \u003Cem>L. monocytogenes\u003C\u002Fem>, particularly given FDA’s history of finding \u003Cem>Listeria\u003C\u002Fem>, including \u003Cem>L. monocytogenes\u003C\u002Fem>, in your processing environment, including on zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> food-contact surfaces.\u003C\u002Fp>\u003Cp>\u003Cstrong>Seafood HACCP Violations (21 CFR Part 123)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\u003Cp>1. You must monitor sanitation conditions and practices during processing with sufficient frequency to ensure compliance with current good manufacturing practice (cGMP) requirements under 21 CFR Part 117, subpart B that are appropriate to your plant and food products (21 CFR 123.11(b)). However, your firm did not monitor the following conditions and practices with sufficient frequency to ensure cGMP compliance. This is a repeat violation from FDA’s 2020 inspection.\u003C\u002Fp>\u003Cp>A. You did not ensure all food-contact surfaces, including utensils, were cleaned as necessary to protect against food contamination, as required by 21 CFR 117.35(d). This is related to the condition and cleanliness of food-contact surfaces, including utensils and gloves, as required by 21 CFR 123.11(b)(2). Specifically, the FDA investigator observed:\u003C\u002Fp>\u003Cp>i. On June 10, 2025, organic fish-like material on tools, such as knives and knife sharpening steels, after the tools were sanitized. The knives were food-contact surfaces used to fillet RTE fresh salmon. Additionally, rust-like material was observed on the knife sharpening steels that contact the blades of the knives. \u003Cem>L. welshimeri\u003C\u002Fem> was found on the blades of the small and large Victorinox knives on the shelf of table \u003Cstrong>(b)(4)\u003C\u002Fstrong>; blades of the black and purple sharpener on the shelf of table \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and the blade of the Victorinox knife on the shelf of table \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Sample 1267630, subs 28, 30, 62, and 65).\u003C\u002Fp>\u003Cp>ii. On June 11, 2025, an employee handling and processing RTE fresh salmon dropped their knife on the fresh fish processing room floor. The employee picked up the knife from the floor and rinsed the knife with water from the metal nozzle attached to a black water hose hanging from the rim of a gray waste barrel. The employee then continued handling and processing RTE fresh salmon without cleaning and sanitizing the knife or washing their hands and changing gloves.\u003C\u002Fp>\u003Cp>B. You did not conduct all food manufacturing, processing, packing, and holding under conditions and controls necessary to minimize the potential growth of microorganisms, contamination of food, and deterioration of food, as required by 21 CFR 117.80(c)(2). This is related to the prevention of cross-contamination from insanitary objects to food, food packaging material, and other food-contact surfaces, including utensils and gloves, as required by 21 CFR 123.11(b)(3)). Specifically, the FDA investigator observed:\u003C\u002Fp>\u003Cp>i. On June 11, 2025, an employee placed a fresh salmon head in a gray waste barrel while handling and processing RTE fresh salmon. The employee then reached their gloved hand into the gray waste barrel, picked up the fresh salmon head, and placed it on cutting board \u003Cstrong>(b)(4)\u003C\u002Fstrong> where RTE fish is prepared. Thereafter, the employee placed the fresh salmon head into a transparent plastic poly bag to be sold and distributed by your firm. \u003Cem>L. welshimeri\u003C\u002Fem> was found on the handles, rim, interior, and wheel of a gray waste barrel in front of table \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> surface of table \u003Cstrong>(b)(4)\u003C\u002Fstrong> (i.e., cutting board \u003Cstrong>(b)(4)\u003C\u002Fstrong>) where RTE fish is prepared, and the rim of a gray waste barrel in front of table \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Sample 1267630, subs 44, 45, 46, 47, 48, 49, 50, 96). Additionally, during FDA’s 2020 inspection, \u003Cem>L. monocytogenes\u003C\u002Fem> was found on the surface of table 2 and the top rim of a gray waste barrel (Sample 1132407, subs 9, 57, and 58).\u003C\u002Fp>\u003Cp>ii. On June 10 and 11, 2025, blue plastic swinging doors heavily soiled with unidentified foreign material at push points located at the entrance\u002Fexit to the fresh fish processing room. Employees touched these blue plastic swinging doors with their gloved hands when transferring RTE fresh salmon from the walk-in cooler to the fresh fish processing room. The same employees continued to handle RTE fresh salmon without washing their hands and changing their gloves. Furthermore, on June 17, 2025, these same blue plastic swinging doors were still heavily soiled with unidentified foreign material at push points located at the entrance\u002Fexit to the fresh fish processing room. \u003Cem>L. welshimeri\u003C\u002Fem> was found on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> side of the \u003Cstrong>(b)(4) \u003C\u002Fstrong>door and \u003Cstrong>(b)(4)\u003C\u002Fstrong> side of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> door leading into the production room, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> side of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> door and \u003Cstrong>(b)(4)\u003C\u002Fstrong> side of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> door leading out of the production room (Sample 1267630, subs 9, 10, 88, and 89).\u003C\u002Fp>\u003Cp>iii. On June 10 and 11, 2025, hanging metal water hose nozzles with build-up of apparent organic fish-like material on the top rims of gray waste barrels while employees were handling and processing RTE fresh salmon in the fresh fish processing room. The waste barrels were not a clean and sanitary surface. These same metal water hose nozzles were used to rinse cutting boards and RTE fresh salmon. Furthermore, these employees continued to handle and process RTE fresh salmon without washing their hands and changing their gloves. \u003Cem>L. welshimeri\u003C\u002Fem> was found on the nozzle and handle of the hose on the shelf of tables \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Sample 1267630, subs 69 and 73). Additionally, during FDA’s 2020 inspection, \u003Cem>L. monocytogenes\u003C\u002Fem> was found on the top rim of a gray waste barrel (Sample 1132407, 57 and 58).\u003C\u002Fp>\u003Cp>iv. On June 10 and 11, 2025, employees handling and processing RTE fresh salmon in the fresh fish processing room were rinsing out the interior surface of Styrofoam containers used for packing RTE fresh salmon. The employees were rinsing one Styrofoam container on its side on a wood pallet, one Styrofoam container on its side and contacting an employee’s boot, and one Styrofoam container on its side and contacting the fresh fish processing room floor. Employees placed RTE fresh salmon into these same Styrofoam containers without any protective packaging.\u003C\u002Fp>\u003Cp>v. On June 10 and 11, 2025, an employee handling and de-scaling RTE fresh salmon in the fresh fish processing room and then moving wood pallets outside of the fresh fish processing room. When re-entering the fresh fish processing room, the employee continued to de-scale RTE fresh salmon without washing their hands and changing their gloves.\u003C\u002Fp>\u003Cp>C. You did not ensure cleaning and sanitizing of utensils and equipment was conducted in a manner that protects against contamination of food, food-contact surfaces, or food-packaging materials, as required by 21 CFR 117.35(a). This is related to protection of food, food packaging material, and food-contact surfaces from adulteration, as required by 21 CFR 123.11(b)(5). On June 10, 2025, while monitoring post processing cleaning and sanitation, the FDA investigator observed back-splash and over-spray of water from high pressure water hoses contacting the floor, causing water droplets to land on the plastic poly bags used to pack RTE fresh salmon. Additionally, these same plastic poly bags were being stored in the fresh fish processing room in yellow plastic crates with evidence of unidentified foreign material build-up on the exterior and interior surfaces of the crates.\u003C\u002Fp>\u003Cp>Your July 3, 2025, response explained that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Additionally, you explained that you installed new plastic curtains in the cooler, and that you have ordered new plastic curtains for the large freezer and cooler entrances and will replace them immediately upon receipt. You also provided an employee training record for training conducted on June 28, 2025, and a photograph of replacement curtains for the cooler. However, your response is inadequate, as you did not discuss any other corrective actions you have taken, such as cleaning and sanitizing of surfaces observed to be insanitary and potentially contaminated. Additionally, you did not provide any sanitation monitoring records required by 21 CFR 123.11(b) demonstrating that you are documenting the monitoring and corrections for conditions and practices during processing.\u003C\u002Fp>\u003Cp>2. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food safety hazards that are reasonably likely to occur and you must have and implement a written HACCP plan to control any food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (b). However, your firm does not have a HACCP plan for fresh tuna portions to control the food safety hazard of scombrotoxin (histamine) formation when receiving tuna on ice and during refrigerated storage in your facility. Specifically, you stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, you do not evaluate adequacy of ice or conduct temperature monitoring checks upon receipt of the tuna. Additionally, you do not monitor refrigerated storage temperatures to control histamine formation.\u003C\u002Fp>\u003Cp>Your July 3, 2025, response stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. To date, we have not received your HACCP plan for fresh tuna portions.\u003C\u002Fp>\u003Cp>3. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b) and (c)(4). However, your firm did not follow the monitoring procedure of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for when products are received with frozen gel packs at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” critical control point to control pathogen growth and toxin formation listed in your HACCP plan for “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” revised October 1, 2024. During the inspection, your firm told the investigator that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, you are not implementing the monitoring procedure listed in your HACCP plan to measure the internal temperature of the product.\u003C\u002Fp>\u003Cp>Your July 3, 2025, response explains that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide critical control point monitoring records for receiving to support your corrective action. You did not demonstrate that you are performing evaluations for adequacy of frozen gel packs or adequacy of ice, in addition to taking the internal product temperature or data loggers that show temperature was maintained below \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F on shipments over \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours as listed in your HACCP plan.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\u003Cp>Please notify FDA in writing within fifteen (15) working days of receipt of this letter, of the specific steps and corrections you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Sheena Phillips, Compliance Officer, via email at Sheena.Phillips@fda.hhs.gov.If you have any questions regarding this letter, you may contact Sheena Phillips, Compliance Officer, via email at Sheena.Phillips@fda.hhs.gov. Please reference CMS #718312 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, J.D., M.B.A.\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRenfen Qiu\n\nRecipient Title\n\nPresident\u002FOwner\n\nMin Jiang Food Store Inc dba Koi Koi Trading\n\n2710 Yates Avenue\n\nCommerce, CA 90040-2624\n\nUnited States\n\nbobby@koikoitrading.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJanuary 14, 2026\nWARNING LETTER\nRe: CMS Case # 718312\nDear Mr. Qiu:\nThe United States Food and Drug Administration (FDA) conducted an inspection of your ready-to-eat (RTE) seafood processing facility, located at 2710 Yates Avenue, Commerce, CA 90040-2624, from June 10 through June 24, 2025. During our inspection, FDA investigators found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123. Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analysis of the environmental swabs found the presence of non-pathogenic Listeria welshimeri (L. welshimeri).\nBased on FDA’s inspectional and the analytical results for samples collected from your production environment, we have determined that your raw, RTE fish products, including salmon, are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. § 342(a)(4)) in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. Furthermore, in accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)]. Accordingly, your fresh tuna portions are also adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)]. You may find the Act, the seafood HACCP regulation, and the June 2022 Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\nAt the conclusion of the inspection, the FDA investigator issued a Form FDA 483 (FDA-483), Inspectional Observations, listing the violations found at your facility. You provided a response to the inspection on July 3, 2025, describing corrective actions taken or planned by your firm. After reviewing the inspectional findings, analytical results, and the response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility. We address your response below.\nEnvironmental Samples\nFDA investigators collected environmental swabs (FDA Sample 1267630) from various areas in your processing facility on June 17, 2025, during the production of RTE fresh aquacultured imported salmon intended for raw consumption. FDA laboratory analysis found that forty-one (41) of the one hundred ten (110) environmental swabs were positive for non-pathogenic L. welshimeri. Of the 41 positive swabs, (b)(4)% (fourteen (14) swabs) were collected from food-contact surfaces in areas where raw, RTE salmon products are processed. The positive food-contact surfaces included:\nthe blades of the small and large Victorinox knives on the shelf of table (b)(4) that are used to cut RTE fish;\nthe blade of the Victorinox knife on the shelf of table (b)(4) that is used to cut RTE fish;\nthe (b)(4) surface of table (b)(4) where RTE fish is prepared;\nthe (b)(4) surfaces of table (b)(4) where RTE fish is prepared; and\nthe (b)(4) surface of table (b)(4) where RTE fish is prepared.\nFurthermore, your firm has a history of Listeria contamination, including pathogenic Listeria monocytogenes (L. monocytogenes) in your facility. During a previous FDA inspection, environmental sample 1132407 collected on March 9, 2020, from various areas in your firm’s processing facility identified three (3) of ninety-eight (98) swabs positive for L. monocytogenes, including one (1) positive swab from a food-contact surface (i.e., the top of table (b)(4), which is the cutting board used for de-scaling and filleting RTE salmon). Whole genome sequencing (WGS) conducted on these L. monocytogenes isolates revealed that the isolates were genetically identical to one another, representing the same strain. Furthermore, this strain was highly related to another fifteen (15) environmental isolates collected in 2015 and 2016 from another food processing facility in California. Additionally, forty-eight (48) of ninety-eight (98) swabs were positive for Listeria species, including L. innocua and L. welshimeri. We advised you of the importance of these Listeria findings during a Regulatory Meeting held with your firm on May 5, 2020.\nThe high-level of non-pathogenic Listeria species in your facility demonstrates your sanitation procedures have been inadequate to effectively control microbial contamination in your facility. Appropriate control of Listeria species in a food processing environment requires knowledge of the unique characteristics of the organism and implementation of the hygienic practices necessary to control this microbe. Once Listeria species is established in a production area, personnel or equipment can facilitate the microbe’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the harborage sites in the food processing plant and equipment where this organism is able to grow and survive, and to apply controls or take corrective actions as necessary to eradicate the organism by rendering these areas unable to support the survival and growth of the organism and to prevent the organism from being re-established in such sites.\nThe presence of non-pathogenic Listeria species indicates insanitary conditions suitable for the survival and growth of the pathogenic L. monocytogenes, which, as noted above, has been previously found in your facility including on a food-contact surface. If L. monocytogenes is introduced into a food processing facility without proper controls, it can proliferate in food processing facilities where it may contaminate food. Consuming food contaminated with L. monocytogenes can lead to a severe, sometimes life-threatening illness called listeriosis, a foodborne illness which is a major public health concern due to the severity of the disease, its high case-fatality rate, long incubation time, and tendency to affect individuals with underlying conditions.\nWe acknowledge that your July 3, 2025, response included an updated “(b)(4),” revised June 23, 2025, and environmental sampling conducted on June 20 and 27, 2025, that showed negative results for L. monocytogenes for fourteen (14) swabs. However, FDA is unable to evaluate if you are adequately controlling Listeria and if you are monitoring the sanitary conditions and practices in your facility for the reasons discussed below.\nYour updated “(b)(4)” includes (b)(4). However, your program lists analysis methodology for L. monocytogenes and the environmental sampling results you provided used method AOAC 2004.02 to determine that no L. monocytogenes was present. FDA recommends you provide evidence that your environmental monitoring tested for other species of Listeria such as L. welshimeri. Additionally, FDA recommends you provide records with details of the cleaning and sanitizing of the environmental surfaces where FDA detected Listeria species, and provide the corrective actions taken to prevent the recurrence of Listeria species in your facility such as a comprehensive investigation or root cause analysis to identify the source of the Listeria contamination. As a processor of raw, RTE fish, you are responsible for ensuring that you have Listeria controls in your facility to prevent L. monocytogenes from contaminating your products. If the likely source of contamination cannot be identified, then the root cause analysis should thoroughly investigate and evaluate all potential sources, implemented controls, and problems.\nMoreover, your environmental monitoring program is not clear on when corrective actions will be taken when testing for Listeria species. For example, (b)(4). FDA recommends your environmental monitoring program clearly state the methods of analysis for all Listeria species and a list of corrective actions your firm will take should any Listeria species be detected on a surface (i.e., positive).\nFurthermore, your program states that (b)(4). This is not statistically robust sampling to determine control of L. monocytogenes, particularly given FDA’s history of finding Listeria, including L. monocytogenes, in your processing environment, including on zone (b)(4) food-contact surfaces.\nSeafood HACCP Violations (21 CFR Part 123)\nYour significant violations are as follows:\n1. You must monitor sanitation conditions and practices during processing with sufficient frequency to ensure compliance with current good manufacturing practice (cGMP) requirements under 21 CFR Part 117, subpart B that are appropriate to your plant and food products (21 CFR 123.11(b)). However, your firm did not monitor the following conditions and practices with sufficient frequency to ensure cGMP compliance. This is a repeat violation from FDA’s 2020 inspection.\nA. You did not ensure all food-contact surfaces, including utensils, were cleaned as necessary to protect against food contamination, as required by 21 CFR 117.35(d). This is related to the condition and cleanliness of food-contact surfaces, including utensils and gloves, as required by 21 CFR 123.11(b)(2). Specifically, the FDA investigator observed:\ni. On June 10, 2025, organic fish-like material on tools, such as knives and knife sharpening steels, after the tools were sanitized. The knives were food-contact surfaces used to fillet RTE fresh salmon. Additionally, rust-like material was observed on the knife sharpening steels that contact the blades of the knives. L. welshimeri was found on the blades of the small and large Victorinox knives on the shelf of table (b)(4); blades of the black and purple sharpener on the shelf of table (b)(4); and the blade of the Victorinox knife on the shelf of table (b)(4) (Sample 1267630, subs 28, 30, 62, and 65).\nii. On June 11, 2025, an employee handling and processing RTE fresh salmon dropped their knife on the fresh fish processing room floor. The employee picked up the knife from the floor and rinsed the knife with water from the metal nozzle attached to a black water hose hanging from the rim of a gray waste barrel. The employee then continued handling and processing RTE fresh salmon without cleaning and sanitizing the knife or washing their hands and changing gloves.\nB. You did not conduct all food manufacturing, processing, packing, and holding under conditions and controls necessary to minimize the potential growth of microorganisms, contamination of food, and deterioration of food, as required by 21 CFR 117.80(c)(2). This is related to the prevention of cross-contamination from insanitary objects to food, food packaging material, and other food-contact surfaces, including utensils and gloves, as required by 21 CFR 123.11(b)(3)). Specifically, the FDA investigator observed:\ni. On June 11, 2025, an employee placed a fresh salmon head in a gray waste barrel while handling and processing RTE fresh salmon. The employee then reached their gloved hand into the gray waste barrel, picked up the fresh salmon head, and placed it on cutting board (b)(4) where RTE fish is prepared. Thereafter, the employee placed the fresh salmon head into a transparent plastic poly bag to be sold and distributed by your firm. L. welshimeri was found on the handles, rim, interior, and wheel of a gray waste barrel in front of table (b)(4), on the (b)(4) surface of table (b)(4) (i.e., cutting board (b)(4)) where RTE fish is prepared, and the rim of a gray waste barrel in front of table (b)(4) (Sample 1267630, subs 44, 45, 46, 47, 48, 49, 50, 96). Additionally, during FDA’s 2020 inspection, L. monocytogenes was found on the surface of table 2 and the top rim of a gray waste barrel (Sample 1132407, subs 9, 57, and 58).\nii. On June 10 and 11, 2025, blue plastic swinging doors heavily soiled with unidentified foreign material at push points located at the entrance\u002Fexit to the fresh fish processing room. Employees touched these blue plastic swinging doors with their gloved hands when transferring RTE fresh salmon from the walk-in cooler to the fresh fish processing room. The same employees continued to handle RTE fresh salmon without washing their hands and changing their gloves. Furthermore, on June 17, 2025, these same blue plastic swinging doors were still heavily soiled with unidentified foreign material at push points located at the entrance\u002Fexit to the fresh fish processing room. L. welshimeri was found on the (b)(4) side of the (b)(4) door and (b)(4) side of the (b)(4) door leading into the production room, and (b)(4) side of the (b)(4) door and (b)(4) side of the (b)(4) door leading out of the production room (Sample 1267630, subs 9, 10, 88, and 89).\niii. On June 10 and 11, 2025, hanging metal water hose nozzles with build-up of apparent organic fish-like material on the top rims of gray waste barrels while employees were handling and processing RTE fresh salmon in the fresh fish processing room. The waste barrels were not a clean and sanitary surface. These same metal water hose nozzles were used to rinse cutting boards and RTE fresh salmon. Furthermore, these employees continued to handle and process RTE fresh salmon without washing their hands and changing their gloves. L. welshimeri was found on the nozzle and handle of the hose on the shelf of tables (b)(4) (Sample 1267630, subs 69 and 73). Additionally, during FDA’s 2020 inspection, L. monocytogenes was found on the top rim of a gray waste barrel (Sample 1132407, 57 and 58).\niv. On June 10 and 11, 2025, employees handling and processing RTE fresh salmon in the fresh fish processing room were rinsing out the interior surface of Styrofoam containers used for packing RTE fresh salmon. The employees were rinsing one Styrofoam container on its side on a wood pallet, one Styrofoam container on its side and contacting an employee’s boot, and one Styrofoam container on its side and contacting the fresh fish processing room floor. Employees placed RTE fresh salmon into these same Styrofoam containers without any protective packaging.\nv. On June 10 and 11, 2025, an employee handling and de-scaling RTE fresh salmon in the fresh fish processing room and then moving wood pallets outside of the fresh fish processing room. When re-entering the fresh fish processing room, the employee continued to de-scale RTE fresh salmon without washing their hands and changing their gloves.\nC. You did not ensure cleaning and sanitizing of utensils and equipment was conducted in a manner that protects against contamination of food, food-contact surfaces, or food-packaging materials, as required by 21 CFR 117.35(a). This is related to protection of food, food packaging material, and food-contact surfaces from adulteration, as required by 21 CFR 123.11(b)(5). On June 10, 2025, while monitoring post processing cleaning and sanitation, the FDA investigator observed back-splash and over-spray of water from high pressure water hoses contacting the floor, causing water droplets to land on the plastic poly bags used to pack RTE fresh salmon. Additionally, these same plastic poly bags were being stored in the fresh fish processing room in yellow plastic crates with evidence of unidentified foreign material build-up on the exterior and interior surfaces of the crates.\nYour July 3, 2025, response explained that “(b)(4).” Additionally, you explained that you installed new plastic curtains in the cooler, and that you have ordered new plastic curtains for the large freezer and cooler entrances and will replace them immediately upon receipt. You also provided an employee training record for training conducted on June 28, 2025, and a photograph of replacement curtains for the cooler. However, your response is inadequate, as you did not discuss any other corrective actions you have taken, such as cleaning and sanitizing of surfaces observed to be insanitary and potentially contaminated. Additionally, you did not provide any sanitation monitoring records required by 21 CFR 123.11(b) demonstrating that you are documenting the monitoring and corrections for conditions and practices during processing.\n2. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food safety hazards that are reasonably likely to occur and you must have and implement a written HACCP plan to control any food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (b). However, your firm does not have a HACCP plan for fresh tuna portions to control the food safety hazard of scombrotoxin (histamine) formation when receiving tuna on ice and during refrigerated storage in your facility. Specifically, you stated that (b)(4); however, you do not evaluate adequacy of ice or conduct temperature monitoring checks upon receipt of the tuna. Additionally, you do not monitor refrigerated storage temperatures to control histamine formation.\nYour July 3, 2025, response stated that (b)(4). To date, we have not received your HACCP plan for fresh tuna portions.\n3. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b) and (c)(4). However, your firm did not follow the monitoring procedure of “(b)(4)” for when products are received with frozen gel packs at the “(b)(4)” critical control point to control pathogen growth and toxin formation listed in your HACCP plan for “(b)(4),” revised October 1, 2024. During the inspection, your firm told the investigator that (b)(4). Therefore, you are not implementing the monitoring procedure listed in your HACCP plan to measure the internal temperature of the product.\nYour July 3, 2025, response explains that (b)(4). However, you did not provide critical control point monitoring records for receiving to support your corrective action. You did not demonstrate that you are performing evaluations for adequacy of frozen gel packs or adequacy of ice, in addition to taking the internal product temperature or data loggers that show temperature was maintained below (b)(4)°F on shipments over (b)(4) hours as listed in your HACCP plan.\nThe violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\nPlease notify FDA in writing within fifteen (15) working days of receipt of this letter, of the specific steps and corrections you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to the Food and Drug Administration, Attention: Sheena Phillips, Compliance Officer, via email at Sheena.Phillips@fda.hhs.gov.If you have any questions regarding this letter, you may contact Sheena Phillips, Compliance Officer, via email at Sheena.Phillips@fda.hhs.gov. Please reference CMS #718312 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, J.D., M.B.A.\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\nFood and Drug Administration","Min Jiang Food Store Inc dba Koi Koi Trading","min-jiang-food-store-inc-dba-koi-koi-trading-718312-01142026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmin-jiang-food-store-inc-dba-koi-koi-trading-718312-01142026","2026-10-26T08:09:25.953736+00:00","2026-05-05","718312","Renfen Qiu","2026-08-19T04:44:32.264+00:00","2026-01-14",{"id":374,"raw":375,"subject":379,"body_html":380,"body_text":381,"firm_name":382,"letter_id":383,"created_at":190,"fei_number":19,"letter_url":384,"updated_at":385,"action_type":22,"case_status":23,"posted_date":386,"marcs_cms_no":387,"product_type":50,"closeout_date":19,"issuing_office":37,"recipient_name":388,"body_fetched_at":389,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":390,"medical_device_id":19,"response_letter_date":19},31,[376,377,378,37,379,13,13,13],"\u003Ctime datetime=\"2026-07-14T04:00:00Z\">07\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-12T04:00:00Z\">06\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnihon-kohden-digital-health-solutions-llc-727803-06122026\">Nihon Kohden Digital Health Solutions, LLC\u003C\u002Fa>","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Harsh Dharwad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nihon Kohden Digital Health Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14 Bunsen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #727803\u003C\u002Fp>\u003Cp>June 12, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Dharwad:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Irvine, CA from February 23, 2026 through February 24, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Next Generation NetKonnect software device, which is a Patient Physiological Monitor device with Arrhythmia detector and alarm (including ST-segment measurement and alarm). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your Next Generation NetKonnect (NGNK) software device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.\u003C\u002Fp>\u003Cp>Specifically, your firm’s Next Generation NetKonnect software devices are class II devices regulated under 21 CFR 870.1025 - Arrhythmia detector and alarm (including ST-segment measurement and alarm). Your device was most recently cleared as K220989 on July 29, 2022. On October 22, 2022, you implemented a software change to the device which included the ability to enable a Silence Alarms function. This introduced a device functionality that was not included in the originally cleared device. You completed a Regulatory Assessment for the modification in which you determined it would not significantly affect the safety and efficacy of the device, and that a Letter-to-File was appropriate. At decision point B2 of the assessment, “Is it a control mechanism, operating principles, or energy type change?” you selected “No.” You did not submit a premarket notification for this modification.\u003C\u002Fp>\u003Cp>However, we disagree with this assessment because adding the Silence Alarms function is a change to a control mechanism of the device and we believe that “Yes” should have been selected, leading to “New 510(k).” The addition of a Silence Alarms function is a change to a control mechanism because it modifies the manner in which the user controls the device, which could result in the alarms not operating as the user intends. This change may result in missed alarms for life-threatening conditions that require immediate attention, leading to patient harm such as serious injury and\u002For death. As such, the modification of the device is a change or modification in the device that could significantly affect its safety or effectiveness and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>Additionally, the evidence indicates that you are distributing the NGNK software device with an unauthorized intended use that is different from that cleared under K220989. Namely, the labeling of your device indicates that the NGNK device is now intended to have “device-agnostic compatibility.” During the inspection, your firm’s management explained that “device-agnostic” describes NGNK’s ability to 1) run on any brand of commercial off-the-shelf computer and 2) support input from non-Nihon Kohden devices. However, your device was cleared under K220989 to support inputs from only other Nihon Kohden devices, and not from any device from other manufacturers. Therefore, “device-agnostic compatibility” is beyond the scope of the intended use that was cleared for the Next Generation NetKonnect. This change may introduce patient risks because of the use of additional input devices that have not been validated for compatibility with the NGNK software. Inadequate interoperability can result in incorrect vital sign measurements or loss of expected monitoring, which may result in delay of diagnosis or misdiagnosis. This is a major change or modification in the intended use of the device and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727803” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Mr. Arthur E. Webb, Director of Software Quality and Regulatory Affairs, art_webb@nihonkohden.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nHarsh Dharwad\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nNihon Kohden Digital Health Solutions, LLC\n\n14 Bunsen\n\nIrvine, CA 92618\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #727803\nJune 12, 2026\nDear Mr. Dharwad:\nDuring an inspection of your firm located in Irvine, CA from February 23, 2026 through February 24, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Next Generation NetKonnect software device, which is a Patient Physiological Monitor device with Arrhythmia detector and alarm (including ST-segment measurement and alarm). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violation(s)\nOur inspection revealed that your Next Generation NetKonnect (NGNK) software device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.\nSpecifically, your firm’s Next Generation NetKonnect software devices are class II devices regulated under 21 CFR 870.1025 - Arrhythmia detector and alarm (including ST-segment measurement and alarm). Your device was most recently cleared as K220989 on July 29, 2022. On October 22, 2022, you implemented a software change to the device which included the ability to enable a Silence Alarms function. This introduced a device functionality that was not included in the originally cleared device. You completed a Regulatory Assessment for the modification in which you determined it would not significantly affect the safety and efficacy of the device, and that a Letter-to-File was appropriate. At decision point B2 of the assessment, “Is it a control mechanism, operating principles, or energy type change?” you selected “No.” You did not submit a premarket notification for this modification.\nHowever, we disagree with this assessment because adding the Silence Alarms function is a change to a control mechanism of the device and we believe that “Yes” should have been selected, leading to “New 510(k).” The addition of a Silence Alarms function is a change to a control mechanism because it modifies the manner in which the user controls the device, which could result in the alarms not operating as the user intends. This change may result in missed alarms for life-threatening conditions that require immediate attention, leading to patient harm such as serious injury and\u002For death. As such, the modification of the device is a change or modification in the device that could significantly affect its safety or effectiveness and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(i).\nAdditionally, the evidence indicates that you are distributing the NGNK software device with an unauthorized intended use that is different from that cleared under K220989. Namely, the labeling of your device indicates that the NGNK device is now intended to have “device-agnostic compatibility.” During the inspection, your firm’s management explained that “device-agnostic” describes NGNK’s ability to 1) run on any brand of commercial off-the-shelf computer and 2) support input from non-Nihon Kohden devices. However, your device was cleared under K220989 to support inputs from only other Nihon Kohden devices, and not from any device from other manufacturers. Therefore, “device-agnostic compatibility” is beyond the scope of the intended use that was cleared for the Next Generation NetKonnect. This change may introduce patient risks because of the use of additional input devices that have not been validated for compatibility with the NGNK software. Inadequate interoperability can result in incorrect vital sign measurements or loss of expected monitoring, which may result in delay of diagnosis or misdiagnosis. This is a major change or modification in the intended use of the device and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(ii).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727803” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCDR Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Mr. Arthur E. Webb, Director of Software Quality and Regulatory Affairs, art_webb@nihonkohden.com","Nihon Kohden Digital Health Solutions, LLC","nihon-kohden-digital-health-solutions-llc-727803-06122026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnihon-kohden-digital-health-solutions-llc-727803-06122026","2026-10-26T08:09:33.79279+00:00","2026-07-14","727803","Harsh Dharwad","2026-08-19T04:30:04.336+00:00","2026-06-12",{"id":392,"raw":393,"subject":12,"body_html":399,"body_text":400,"firm_name":401,"letter_id":402,"created_at":66,"fei_number":19,"letter_url":403,"updated_at":404,"action_type":22,"case_status":47,"posted_date":405,"marcs_cms_no":406,"product_type":26,"closeout_date":51,"issuing_office":165,"recipient_name":407,"body_fetched_at":408,"delivery_method":177,"recipient_title":19,"reference_number":19,"action_taken_date":409,"medical_device_id":19,"response_letter_date":19},1948,[394,395,396,165,397,13,398,13],"\u003Ctime datetime=\"2023-08-08T13:20:00Z\">08\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-03T04:00:00Z\">08\u002F03\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftan-alize-kozmetik-ve-temizlik-urunleri-659854-08032023\">Tan Alize Kozmetik Ve Temizlik Urunleri\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftan-alize-kozmetick-ve-temizlik-urunleri-sanayi-ve-ticaret-659854-08142024\">\u003Ctime datetime=\"2024-08-30T04:00:00Z\">08\u002F30\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Latife Nesrin Ozdemir\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Product Development and Regulatory Affairs Executive\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tan Alize Kozmetik Ve Temizlik Urunleri\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Sanayi Ve Ticaret Anonim Sirketi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>No. 32 Omerli Mahallesi Uran Caddesi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>34799\u003C\u002Fspan> \u003Cspan>Cekmekoy\u003C\u002Fspan>\u002F\u003Cspan>İstanbul\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Turkey\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Nesrin.Ozdemir@farmasi.com.tr\"> Nesrin.Ozdemir@farmasi.com.tr\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-29\u003C\u002Fp>\n\n\u003Cp>August 3, 2023\u003Cbr>\n\u003Cbr>\nDear Ms. Latife Nesrin Ozdemir:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our April 13, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Tan Alize Kosmetik, FEI 3004135088, No. 32 Omerli Mahallesi Uran Caddesi, Cekmekoy, Istanbul 34799, Turkey.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture several over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and sunscreen. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination.\u003C\u002Fp>\n\n\u003Cp>These include, but are not limited to, testing of glycerin, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities &amp; Equipment, Laboratory Controls, and Packaging &amp; Labelling Systems.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on June 23, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004135088 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC (U.S. Agent via email):\u003Cbr>\nRegistrar Corp.\u003Cbr>\ndrugs@registrarcorp.com\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLatife Nesrin Ozdemir\n\nRecipient Title\n\nProduct Development and Regulatory Affairs Executive\n\nTan Alize Kozmetik Ve Temizlik Urunleri\n\nSanayi Ve Ticaret Anonim Sirketi\n\nNo. 32 Omerli Mahallesi Uran Caddesi\n\n34799 Cekmekoy\u002Fİstanbul\n\nTurkey\n\nNesrin.Ozdemir@farmasi.com.tr\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-29\n\nAugust 3, 2023\n\nDear Ms. Latife Nesrin Ozdemir:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our April 13, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Tan Alize Kosmetik, FEI 3004135088, No. 32 Omerli Mahallesi Uran Caddesi, Cekmekoy, Istanbul 34799, Turkey.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou manufacture several over-the-counter (OTC) drug products, including (b)(4), (b)(4), (b)(4), and sunscreen. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination.\n\nThese include, but are not limited to, testing of glycerin, (b)(4) and (b)(4) you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components1 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, (b)(4), and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labelling Systems.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on June 23, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004135088 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC (U.S. Agent via email):\n\nRegistrar Corp.\n\ndrugs@registrarcorp.com\n\n___________________\n\n1 Components with higher risk of DEG or EG contamination compared to other drug components.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Tan Alize Kozmetik Ve Temizlik Urunleri","tan-alize-kozmetik-ve-temizlik-urunleri-659854-08032023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftan-alize-kozmetik-ve-temizlik-urunleri-659854-08032023","2026-10-26T08:10:09.797474+00:00","2023-08-08","659854","Latife Nesrin Ozdemir","2026-08-20T00:49:20.364+00:00","2023-08-03",26,{"510k":412,"classification":413,"enforcement":414,"event":415,"event_backfill":416,"pma":417,"warning_letter":418},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]